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ABSTRACT OF THE DISSERTATION
Discoidin Domain Receptor 2 as a Therapeutic Target in Breast and Ovarian Cancer
by
Whitney Rose Grither
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry
Washington University in St. Louis, 2019
Professor Gregory Longmore, Chair
Discoidin Domain Receptor 2 (DDR2) is a receptor tyrosine kinase that utilizes
the extracellular matrix protein collagen as its ligand. Recently, DDR2 was shown to be
critical in facilitating breast cancer metastasis. DDR2 stabilizes protein levels of the
epithelial-mesenchymal-transition (EMT) inducing transcription factor, SNAIL1 in basal
K14+ epithelial cells that are known to be important for invasive leader cell properties
during collective invasion/migration. DDR2 expression is present in a majority of human
invasive ductal breast carcinomas, and expression is localized to the tumor-stroma
boundary. Additionally, in genetic models of breast cancer, deletion of DDR2 within the
stroma (MMTV-PyMT; DDR2 fl/fl; FSP-Cre) leads to a dramatic inhibition of tumor
metastasis. This indicates that DDR2 also functions within the stromal compartment to
facilitate metastasis, presumably through its function in cancer-associated fibroblasts
(CAFs). In CAFs DDR2 is critical for fibrillar collagen and ECM production and the
organization and architecture of collagen fibers. Additionally, paracrine factors from
xi

DDR2 expressing CAFs promote the invasion of surrounding tumor cells. Therefore, it
appears that DDR2 engagement by collagen provides a means for both tumor and
stromal cells to communicate with the surrounding environment to enhance metastatic
potential.
Additionally, we have established the action of DDR2 as critical for metastasis of
ovarian cancer. In both breast and ovarian tumor cells DDR2 expression, which is
absent in normal epithelium, is induced during EMT. The mesenchymal gene program
has been shown to promote the metastatic progression of ovarian cancer; however,
specific proteins induced by this program that lead to these metastatic behaviors have
not been identified. We found that the EMT transcription factor TWIST1 drives
expression of DDR2 upon EMT induction. In ovarian cancer, the expression and action
of DDR2 was critical for mesothelial cell clearance, invasion and migration in ovarian
tumor cells. It does so, in part, by upregulating expression and activity of matrix
remodeling enzymes that lead to increased cleavage of fibronectin and spreading of
tumor cells. In vivo studies demonstrated that the presence of DDR2 promotes ovarian
cancer metastasis. These findings indicate the critical importance of DDR2 for multiple
steps of ovarian cancer progression to metastasis, and thus, identifies DDR2 as a
potential new target for the treatment of metastatic ovarian cancer.
As such, DDR2 is a novel RTK target for the treatment of cancer metastasis,
leading us to hypothesize that the development of small molecule inhibitors to target
DDR2 function in both the tumor and stromal cells could provide a means of blunting
cancer metastasis. Using an in vitro binding assay, followed by medicinal chemistry
optimization of lead compounds, we identified potent and selective small molecule
xii

inhibitors of DDR2. The developed inhibitors have nanomolar potency at blocking
DDR2 activation. Unlike traditional tyrosine kinase inhibitors (TKIs) that target the
intracellular kinase domain, these inhibitors act on the extracellular domain (ECD) of
DDR2, and disrupt DDR2 signaling by accelerating the disassembly of DDR2-collagen
complexes, potentially by disrupting oligomerization of the receptor ECD. Therefore,
these inhibitors have a unique mode of action and are able to attenuate DDR2 signaling
both in cell culture, as well as in vivo as demonstrated by using a Snail1-clic beetle
green reporter in a xenograft transplant model. In co-culture assays, treating CAFs with
the developed inhibitors reduces the paracrine effect on invading tumor organoids.
Furthermore, using mouse models of late stage breast tumor metastasis, we have
shown that these inhibitors reduce metastatic burden in the lungs of mice, to a level
comparable of that of genetic knockdown of DDR2. Together these data support further
investigation of this novel class of DDR2 inhibitors as anti-metastasis agents, potentially
for use in combination with standard of care therapy to halt cancer progression and
prevent relapse. Further, it will be important to study the role of these inhibitors in other
cancers where DDR2 expression has been shown to promote metastasis, including, but
not limited to, ovarian, head and neck, and non-small cell lung carcinoma.

xiii

Chapter 1
Introduction
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Breast Cancer and metastasis
In the United States, breast cancer is the most common type of cancer in women
and the second leading cause of cancer related death among women. It is estimated
that in 2017 there will be 252,710 newly diagnosed cases of breast cancer, and 40,610
deaths from the disease1. Breast cancer development follows a stepwise model,
beginning with epithelial hyperplasia and transitioning to ductal carcinoma in situ
(DCIS). DCIS is the premalignant proliferation of neoplastic epithelial cells contained
within the lumen of mammary ducts, and is considered the precursor of invasive ductal
carcinomas (IDC)2. IDC is characterized by the invasion of tumor cells through the layer
of myoepithelial cells surrounding the mammary duct, and then breaching the basement
membrane2. At this stage, the cancer can then further spread to distant organs, giving
rise to metastasis. The vast majority of breast cancer deaths are due to metastasis,
which accounts for over 90% of disease related mortality3 The molecular and genetic
underpinnings of how breast cancer cells progress from DCIS to IDC to metastasis are
poorly understood, thereby posing difficulty in predicting which lesions will progress to
the next stage of development in patients. These insights are desperately needed, as
the median patient survival once disease has disseminated is only 2-3 years 4.
Epithelial cells accumulate somatic mutations in a stochastic manner over their
lifetime. Breast cancer arises when the epithelial cells of the mammary gland
accumulate mutations that affect their cell growth and survival, allowing for aberrant cell
growth and evasion of the growth suppressive pathways that are in place in the normal
epithelium5. This random acquisition of mutations leads to tumors that are
heterogeneous at the molecular, cellular and patient levels. Commonly used
2

chemotherapeutics target this highly proliferative behavior, irrespective of tumor specific
mutations. This non-specific targeting, while effective to some degree, carries inherent
toxicity to healthy cells as well as the risk of leaving behind resistant sub-populations.
In addition to uncontrolled cell growth and proliferation, the cells must also
acquire the ability to evade the body’s immune system, stimulate growth of new blood
vessels, and invade surrounding tissues5. While all of these characteristics are crucial
to the survival of the cancer cell, perhaps the most detrimental from a clinical
perspective is the ability of the cancer cell to invade and migrate. A confined breast
tumor, or DCIS, is amendable to multiple treatment options, and prognosis is generally
favorable. However, once tumor cells have invaded surrounding basement membrane,
now considered an IDC, there is a large reduction in overall survival and limited
additional treatment options, as the molecular basis of this transition is poorly
understood6.
The process of metastasis involves multiple distinct steps, each orchestrated by
distinct molecular pathways. As mentioned, the IDC must first invade the confining
myopeithelial lumen and basement membrane. The cell then invades through the
surrounding extracellular matrix (ECM) to reach nearby blood vessels, at which time it
must intravasate into the circulatory of lymphatic system, survive transport, and then
extravasate into the tissue at a distant site7. Once there, the cancer cell must survive in
this foreign environment and eventually proliferate to generate macroscopic metastases
capable of compromising organ function (Figure 1.1)5. While this process is rife with
inefficiency, and the majority of cells that escape from the primary site do not survive,
the impact of the few surviving cells on patient survival is significant. A great deal of
3

research has focused on identifying molecular targets of the DCIS to IDC progression,
however these have failed to identify tumor stage specific gene expression profiles8,
and a better understanding is imperative to improve treatment options for breast cancer
patients at risk of developing invasive disease.
Breast tumor microenvironment
While there remains a lack of understanding at the progression of breast tumor
cells from benign to invasive, research in the field of tumor metastasis has led to the
establishment of new concepts regarding the motility, dormancy, and establishment of
tumors at distant locations9. It is now appreciated that crosstalk between the tumor
cells and the surrounding cellular, chemical, and physical microenvironment influences
tumor development, progression, metastasis, and response to treatment 10, 11. In breast
tumors these stromal components differ from their normal tissue counterparts in
composition, architecture, and function (Figure 1.2). Furthermore, given the critical role
the supporting environment plays in tumor progression, this opens the door to new
strategies for therapeutic intervention that are often more consistent across different
tumors.
Non-neoplastic cells of the breast tumor microenvironment in the preinvasive
stages include myoepithelial and inflammatory cells. The players in the invasive stage
of progression become more numerous, and include fibroblasts, myofibroblasts,
adipocytes, inflammatory cells and endothelial cells (Figure 1.2)12,13. Significant
differences in gene expression in the cells of the tumor microenvironment has been
documented, both when comparing normal to DCIS-associated stroma, as well as
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differences between DCIS to IDC transition 8,14. Importantly, interactions between
carcinoma cells and these non-neoplastic stromal cells are crucial at every step of the
invasion-metastasis cascade3.
Additionally, the physical microenvironment is known to play a part in promoting
invasion and metastasis. This includes the various extracellular matrix (ECM) proteins
of the stroma, as well as the organizational arrangement of those components. Studies
have shown that in contact with basement membrane, malignant mammary cells are
fairly indolent in their invasiveness, but when placed in collagen I, those same tumor
cells show increased invasion15. Data such as this indicates that cell-ECM contacts are
critical in promoting migration of tumor cells. Collagen fibers are the most abundant
protein within the extracellular matrix (ECM) of breast tumor stroma, and play a key role
in breast cancer development and progression16. Increased collagen deposition
contributes to breast density, and women with dense breasts have increased risk for
developing breast cancer, with the resulting cases tending to be more aggressive17.
Modulation of ECM stiffness, via collagen crosslinking, enhances breast carcinoma
progression, in part via altered integrin signaling18. Additionally, increased tumor
stiffness results in the development of both tissue stress and interstitial fluid pressure,
which can alter many aspects of cell behavior19. It is not just an increase in these fibers,
but also the orientation that can influence the behavior of tumor cells. Stromal collagen
surrounding mammary tumors is frequently aligned and reoriented perpendicular to the
tumor boundary, and this alignment is correlated with poor prognosis20. Alignment of
collagen matrix can enhance invasion by increasing directional persistence of tumor
protrusion, and increasing the efficiency of the migrating cell21.

5

Determining effective ways to halt cancer metastasis remains an elusive goal. A
proposed reason for the limited success of current molecular therapies in the metastatic
setting is the lack of modulating both tumor cells and the tumor microenvironment22.This
points towards the need for therapeutic strategies that target both tumor cells and the
surrounding stroma as a more effective means to stop metastatic spread.
Ovarian cancer and metastasis
Ovarian cancer is the most lethal gynecologic malignancy, in part due to the
poorly understood origin and pathogenesis of the disease. In 2017 it is estimated that
there will be 22,440 newly diagnosed cases in the United States, and 14,080 deaths,
making it one of the most lethal cancers in the U.S. 1. The diverse array of ovarian
tumors are broadly categorized into two groups based on morphologic and molecular
genetic features. Type I tumors are composed of low-grade serous, low-grade
endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas. These are
generally indolent and confined to the ovary at presentation. In contrast, type II tumors,
which represent approximately 75% of all ovarian carcinomas and are responsible for
90% of ovarian cancer deaths, include conventional high-grade serous carcinoma
(HGSOC), undifferentiated carcinoma and malignant mixed mesodermal tumors
(carcinosarcoma). These type II tumors are highly aggressive and almost always
present in advanced stage. Genetically, type II tumors displayTP53 mutations in over
80% of cases23,24.
Recently, it has been proposed that HGSOC actually arise from the implantation
of tissue derived from the fallopian tube epithelium, rather than ovarian surface
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epithelium25,26. These serous intraepithelial tubal carcinomas (STIC) arise in the
fimbriated end of the fallopian tube and resemble high grade ovarian serous carcinoma
both morphologically and molecularly25. Additional studies have confirmed that STIC
possess most of the genomic aberrations present in advanced cancers, supporting
STIC as a precursor lesion. However, that same study identified STIC as metastasis in
a number of patients, indicating that they can also represent intraepithelial metastasis to
the fallopian tube rather than the origin of HGSOC27. With a lack of early detection and
screening strategies, and limited treatment options, in order to improve prognosis for
patients with HGSOC a better understanding of the origin and spread of the tumor is
needed.
While other malignancies of epithelial origin utilize hematogenous or
lymphatogenous routes to metastasize, ovarian cancer is unique in that the metastatic
cascade of ovarian tumors most commonly occurs via the peritoneal circulation. While
metastasis of epithelial ovarian cancer can occur via the lymphatic or circulatory
systems, transcoelomic metastasis is the most common. This results in the majority of
metastases being confined within the abdominal peritoneal cavity28, which contributes
substantially to the morbidity and mortality associated with the disease due to the
frequency, ability to affect multiple vital organs, and development of malignant ascites29.
At diagnosis, two thirds of the patients with ovarian cancer have already developed
peritoneal metastasis.30
After tumor cell detachment from the primary site in the ovary, tumor cells are
transported throughout the peritoneal cavity by intraperitoneal fluid, and must evade
immune surveillance. Upon reaching the secondary site, the tumor cells encounter a
7

unique cell type of the ovarian microenvironment—a continuous mesothelial cell
monolayer that covers the surfaces within the peritoneal cavity(Figure 1.3). This
protective monolayer is the first contact site for ovarian cancer cells that have
disseminated from their site of origin. It is thought to act as barrier to ovarian tumor
metastasis, as mesothelial cells markedly inhibit the initial attachment of ovarian cancer
cells31.
The tumor cells therefore must adopt mechanisms to attach to the mesothelial
cells covering the peritoneal and pleural organs, then clear the mesothelial layer to
invade through the underlying basement membrane and extracellular matrix (ECM) to
form metastatic implants(Figure 1.3)32. This involves both adhesion to, and remodeling
of, the surrounding ECM by the ovarian cancer cell for efficient metastasis to occur33,34.
The mesothelial cells themselves secrete the ECM protein fibronectin, and ovarian
tumor cells have been shown to adhere to and remodel this fibronectin network to
invade within the peritoneal cavity34,35. Further, once the mesothelial cells are cleared,
and underlying basement membrane is breached, ovarian tumor cells reach a thick
network of collagen I fibers that are entwined with stromal fibroblasts(Figure 1.3). Both
of these microenvironment components have shown to be important for ovarian cancer
progression and invasion. Collagen I is a strong adhesive substrate for ovarian tumor
cells31,36 and has been shown to be upregulated in ovarian metastatic lesions. Stromal
fibroblasts have been shown to enhance the invasiveness of ovarian cancer cells, via
both direct contact and secreted factors31. Additionally, activated fibroblasts secrete and
remodel ECM within the microenvironment, with this desmoplastic stroma providing a
feed forward loop to invading tumor cells37. Identifying cellular and molecular targets

8

important for one or more of these steps of metastasis could have tremendous clinical
impact by enabling the development of therapeutics that block these critical steps.
Epithelial-to-Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is the transdifferentiation of epithelial
cells into motile, mesenchymal cells. This process is integral to development, and the
program is reactivated in pathologic states such as wound healing, fibrosis, and cancer
progression38. This switch in cell differentiation is initiated by a number of diverse
signals, which tend to be cell type or tissue type specific. Major developmental
signaling pathways, such as TGF-β, Wnt, Notch and growth factor receptor signaling
have been implicated in EMT. Additionally, inflammatory cytokines and hypoxia in the
tumor microenvironment have been shown to promote EMT39.
Regardless of the signal, these effector pathways converge on three core groups of
transcriptional regulators that are regarded as the master regulators of EMT. The first
group is the Snail zinc finger family (Snail1 and Snail2), which directly bind to the Eboxes of target epithelial genes to repress their expression. The second group is the
zinc finger E-box binding homeobox family of proteins (Zeb1 and Zeb2). These proteins
often recruit a C-terminal binding protein co-repressor to exert their action. The third
group is the basic helix-loop-helix family of transcription factors (Twist1, Twist2, and
E12/E47)38,39. The end result of expression of these master EMT regulators is the
repression of epithelial genes (i.e. E-Cadherin, occludin), and the activation of
mesenchymal gene expression (i.e. N-cadherin, vimentin, fibronectin, CD4440. The end
product of these transcriptional changes results in the dissolution of cell-cell junctions,
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loss of apical-basal polarity, reorganization of the cytoskeleton, and increased cell
protrusions and motility(Figure 1.4)38.
In breast cancer, a cooperation of the various EMT transcription factors to induce
and sustain EMT is critical for metastasis. For example, it has been shown that SNAIL1
is required for EMT initiation, while TWIST1 is required to maintain EMT in those cells41.
Deletion of SNAIL1 in mouse models of breast cancer (MMTV-PyMT) in both early and
late stages of primary tumor development led to a decrease in lung metastasis42. There
is strong clinical and experimental evidence supporting a role for SNAIL1 in breast
cancer metastasis43-45. SNAIL1 protein has a very short half-life and when cytosolic is
rapidly degraded by the ubiquitin-proteasome system. While EMT-stimulating signals
are able to induce SNAIL1 transcription, other modes of post-transcriptional and posttranslational regulation influence SNAIL1 stability and subcellular localization, which is
critical for its capacity to sustain cancer EMT46-48. In tumor samples, expression of
SNAIL1 protein and mRNA are discordant; SNAIL1 mRNA is present in most cells
within the tumor, but SNAIL1 protein is only detected in tumor cells at the tumor/ECM
boundary and in mesenchymal cells within the tumor associated stroma49. This
suggests that SNAIL1 protein levels are regulated post-transcriptionally by a uniquely
localized signal. A human kinome/phosphatome RNAi screen identified the receptor
tyrosine kinase (RTK) Discoidin Domain Receptor 2 (DDR2) as an indirect posttranscriptional regulator of SNAIL1 protein levels48, indicating that upstream regulation
of these transcription factors plays a critical role in maintaining their expression in cells.
In ovary, studies have suggested that ovarian surface epithelium can undergo
epithelial-to-mesenchymal transition (EMT) in response to regenerative stimuli (such as
10

ovulatory rupture) in order to repair the surface after ovulation51. While under normal
conditions EMT likely confers advantages during postovulatory repair, the ability of
ovarian cancer cells to adopt a mesenchymal gene program has been shown to
promote ovarian cancer metastasis52. Induction of epithelial-to-mesenchymal transition
(EMT) in ovarian cancer cells through expression of EMT transcription factors TWIST1,
SNAIL1, or ZEB1 promotes mesothelial cell clearance52. These factors also promote the
ability of an ovarian cancer cell to invade the basement membrane and extracellular
matrix, and form metastatic implants53,54. While these EMT transcription factors induce a
mesenchymal program crucial for ovarian cancer metastasis, the specific proteins
whose expression is regulated during EMT that functionally mediate mesothelial cell
attachment, clearance, and tumor cell invasion are not fully appreciated.
EMT is appreciated to be critical for localized carcinoma to gain invasive
potential, thus giving rise to metastatic tumor cells44. EMT in a tumor cell bestows the
cell with the ability to invade through the basement membrane and migrate along the
extracellular matrix network43,44. Furthermore, in the context of cancer, many cells
express both epithelial and mesenchymal markers, concurrently. This is likely a
reflection of EMT not existing as a binary switch, but rather, a continuum along which
the cancer cell progresses in either direction depending on the various cues within its
surrounding environment(Figure 1.4)39,55. Additionally, while EMT seems to facilitate the
metastatic dissemination of tumor cells, to establish a metastatic colony, the
disseminated cell must again become epithelial in nature and proliferate. This requires
the notion is EMT is itself transient in nature, and the cancer cells undergo a
mesenchymal-to-epithelial transition when they reach the secondary site (Figure 1.4)56.

11

Indeed, if SNAIL1 is continuously overexpressed in the primary breast tumors of MMTVNeuNT mice, there is decrease in lung metastasis despite an increase in dissemination
of tumor cells42, indicating that the cells must be able to revert upon reaching a
secondary site. This notion is also supported by recent in vivo, live imaging data
illustrating that cells undergoing EMT are the migratory cells within a tumor, and that
once arriving at the secondary site, cells convert to the epithelial state within one or two
divisions57. Further studies into the various cues that control these EMT and MET
switches, as well as EMT effector pathways that drive these behaviors may provide
insight into more effective approaches to treating or preventing metastatic disease.
Receptor tyrosine kinases in the cancer setting
Receptor tyrosine kinases (RTKs) are a diverse family of membrane spanning
proteins with intrinsic phosphotyrosine kinase activity. In humans there are 58 members
that can be divided into 20 different subfamilies. One canonical feature of all RTKs is
the presence of an extracellular ligand binding domain (Lemmon and Schlessinger,
2010). The ligands that activate these receptors are typically polypeptide growth factors
(i.e. IGF, EGFR, FGF, PDGF) or cytokines, with one distinct exception—the Discoidin
Domain Receptor family that utilizes collagen, a structural protein, as ligand (Vogel W,
1997, Shrivastava A, 1997). When these ligands bind to their cognate receptors, this
catalyzes phosphorylation of select tyrosine residues in target proteins, and this
modification is a pivotal component of cellular communication and signaling. The
phosphorylated tyrosine residues serve as docking sites for cytoplasmic signaling
proteins containing Src homology-2 and protein tyrosine binding domains, which then
assemble signaling complexes to activate a cascade of intracellular biochemical signals
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that define a response to a given external signal58. This signal transduction plays key
roles in cellular processes such as growth, differentiation, metabolism, and motility59.
RTKs exist in their active form as dimers, and ligand binding to the extracellular
domain either promotes this dimerization, or stabilizes the formation of an active dimer
conformation and subsequent activation60. Furthermore, studies have provided
evidence that receptor oligomerization increases the local concentration of RTKs,
leading to more efficient transphosphorylation of tyrosine residues in the active loop58,
or an increase in affinity to ligand61,62. It appears that activation of certain RTKs may be
dependent on the formation of larger oligomers59.
In addition to self-catalyzed phosphorylation in response to cognate ligand,
crosstalk between RTKs also exists at the receptor level. For instance, an RTK can
induce activation of a structurally unrelated RTK. This can occur by direct heterodimerization of the distinct RTKs, such as the case for c-Met/ErbB or EGFR/ErbB2.
Another mechanism is whereby a transactivation is mediated by a cytoplasmic tyrosine
kinase such as Src being activated by one receptor and then binding to and
phosphorylating a member of the heterodimeric pair, such as with IGF-1R and
EGFR63,64.
In addition to the functions of RTKs mediated by their kinase activity, evidence
suggests that a number of non-catalytic properties are also essential for their function.
These roles include acting as scaffolds for protein complexes, allosteric effects on other
enzymes, and DNA binding65. For example, EGFR has been shown to interact with and
stabilize the sodium/glucose cotransporter SGLT1. This stabilization occurs
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independent of EGFR kinase activity, and promotes glucose uptake into the cancer cell
to maintain intracellular glucose levels66. In the case of the ErbB4 receptor, cleavage
of its ectodomain leads to a C-terminal fragment that translocates to the nucleus to
affect the transcription of target genes. The C-terminal fragment of ErbB4 is able to
activate transcription by associating with YAP2 transcription factor, and this occurs even
when the fragment is lacking the kinase domain, suggesting this function may be
independent of kinase activity of ErbB465,67. In the developing neuron, EphB2 receptors
influence depotentiation and long term potentiation independent of kinase signaling68.
Therefore, the possibility of non-catalytic function of a given RTK must be taken into
consideration when evaluating its function.
Therapeutic targeting of RTKs
Given their critical roles in cell signaling, RTKs are well appreciated therapeutic
targets for the treatment of cancer (Gschwind et al., 2004). Cancer is hallmarked by
aberrant cell growth, evasion of apoptosis, and increased invasion, and many of these
signals are regulated by the activity of RTKs69. Oncogenic activation of RTKs is
achieved in numerous ways. This includes mutations within the extracellular domain of
the protein leading to constitutive activation, mutations within the kinase domain leading
to uncontrolled activation, aberrant overexpression of the receptor, or overexpression of
an RTK ligand58.
Most drugs targeting RTKs are of two classes—antibodies that block ligand
binding, receptor dimerization, or alter receptor internalization; or small molecule
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tyrosine kinase inhibitors (TKIs) that interact with the intracellular kinase domain of the
proteins70-73
A number of different strategies have been employed using monoclonal
antibodies (mAbs) to target RTKs. For example, mAbs such as cetuximab bind the
extracellular domain of the EGFR receptor and block dimerization that is necessary for
activation. There are also mAbs that bind to RTKs and orthosterically block ligand
binding, such as icrucumab for VEGFR1 or olaratumab for PDGFRa. Several IGF1R
antibodies have been developed that bind to the receptor and cause internalization,
thereby preventing binding to ligand. Ligand trapping, such as that achieved with the
anti-VEGF mAb bevacizumab, represents yet another strategy utilized to target RTK
signaling74. While efficacious in some settings, several therapeutic antibodies that bind
to receptors do not inhibit the activity of oncogenic RTKs that harbor activating
mutations in their kinase domains59.
As the ATP-binding site of RTKs is highly conserved, small molecule TKIs tend to
affect many tyrosine kinases in addition to their intended target. For example, Gleevec
(imatinib) which is used clinically to inhibit constitutive tyrosine kinase activation of a
Bcr-Abl fusion in chronic myeloid leukemia, was actually identified in the development of
PDGFR inhibitors59. While many of these drugs have shown success clinically, effective
and lasting use of traditional TKI strategies have been hampered by the emergence of
drug resistance73. This resistance is commonly achieved through the acquisition of
gatekeeper mutations that stabilize a “hydrophobic spine” characteristic of the active
state of several kinases75. Additionally, the growing body of literature demonstrating
kinase independent functions of RTKs suggest that the use of TKIs to inhibit these
15

receptors may be short-sighted, as non-catalytic functions of the receptors may prevent
the efficacy of such inhibition strategies.
Therefore, development of inhibitors of RTKs with alternative mechanisms of
action could be highly advantageous. Recently, a small molecule inhibitor targeting the
extracellular domain of the fibroblast growth factor receptor (FGFR) was
described(Bono et al., 2013, Herbert et al., 2013). This compound inhibits the signaling
linked to receptor internalization in an allosteric manner. Non-classical small molecule
inhibitors that disrupt protein complexes have been reported (He et al., 2005, Berg,
2003), but no such inhibitors have been identified for any RTK. These types of nonclassical or allosteric inhibitors remain an elusive goal for drug development as they
offer therapeutic advantages such as increased selectivity and safety(Christopoulos,
2002, Wenthur et al., 2014).
Discoidin Domain Receptors
The human discoidin domain receptors, DDR1 and DDR2, are members of the
receptor tyrosine kinase (RTK) family. DDR1 is present in epithelial cells, whereas
DDR2 is expressed primarily in mesenchymal cells. Unlike typical RTKs, the DDRs are
not activated by soluble growth factors. Rather, various forms of the extracellular matrix
protein collagen act as ligands for DDRs76,77. The DDRs are composed of an
extracellular region, a transmembrane domain, a cytosolic juxtamembrane domain, and
a C-terminal tyrosine kinase domain. The extracellular region consists of a collagen
binding discoidin (DS) domain, an accessory discoidin-like (DSL) domain, and a small
juxtamembrane domain (Figure 1.5)78. NMR79and X-ray80,81 crystallographic studies
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have revealed the three dimensional structure of the extracellular discoidin domain of
DDRs--a jelly roll motif82 where five loops comprise the top of the barrel, three of which
are involved in binding to fibrillar collagen83. These three loops form an ampiphillic
trench which accommodates the collagen triple helix and contains the central collagenbinding residues of DDR279,80. Collagen binding by this region within the DS domain
leads to slow and prolonged activation of the receptors, a unique feature of the DDRs76.
The DDRs are activated by collagen only when it is in its native, triple-helical form,
as heat denatured collagen fails to induce kinase activity84. Both DDR1 and DDR2 bind
to and are activated by fibrillar collagens, including collagens I-III and V, which are the
collagens common to the extracellular matrix (ECM) surrounding tumors. The two
receptors recognize a GVMGFO motif present in fibrillar collagens85. Notably, this is
distinct from the GFOGER motif within collagen that serves as the high affinity binding
site for collagen binding integrins the well-studied family of transmembrane collagen
receptors known to contribute to breast cancer metastasis85-87. Interestingly, while
DDR1 also binds to collagen IV, which is present in the basement membrane (BM) 76,77,
DDR2 does not bind and recognize this non-fibrillar collagen. This difference in
collagen IV recognition has been mapped to a small patch of non-conserved residues
near the binding pocket 88. At the cell surface, DDRs exist as dimers in the absence of
ligand84,89,90. How exactly ligand binding produces changes within these DDR dimers to
mediate activation of the receptor remains unknown. Given the prolonged activation
kinetics of this class of receptors it is likely that there is a unique mechanism at play.
Studies on DDR1 have illustrated that receptor oligomerization and internalization
occurs at timescales much shorter than receptor activation89, and DDR1 extracellular
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domain plays a crucial role in receptor oligomerization that mediates high affinity
interactions with collagen ligand61,62.
The cellular functions of the DDRs have gained increased attention in recent
years, and are still being explored91. Genetic deletion of DDR1 or DDR2 in mice causes
dwarfism92,93. In DDR2 mice this phenotype has been shown to be caused by a reduced
proliferation of chondrocytes93. This defect is manifested in humans with spondylometa-epiphyseal dysplasia (SMED-SL), a rare genetic condition caused by a mutation in
DDR2 that leads to short stature and limbs, and bone abnormalities94. While DDR1 null
mice exhibit defective mammary gland development92, no mammary glad phenotype
has been documented for DDR2. DDR2 null mice are infertile due to defects in
spermatogenesis and ovulation95. DDR2 is required for the migration of fibroblasts and
neutrophils in 3D matrices96,97, in part by regulating the activity of matrix
metalloproteinases (MMPs), a family of zinc-dependent proteases that degrade the
ECM. The DDRs play pivotal roles in regulating the expression and activity of several
MMPs, and aberrant activity of many MMPs have been shown to contribute to the
pathology of a number of diseases91.
DDR2 in cancer
Genomic analysis and histologic evaluation of human tumor samples reveal that
in a significant number of different human tumors expression of both DDR1 and DDR2
is either present or increased 98. DDR2 expression is associated with cancer
metastasis in a number of different human cancers types. These include breast50,99,100,
prostate 101, papillary thyroid 102, nasopharyngeal 103, hepatocellular104, lung squamous
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cell 105, and head and neck squamous cell106 carcinomas. In invasive breast cancer, for
example, over 70% of tumors, across all clinical subtypes expressed DDR2, while
normal breast epithelium does not express DDR2 (Figure 1.6)50 107. DDR2 expression
has also been detected in tumor associated stromal cells such as cancer associated
fibroblasts (CAFs)50, endothelial cells 108, and myeloid cells 96. This highlights a possible
cancer role for DDR2 in the tumor microenvironment as well as tumor cells. While
DDR2 expression in tumors is well documented, mutations in DDR2 are much less
common. In 3.8% of squamous cell lung carcinomas mutations in DDR2 were found and
these occurred throughout the entire coding region 109. Some mutations resulted in gainof-function phenotypes (proliferation) when expressed in cell lines. In the breast cancer
TCGA project, 5% of patients exhibited amplified expression of DDR2, for unclear
reasons, and these patients have decreased survival 50.
In multiple different tumor cell ex vivo cell-based studies DDR2 has been shown
to exhibit pro- and anti-proliferative effects, positively cell-ECM adhesion, and positively
influence tumor cell invasion and migration 98. DDR expression has been found to
correlate with both developmental and cancer EMT. During EMT induced by many
different environmental signals (e.g., TGF-B, hypoxia, collagen I) and in different
epithelial and tumor cell lines, DDR1 expression decreases and DDR2 expression
increases as cells become less epithelial and more mesenchymal in nature. A number
of cell-based studies have implicated DDRs as important regulators of cancer EMT. In
renal tubule epithelial cells and lung cancer cells RNAi-mediated deletion of DDR2
inhibited TGF-β-mediated EMT 110. Hypoxia induced EMT was inhibited in breast
cancer cell lines transduced with DDR2 shRNAi 100. Forcing cells to undergo EMT by
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overexpression of the EMT inducing factor SNAIL2 led to DDR switching from DDR1 in
parental MDCK cells, to DDR2 expression in SNAIL2-MDCK cells111. When breast
epithelial cell lines that do not express SNAIL1 are induced to undergo TGF-β-mediated
EMT, DDR1 levels decrease and DDR2 levels increase, but DDR2 expression was not
necessary for EMT induction 50.
In regards to breast cancer, the function of DDR2 in both the tumor 50,100 and
tumor stroma 99 has been shown to play a critical role in metastasis. While not
expressed in normal breast epithelium, DDR2 is expressed in the majority of human
invasive ductal carcinomas, and contributes to enhanced or sustained invasion and
migration of K14+ leader cells by maintaining the cellular levels and activity of the EMT
transcription factor SNAIL1(Figure 1.6)50,99. In the breast tumor stroma, the action of
DDR2 in cancer associated fibroblasts (CAFs) influences extracellular matrix (ECM)
synthesis and remodeling 99,112 leading to the production of a more invasive collagen
organization within tumors. Additionally, the action of DDR2 in CAFs influences the
collective invasiveness of surrounding breast tumor cells in a paracrine manner99.
DDR2 in other pathologic states
In addition to its role in cancer progression and metastasis, DDR2 also plays a
role in other pathologic states. Perhaps not surprisingly, most evidence for DDR2
related pathogenesis has been illustrated in the context of pro-fibrotic diseases.
DDRs and Arthritis
Osteoarthritis (OA) involves degeneration of articular cartilage. Injury results in
activation of MMP13 that degrades collagen II, the major collagen present in articular
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cartilage. Since collagen II is a ligand for DDR2 several studies have explored possible
roles for DDR2 in the pathogenesis of OA. DDR2 expression is increased in
chondrocytes of OA patients and mouse models of OA 113 114. Activation of DDR2 in
chondrocytes leads to MMP13 upregulation 114. Overexpression of DDR2 alone in
chondrocytes does not result in OA in normal mice, likely because normal articular
chondrocytes are not directly exposed to collagen II 115. However, injury can expose
chondrocytes to collagen II and the development of OA 115. Genetically reducing DDR2
levels in mouse genetic models and injury models of OA attenuates OA progression 116
117

.
Whether DDRs contributes to rheumatoid arthritis has not been experimentally

tested but DDR2 is highly expressed in synovial fibroblasts from patients with RA 118,119,
and may act as one of the stimulators of the over-expression of MMP-1 in RA synovial
fibroblasts120, and may also stimulate other pathways that contribute to RA
pathogenesis119.
DDRs and Fibrosis
In lung fibrosis, DDR2 has been shown to play a role in the induction of fibrosis
and angiogenesis. DDR2 null mice were shown to be refractory to bleomycin induced
lung fibrosis, and in vitro, DDR2 was shown to stimulate myofibroblastic changes in lung
fibroblasts121. For DDR2 there are conflicting reports about its role in liver fibrosis.
DDR2-/- mice exhibit increased liver inflammation and fibrosis in response to carbon
tetrachloride injury 122. But the same group has previously shown that DDR2 is
important for hepatic stellate cell activation – a profibrotic state 123. In rats, RNAi
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deletion of DDR2 in liver stellate cells protects against alcohol-induced liver injury and
fibrosis 124. Since Snail1 expression in liver hepatocytes has been shown to be
important for liver fibrosis in response to injury 125, and DDR2 stabilizes Snail1, this
suggests that a DDR2-Snail1 signaling pathway could be critical for pathologic fibrosis.
DDR2 Therapeutic targeting
As a major contributor to fibrotic diseases and cancer progression, this implies
that blocking the actions of DDR2 might represent a promising therapeutic strategy
(Figure 1.7). Thus far, identification of small molecule antagonists of DDR2 activity
have been limited to pharmacological agents directed against the kinase domain of
DDR2 126,127 or uncharacterized, low-potency inhibitors of DDR2-collagen binding128.
Antibodies that target the DS-like domain of DDR1 and inhibit activation have been
developed81, however no such antibodies have been reported for DDR2. While
progress has been made towards the development of traditional TKI agents for DDR2,
these compounds exhibit only a preference for DDR2 inhibition and still show significant
inhibitory profiles towards other kinases126,127,129. Furthermore, effective and lasting use
of traditional TKI strategies have been hampered by the emergence of drug resistance,
and acquired gatekeeper mutations in DDR2 treated with TKIs have already been
reported130.
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Summary and thesis objectives
The goal of this thesis was to address the role of DDR2 as a therapeutic target in
the setting of metastasis. In breast cancer, we asked whether DDR2 was a candidate
therapeutic target for metastasis by temporally depleting Ddr2 in early stage tumors in
MMTV-PyMT mice. We developed small molecule inhibitors of DDR2 that target the
extracellular domain of the receptor to inhibit ligand binding in a non-orthosteric manner.
These compounds actively inhibit DDR2 activation and downstream signaling in
response to collagen in both breast tumor cells and in vivo. We also elucidated a region
at the interface of the two DDR2 extracellular domains that is important for receptor
binding and activation. Furthermore, we have documented kinase independent
functions of the DDR2 receptor, and identified putative interacting partners of the protein
in breast cancer cells.

In ovarian cancer, we established DDR2 as critical for

metastasis. Additionally, we detailed a pathway whereby DDR2 expression is regulated
in invasive tumor cells. Upon induction of EMT, the EMT transcription factor TWIST1
drives the expression of DDR2, which in turn stabilizes the transcription factor SNAIL1
to sustain EMT. DDR2 in ovarian cells drives the cleavage and remodeling of
fibronectin, which promotes mesothelial cell clearance by the cancer cell.
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Figure 1.1: Breast cancer progression and the metastatic cascade
Breast cancer is initiated by the accumulation of genetic mutations in the epithelial cells
of the mammary gland. Invasive cells must breach the basement membrane and
traverse the microenvironment to reach the vasculature. This microenvironment is also
changed in the context of malignancy, and fibroblasts become activated, immune cells
infltrate, and the extracellular matrix is remodeled. After migrating through this altered
environment, cells intravasate into the blood stream, survive in the circulation,
extravasate at the metastatic site, and reinitiate proliferative programs to form
detectable metastasis. Adapted from Reyymond, Borda d’Agua, and Ridley 2013.
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Figure 1.2: The breast tumor microenvironment
During tumor development, mammary epithellial cells begin to divide uncontrollably and
lose polarity. Tumor angiogenesis increases the bloodflow to the malignant cells.
Fibroblasts within the stroma become activated, and secrete increased amounts of
extracelllular matrix proteins and remodel the existing matrix, leading to a more fibrotic
environment. Adipocytes secrete growth factors, resisdent immune cells become
activated, and non-resident immune cells infiltrate into the tumor and surrounding
tissue. Adapted from Pattabiraman and Weinberg 2014.

25

matrix proteins

Fibroblasts

Figure1.3: Ovarian cancer metastasis
Ovarian cells undergo transcoelomic metastasis, where they are transported throughout
the peritoneal cavity. Potential secondary sites of metastasis are covered in a
monolayer of mesothelial cells, a barrier the ovarian cancer cell must clear before
reaching the stroma of the secondary site to establish metastasis. Adapted from
Masoumi Moghaddam et al. 2011.
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Figure 1.4: epithelial-mesenchymal transition—cell plasticity between states
Features of epithelial and mesenchymal cells, and signals that initiate EMT and MET.
Epithelial cells are polarized and adhere tightly to one another. As epithelial cell
proliferated , EMT contributes to a loss of polarity and detachment of cells to one
another. These elongated mesenchymal cells have invasive properties that promote
migration out of the primary tumor, through the stroma, and into the bloodstream. Once
reaching the secondary site, the cell must undergo the reverse process, MET, to reestablish growth and form macrometastasis. Adapted from Martin et al. 2012.
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Figure 1.5: Domain structure of the discoidin domain receptors
The discodin domain recepotrs are type I transmembrane receptor proteins that contain
a discoidin (DS) ligand binding domain, a discodin-like domain (DS-like), an
extracellular juxtamembrane regoin, transmembrane domain, intracellular
juxtamembrane domain, and intracellular kinase domain. Amino acid residue numbers
delineating these domains are pictured, as well as N- and O- glycosylation sites.
Adapted from Fu et al. 2013.
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Figure 1.6: DDR2 is expressed in human invasive ductal carcinomas, but not in
normal mammary epithelia
Immunohistochemical staining of DDR2 in human invasive ductal carcinoma or cancer
associated normal breast tissue. Both epithelial tumor cells and adjacent stromal
fibroblasts show DDR2 expression in the invasive ductal carcinoma. Adapted from
Zhang et al. 2013.
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Figure 1.7: Therapeutic targeting of DDR2
Diagram depicting of DDR2 expression/activation can be targeted therapeutically. This
includes targeting of the extracellular domain to inhibit collagen binding, inhibiting
activation with antibodies, and traditional tyrosine kinase inhibitors. Adapted from Borza
and Pozzi 2014.
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Introduction
With advances in the management of local breast cancers, metastatic spread is
now responsible for greater than 90% of breast cancer-related deaths. Crosstalk
between tumor cells and their surrounding cellular, chemical, and physical
microenvironment is now appreciated to influence breast tumor development,
progression, metastasis, and response to treatment1,2. In breast tumors, these stromal
components differ from their normal tissue counterparts in composition, architecture,
and function. Therefore, a proposed reason for the limited success of current therapies
in the metastatic setting is the lack of modulating both tumor cells and the tumor
microenvironment3.
Collagen fibers are the most abundant protein within the extracellular matrix
(ECM) of breast tumor stroma and play key roles in breast cancer development and
progression4. Increased collagen deposition contributes to breast density and women
with dense breasts have an increased risk for developing aggressive breast cancers5.
Excessive collagen deposition, altered collagen fiber organization, and the resulting
alterations in mechanical properties of the breast tumor stroma are all correlated with
more aggressive disease and poor outcome6.
Receptor Tyrosine Kinases (RTKs) are well appreciated therapeutic targets for
the treatment of cancer7. A defining feature of all RTKs is the presence of an
extracellular ligand binding domain8. The ligands that activate these receptors are
typically polypeptide growth factors or cytokines, with one distinct exception - the
Discoidin Domain Receptor family. Their ligand is fibrillar collagen, a structural
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protein9,10. Recent human clinical data and preclinical mouse genetic models have
established Discoidin Domain Receptor 2 (DDR2) as a potential therapeutic target for
the treatment of cancer metastasis. DDR2 expression is associated with cancer
metastasis in a number of different human cancers types including: breast11-14,
prostate15, papillary thyroid16, nasopharyngeal17, hepatocellular18, lung squamous cell19,
and head and neck squamous cell20 carcinomas. In regards to breast cancer, the
function of DDR2 in both tumor cells11,13 and tumor stroma cells14 has been shown to
play a role in metastasis.
While not expressed in normal breast epithelium, DDR2 expression is induced in
the majority of human invasive ductal carcinomas. In breast tumor cells the action of
DDR2 sustains their invasive and migratory capacity by maintaining the cellular level
and activity of SNAIL1, an epithelial mesenchymal transition (EMT) inducer important
for breast cancer metastasis 11,21-23. In the breast tumor stroma, the action of DDR2 in
cancer associated fibroblasts (CAFs) influences extracellular matrix (ECM) synthesis
and remodeling14,24 leading to a more pro-invasive collagen organization14. DDR2 action
in CAFs also influences the invasiveness of breast tumor cells, through a paracrine
function 14. Together, these data suggest that DDR2 could be an important target for the
development of inhibitors capable of modulating both the tumor cell and
microenvironment, concurrently.
Most drugs targeting RTKs are of two classes. The first are receptor antibodies
that block ligand binding, receptor dimerization, or alter receptor internalization25,26.
Second, small molecule tyrosine kinase inhibitors (TKIs) that interact with the
intracellular kinase domain have been developed 27,28. While TKIs inhibiting DDR2 have
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been identified, these compounds exhibit only a preference for DDR2 inhibition and
show significant inhibitory profiles towards other kinases29,30. Effective and lasting use
of traditional TKI strategies have also been hampered by the emergence of drug
resistance28. Indeed, acquired gatekeeper mutations in DDR2 treated with TKIs have
already been reported31. Therefore, development of inhibitors of DDR2 with alternative
mechanisms of action could be highly advantageous.
Although allosteric modulators for ligand-gated ion channels and G proteincoupled receptors have been identified, only recently has a small molecule allosteric
regulator that targets the extracellular domain of an RTK been described32,33. Nonclassical small molecule inhibitors that disrupt protein complexes have been
reported34,35, but no such inhibitors exist for RTKs. Allosteric or non-classical small
molecule inhibitors of RTKs offer significant therapeutic advantages, such as increased
selectivity and safety36,37. Here we describe the identification and characterization of an
extracellularly acting small molecule inhibitor of DDR2 that functions in an allosteric
manner to disrupt DDR2 receptor-collagen ligand interaction.
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Results
Identification of a selective, small molecule inhibitor of DDR2 binding to collagen
I and receptor activation by collagen I
In a high-throughput in vitro screen for inhibitors of DDR2 binding to type I
collagen, the natural antibiotic Actinomycin D was identified as a weak inhibitor38. We
confirmed this (Figure 2.1A). Due to its low potency and high toxicity profile39,
Actinomycin D would not be considered a clinically suitable inhibitor of DDR2.
Therefore, we asked whether deconstruction of Actinomycin D to various component
chemical scaffolds might identify the active portion, allowing for further derivatization to
develop lower toxicity, higher potency inhibitors.
To do so, we adapted a DDR2 binding assay40. Dimeric DDR2 extracellular
domain, consisting of the discoidin (DS) and discoidin-like (DSL) domain with a Cterminal myc and his tag (DDR2- his), was shown to bind a DDR2-selective collagen II
triple helical peptide with high affinity41,42 (Figure 2.1B). We then tested compounds that
contained elements of structural overlap with Actinomycin D and found that the scaffold
7-hydroxy-phenoxazin-3-one inhibited DDR2 binding with an IC50 of 16µM (Figures 2.1A
and 2.3A). Medicinal chemistry based optimization was performed to generate a library
of lead compounds (Figure 2.2) with higher inhibitory activity towards DDR2-ligand
binding (Figure 2.3A). One of these, WRG-28 (Figures 2.2 and 2.3B), showed moderate
potency as an antagonist of DDR2-ligand binding (IC50 230±75nM) (Figures 2.1A and
2.3A) and was chosen for further study. We further confirmed that WRG-28 was not
irreversibly modifying DDR2 by incubating recombinant DDR2-his protein with WRG-28,
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followed 2 rounds of dialysis, and then the dialyzed protein was subjected to binding in
the in vitro assay. After dialysis to remove the compound, the protein was once again
able to bind collagen, indicating an irreversible mechanism was not at play(Figure
2.3C). Further, to rule out a redox based mechanism of action, we preformed the in
vitro binding assay in the presence of 1mM glutathione as a redox trap. The presence
of glutathione did not substantially affect the inhibitory ability of WRG-28 (Figure 2.3D),
suggesting that a redox mediated mechanism of action is not likely.
WRG-28 also blunted collagen I-mediated DDR2 activation (tyrosine
phosphorylation) in HEK293 cells expressing DDR2 (HEK-DDR2) (Figure 2.4A).
Activation of DDR2 by collagen I can lead to increased SNAIL1 protein level in cells via
an ERK2 mediated pathway11. When HEK-DDR2 cells were stimulated with collagen I,
phospho-ERK2 levels increased, and treatment with 1µM WRG-28 inhibited
phosphorylation of ERK2 and reduced SNAIL1 protein level (Figure 2.4B). WRG-28 was
not nonspecifically toxic to cells, as treatment (1µM) of non-DDR2 expressing, normal
mammary epithelial MCF10A cells did not affect their proliferation or survival (Figure
2.4C).
To determine if the inhibitory activity of WRG-28 was selective for DDR2, we
asked whether it inhibited collagen mediated activation of the homologous family
member DDR1. DDR1 tyrosine phosphorylation in HEK293 cells expressing DDR1 was
unaffected by the presence of WRG-28 (Figure 2.4D). Furthermore, using biolayer
interferometry (BLI) when biotinylated DDR2 or DDR1 was immobilized on a
streptavidin-coated BLI pin, dose dependent association of WRG-28 was seen for
DDR2, but not DDR1 (Figure 2.5A-C). Additionally, in an analogous solid phase binding
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assay as that used for DDR2, WRG-28 did not inhibit the unrelated collagen I receptor
α1β1 integrin extracellular domain from binding to its high affinity collagen I triple helical
peptide43 (Figure 2.5D). WRG-28 treatment did not affect phosphorylation of other
unrelated RTKs, as determined by a PathScan RTK signaling array (Figure 2.6A).
In summary, in in vitro binding and cell-based assays WRG-28 appeared to be a
potent and selective small molecule inhibitor of DDR2 extracellular domain binding to
collagen I, and inhibited collagen I mediated DDR2 activation in cells.

WRG-28 inhibits DDR2-Collagen I interaction in an allosteric manner
Since no extracellular domain inhibitors of DDR2 have been described, we
sought to determine the mode of inhibition of WRG-28. First, we asked whether a
classical competitive mechanism was utilized. Using a fluorescein conjugated analog of
the collagen II binding peptide for DDR2, we confirmed that when increasing amounts of
collagen II peptide were added to plates, increased peptide was adsorbed onto the
plates (Figure 2.7A). In the range of substrate concentrations examined, linear
adsorption of the DDR2 binding collagen II peptide was observed, and was not reduced
upon washing (Figure 2.7A). Fluorescein conjugation did not alter DDR2 binding to
collagen II peptide (Figure 2.7B). Using the amount of collagen II peptide plated as a
measure of available ligand, the availability of increasing concentration of collagen II
peptide did not outcompete the inhibitory effects of WRG-28 (Figure 2.7C). This result
suggested that WRG-28 was likely not acting as a strong orthosteric inhibitor of collagen
binding.
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Next, we asked whether WRG-28 could displace DDR2 from pre-bound DDR2collagen II peptide ligand complex. After allowing the receptor-ligand complex to reach
equilibrium, the complex was treated with buffer containing WRG-28 or control DMSO.
In the absence of inhibitor there was very little dissociation of DDR2 over the 90 minutes
assayed (Figure 2.7D). However, in the presence of WRG-28, there was a dramatic
acceleration of DDR2 dissociation in a dose dependent manner (Figure 2.7D).
Previous reports using similar solid phase assays showed that for DDR2 to bind
collagen it must exist as at least a dimer40 or possibly higher order multimers44.
Therefore, we asked whether WRG-28 effects on DDR2 ligand binding and signaling
resulted from an impairment or disruption of receptor dimerization or multimerization. To
do so, we made use of a DDR2 extracellular domain protein where dimerization is
covalently fused by the addition of an Fc tag to the C-terminus of the DS-like domain
(DDR2-Fc)45. In the solid phase binding assay, the ability of WRG-28 to inhibit DDR2-Fc
binding to collagen II peptide was dramatically reduced (Figure 2.7E), suggesting that
inhibition by WRG-28 could be due to DDR2 dimer or multimer disruption.
To further test this possibility, we analyzed the organization of the DDR2
extracellular domain in the presence or absence of WRG-28 by size exclusion
chromatography. Consistent with previous reports, in solution ~20% of the DDR2
extracellular domain (DS-DSL) eluted as an oligomer, while the majority existed as
dimers, with very little monomer present (Figure 2.8A). To assign peaks, elution
fractions were concentrated, run on a native gel, and compared to the DDR2 protein
solution added to the column (Figue 2.8B). When the DDR2 protein solution was treated
with 1µM of WRG-28, the oligomer fraction was significantly reduced(Figures 2.8A and
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2.8C). There also appeared to be an increase in the monomeric state, however as the
monomer often appeared as a shoulder of the dimer peak and was not well resolved, it
could not be accurately quantified (Figure 2.8E). Additionally, the DDR2 oligomeric and
dimeric peaks were collected, protein concentration normalized, and subjected to in
vitro binding analysis using the solid phase assay (Figure 2.8D). In this assay, the
oligomeric species bound to the collagen II peptide with nearly three fold affinity,
illustrating the functional relevance of this higher order species.
In another approach, we performed chemical cross-linking experiments of
HEK293-DDR2 cells with the membrane-impermeable cross-linker BS3. Consistent with
previous reports, full length DDR2 existed as dimers on the cell surface in the absence
of collagen (Figure 2.8F) 46. When HEK293-DDR2 cells were treated with WRG-28, we
did not detect significant disruption of cell surface DDR2 dimerization (Figure 2.8F). This
could be due to the fact that in cells DDR dimerization is strongly influenced by the
transmembrane domain46. While inhibition of extracellular domain clustering by WRG-28
appeared to be sufficient to blunt receptor activation (Figure 2.4A), WRG-28 was not
capable of complete disruption of full-length, cell surface dimers.
In sum, these results were consistent with non-active site receptor modulation by
WRG-28 as contributing to its inhibitory action on the DDR2-collagen interaction. This is
consistent with allosteric regulation of DDR2 activity by WRG-28, potentially due to
impairment in clustering of the extracellular domain.
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Identification of DS-DSL domain interface residues required for DDR2-collagen
binding and signaling
The extracellular portion of the DDR proteins consists of 3 domains—the Nterminal collagen binding discoidin (DS) domain, a DDR unique discoidin-like (DSL)
domain, and a short membrane proximal juxtamembrane domain. The collagen binding
motif is in the DS domain and highly conserved between DDR1 and DDR247. To gain
further insight into the structural determinants of DDR2 inhibition by WRG-28, we
employed in silico modeling. SWISS-MODEL48-50 was used to construct a homology
model of the three-dimensional structure of the DDR2 extracellular domain, using the
existing crystal structure of the DDR1 extracellular domain. This structure and the
resulting model contain the DS and DS-like domains but lack the juxtamembrane
domain (PDB: 4AG4)51. In order to identify putative WRG-28 binding sites, in silico
docking analysis with AutoDock Vina52 was performed against the homology model of
the DDR2. Of the top 9 WRG-28 binding solutions to arise from these studies, 5 low
energy conformations clustered around a similar site located at the DS-DSL domains
interface region (Figure 2.9A-D). Such interface binding can be a common mode of
action of allosteric inhibitors53,54, as conformational changes along interfaces are often
needed for proper receptor function55.
In the lowest energy configuration, several key interactions were suggested
(Figure 2.9D). These included polar contacts with Arg135, Glu247, Thr98, and
hydrophobic interactions with Phe96, Trp187. Residues within the interdomain region
have been shown to make important interdomain contacts in the crystallized structure of
DDR151. WRG-28 did not show inhibitory activity against the highly homologous family
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member DDR1, despite 53% sequence identity shared between the extracellular
domains of the two proteins. Among the interface region, two key potential interacting
residues, Phe96 and Thr98, are not conserved between DDR2 and DDR1 (DDR1:
Leu96 and Ala98, respectively). Assuming similar modes of activation between DDR2
and DDR1 this divergence could correspond to functional importance for WRG-28
action against DDR2.
Single F96A or T98A point mutations in DDR2 showed no appreciable effect on
DDR2 binding to collagen in vitro, phosphorylation in cells, or inhibition by WRG-28
(Figures 2.10A-C). However, when we produced the extracellular domain of a
DDR2F96A/T98A double mutant as a recombinant protein, it no longer bound to the
collagen II peptide at concentrations of peptide where binding was saturated for the wild
type DDR2 receptor (Figure 2.10D). Interestingly, when DDR2F96A/T98A was analyzed by
size exclusion chromatography it existed only as a dimer fraction with virtually no higher
order oligomers in solution (Figure 2.10E). This further suggested that receptor
clustering may be important for receptor binding to collagen ligand in solid phase
assays. DDR2F96A/T98A expressed as a full length receptor in HEK293 cells was present
at the cell surface and dimerized (Figures 2.10G and 2.10H). However, collagen
mediated DDR2F96A/T98A receptor activation in cells was dramatically reduced compared
to wild type receptor (Figure 2.10F).
As these two residues are not conserved between DDR1 and DDR2, and the
inhibitory action of WRG-28 is selective for DDR2, we asked whether we could confer
inhibition by WRG-28 on DDR1 by replacing Leu96 and Ala98 residues in DDR1 with
the key interacting residues of the DDR2 counterpart (Phe and Thr, respectively). When
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a DDR1L96F/A98T mutant was expressed in HEK293 cells and subjected to treatment with
WRG-28, unlike wild type DDR1 (2.4D), DDR1L96F/A98T exhibited diminished
phosphorylation in response to collagen in the presence of WRG-28 (Figure 2.10I).
Mutants made within an alternative, lower probability WRG-28 binding site (Site
3, Figure 2.9A) within DDR2 did not affect collagen II peptide binding, collagen-induced
receptor phosphorylation, or WRG-28 inhibitory activity (Figures 2.11A-E).
In sum, these modeling studies coupled with in vitro and cell based experiments
of putative WRG-28 interacting receptor mutants, suggested that Phe96 and Thr98
residues in DDR2 are critical for sustained receptor interaction with collagen in vitro,
and receptor activation in cells. Moreover, by introducing these two residues into DDR1,
they appeared, in part, to be responsible for directing WRG-28 inhibition of DDR2.

WRG-28 inhibition of DDR2 blunts tumor cell invasion and migration
Previous genetic studies in cell lines and in vivo have shown that the action of
DDR2 in breast tumor cells is critical for invasion and migration, without affecting tumor
proliferation 11,13,14. Treatment of BT549 human breast cancer cells (endogenous DDR2
expression) with WRG-28 inhibited their invasion/migration in 3D collagen I matrices to
an extent comparable to BT549 cells RNAi-depleted of DDR2 (Figure 2.12A and 2.12B).
Treatment of BT549 cells with WRG-28 did not affect their proliferation (Figure 2.12C).
WRG-28 also inhibited invasion of BT549 human breast cancer cells and 4T1 murine
breast cancer cells through Matrigel (Figure 2.12D-F) to an extent comparable to that of
DDR2 RNAi-depletion controls. In BT549 cells and 4T1 murine breast cancer cells,
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WRG-28 treatment also inhibited SNAIL1 protein stabilization in response to exposure
to collagen (Figure 2.13A and 2.13B

WRG-28 shows efficacy against DDR2 gatekeeper mutations
One of the most common setbacks to canonical TKIs is the eventual
development of resistance mutations28. Within the RTK family, gatekeeper mutations
are a common mode of resistance, and these have been documented in DDR2 as
well31. To test whether WRG-28 maintained efficacy against DDR2 gatekeeper
mutations, a DDR2 mutant containing a T654I mutation (documented gatekeeper
mutation in DDR231) was expressed in HEK293 cells. Consistent with conferring its
inhibitory action via the extracellular domain, WRG-28 inhibited phosphorylation of the
DDR2T654I mutant in response to collagen I (Figure 2.13C. This result suggested the
potential utility of WRG-28 as an alternative to kinase directed inhibition or in cases
where resistance to TKIs have been acquired through gatekeeper mutations to DDR2.

Targeting DDR2 with WRG-28 blocks tumor promoting effects of the
microenvironment
In addition to tumor cell intrinsic prometastic roles, the action of DDR2 in tumor
stromal cells also plays an important role in regulation of metastasis14. In particular, the
action of DDR2 in cancer associated fibroblasts (CAFs) influences their tumor
promoting function by regulating tumor ECM production and remodeling, as well as
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mediating paracrine signals that enhance the collective invasiveness of tumor cells14. To
assess the ability of WRG-28 to modulate such CAF effects, primary MMTV-PyMT;
Ddr2+/+; ROSA-LSL-TdTomato or MMTV-PyMT; Ddr2-/-; ROSA-LSL-TdTomato breast
mouse tumor organoids were plated in a 3D collagen I matrix with mouse CAFs derived
from MMTV-PyMT; Ddr2+/+ or MMTV-PyMT; Ddr2-/- breast tumors, in the presence or
absence of WRG-28 and the number of invasive organoids scored. Treatment of Ddr2+/+
tumor organoids alone with WRG-28 reduced the number of invasive tumor organoids
to a level comparable to that seen with Ddr2-/- tumor organoids (Figure 6.14A-E,
quantified in 6.14F). Addition of Ddr2+/+ CAFs to Ddr2+/+ tumor organoids increased the
number of invasive organoids present, as anticipated14 (Figure 6.14A-E, quantified in
6.14F). WRG-28 treatment potently reduced the number of invasive tumor organoids, to
a level equivalent to that observed when Ddr2-/- breast tumor organoids and Ddr2-/CAFs were co-cultured (Figure6.14A-E, quantified in 6.14F). Expression of Tomato was
used to confirm that invasive foci were composed of invading tumor cells and not CAFs
that had migrated to the tumors (Figure 6.14G). PI/annexin V staining confirmed that the
reduction in invasion was not due to toxic effects of WRG-28 (Figure 6.14H and 6.14I).
These data indicated that not only did WRG-28 inhibit 3D collagen tumor organoid
invasion but also the activity of DDR2 in CAFs to support invasion of tumor organoids.
Thus, WRG-28 inhibited DDR2 action in both breast tumor cells as well as breast tumor
stroma CAFs, in these culture systems.
Additionally, DDR2 has been reported to promote the migratory ability of
fibroblasts56,57. We therefore tested the ability of the developed inhibitor to influence
migration of normal mouse fibroblasts, or mouse tumor derived CAFs in a scratch
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wound assay. WRG-28 showed inhibitory effect on the migratory ability of these
fibroblasts at 24 hours (Figure 6.14J), indicating that inhibition of DDR2 dependent
migratory effects in fibroblasts could also be attenuated with the compound.

Validation of DDR2 as a therapeutic target to prevent breast cancer metastasis
Ubiquitous deletion of Ddr2 or select deletion of Ddr2 in K14 basal epithelial cells
in the MMTV-PyMT mouse model of metastatic breast cancer significantly blunts the
extent of lung metastases14. While these genetic studies establish the importance of
DDR2 in facilitating breast cancer metastasis, Ddr2 was deleted from birth or shortly
thereafter in such models. Therefore, the potential to target DDR2 therapeutically after
cancer has developed to inhibit or treat metastatic disease was still unknown. To
determine whether DDR2 could serve as a therapeutic target for the treatment of
metastasis, we made use of a mouse model of metastatic breast cancer where genetic
deletion of Ddr2 could be temporally controlled. Mice containing a conditional Ddr2fl/fl
allele14 were crossed to mice containing the ROSA-CreERT2 allele to allow for temporal
deletion of Ddr2fl/fl upon treatment with tamoxifen.
To confirm efficient Cre expression following tamoxifen administration,
experimental Ddr2fl/fl; ROSA-CreERT2; ROSA-LSL-TdTomato; MMTV-PyMT and control
Ddr2+/+; ROSA-CreERT2; ROSA-LSL-TdTomato; MMTV-PyMT mice were allowed to
develop primary breast tumors. In the MMTV-PyMT model, malignant transition occurs
between 8 to 12 weeks of age, with evidence for stromal invasion by tumor cells and a
reactive stroma58. Histologic examination of lungs at this stage showed no evidence for
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metastases (data not shown). At 8 weeks of age, mice were administered tamoxifensupplemented dry feed for 2 weeks. Tomato fluorescence in tissues was used to
document Cre activity. In mice not treated with tamoxifen, minimal tomato fluorescence
was detected (Figure 2.15A). In mice treated with tamoxifen, the majority of cells in the
breast and lung showed Tomato fluorescence, confirming ubiquitous and efficient
induction of Cre activity under these treatment conditions (Figure 2.15A). In
experimental mice deletion of Ddr2 in the tumor was confirmed by PCR (Figure 2.15B).
In experimental and control mice there was no difference in latency of primary tumor
formation (time to reach maximum size (2cm)) (Figure 2.15C), or total primary tumor
burden per mouse (Figure 2.15D). However, there was a significant reduction in the
number of lung metastases in mice where Ddr2 was deleted during cancer progression
(Figures 2.15E and 2.15F). These genetic data supported therapeutic targeting of DDR2
in the setting of early stage breast cancer to prevent metastasis.

WRG-28 inhibits DDR2 signaling in vivo
Finally, we asked whether WRG-28 inhibited DDR2 action in breast tumors, in
vivo. Since DDR2 activation by collagen leads to increased SNAIL1 protein level in
breast tumor cells11, we made use of breast tumor cells that contain a SNAIL1-clic
beetle green (SNAIL1.CBG) bioluminescent fusion protein that serves as a surrogate
bioluminescent reporter of SNAIL1 protein level59. 4T1 mouse breast tumor cells stably
expressing SNAIL1.CBG were surgically implanted into the breast tissue of syngeneic
BALB/cJ mice and 1cm tumors allowed to form. Bioluminescence imaging of mice was
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conducted at baseline, and then mice were given a single IV administration of WRG-28
(10mg/kg), and imaged 4 hours later. Compared to control mice (implanted with 4T1SNAIL1.CBG cells and treated with saline) mice treated with WRG-28 exhibited, on
average, a 60% reduction in SNAIL1.CBG level within the tumor as compared to
pretreatment levels (Figures 2.16A and 2.16B). These data indicated that IV
administration of WRG-28 attenuated biochemical signaling of DDR2 in breast tumors in
vivo.

WRG-28 administration reduces metastatic lung colonization of breast tumor
cells
To determine whether WRG-28 has the potential to inhibit metastasis in vivo, we
employed an experimental metastasis model. DDR2-expressing 4T1 mouse breast
tumor cells expressing GFP/luciferase (4T1 GFP/luc) were injected into syngeneic
BALB/cJ mice via tail vein, and metastatic colonization and growth within the lung was
followed by bioluminescence imaging and confirmed histologically. Genetic depletion
(shRNAi) of DDR2 in 4T1 cells significantly reduced lung metastatic colonization in this
model (Figures 2.17A,B and 2.17E). IV administration of WRG-28 (10mg/kg/day)
reduced lung metastasis to a comparable level (Figures 2.17A,B and 2.17E). Histologic
analysis of GFP+ tumors in the lungs isolated at termination (7 days) confirmed the
bioluminescent results (Figure 2.17C,D and 2.17F). These data indicated that WRG-28
had the potential to inhibit colonization of the lung by metastatic breast tumor cells in
vivo.
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Discussion
We have identified a potent and selective small molecule inhibitor of DDR2. In
contrast to other inhibitors of DDR2, WRG-28 acts via the extracellular domain of the
receptor to inhibit receptor activation in an allosteric manner, potentially by disrupting
receptor clustering. In support of the proposed allosteric mode of action, WRG-28 was
not a strong orthosteric inhibitor of ligand binding, was highly selective, dissociated
preformed DDR2-collagen complexes, disrupted receptor clustering in solution, and
inhibited kinase-independent receptor function.
Computational modeling followed by directed mutagenesis analysis of receptor
function and WRG-28 action in vitro and in cells suggest that a region at the interface of
the two extracellular domains (DS and DS-like) could be the binding site of WRG-28.
The short extracellular juxtamembrane region of DDR2 is absent from the current
structural model, so this could not be assessed as a potential binding site for WRG-28.
In the absence of structural data, we cannot definitively confirm the predicted binding
site. However, when key residues withing the highest probability WRG-28 interacting
site are mutated (DDR2F96A/T98A), collagen binding and DDR2 activation are abrogated,
implying that F96 and T98 in DDR2 are important for receptor function. Perhaps the
most compelling evidence for this region being involved in WRG-28 binding is when
these key interacting residues found in DDR2 were substituted into DDR1
(DDR1L96F/A98T mutant, Figure 2.10I), sensitivity of DDR1 to inhibition by WRG-28 was
conferred. Since WRG-28 appears to interfere with receptor clustering, there also
remains the possibility that the WRG-28 binding site could be a composite site formed
by two or more interacting protomers.
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Previous studies have suggested that receptor clustering is critical for DDR2
binding to collagen44, and recent work has demonstrated DDR1 clustering enhances
activation and strengthens DDR1 binding to collagen60,61. If DDR2 oligomerization is
required for efficient collagen binding and receptor activation, the inability of the inactive
DDR2F96A/T98A mutant to form higher order clusters would provide a straightforward
explanation for its lack of binding and activation. We can not exclude the possiblility that
this region could function allosterically to regulate the collagen binding site from a
distance. Such regions exist among matrix protein binding integrins, and are common
among receptors62,63. Alternatively, these residues might contribute to conformational
changes necessary for ligand binding and receptor activation, if residues within the DSDS-like domain interface region act to position two DDR2 protomers for binding and
subsequent activation.
The type of inhibitor described here is among the first extracellularly acting small
molecule RTK inhibitor. To our knowledge there is only one other example of a similar
small molecule inhibition strategy targeting the extracellular domain of a RTK
(FGFR)32,33. That compound inhibits signaling linked to receptor internalization in an
allosteric manner, without affecting orthosteric ligand binding. Our data suggests that
WRG-28 is able to disrupt preformed DDR2-collagen complexes (Figure 2.8A).
Although non-classical small molecular inhibitors that disrupt protein complexes or
multimerization of receptors have been reported 34,35, to our knowledge no such
inhibitors have been identified for any RTK. These types of non-classical or allosteric
inhibitors remain an elusive goal for drug development as they offer a number of
favorable attributes from a therapeutic perspective, such as increased selectivity and
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safety36,37. Allosteric inhibitors are typically more selective as their interaction sites in
target proteins are not conserved between related proteins37. Indeed, neither the
homologous family member DDR1, nor the unrelated collagen receptor α1β1 integrin
are inhibited by WRG-28 (Figure 2.4D and 2.5D). Allosteric modulators often leave a
baseline residual level of signaling downstream of their targets that may allow for
maintained cellular homeostasis and minimize undesired responses 36. In our limited in
vivo treatment (1 week) we did not observe any untoward effects in WRG-28 treated
mice. Additionally, WRG-28 also maintains efficacy against “gatekeeper mutants” of
DDR2, further illustrating its utility as an alternative to canonical TKIs.
Rather than blocking receptor-ligand binding, WRG-28 has the potential to
engage and disrupt preformed receptor complexes. This may be important for its in vivo
efficacy, where the ligand (fibrillar collagen) is in great excess. WRG-28 binding to
DDR2-collagen complexes appears to accelerate the intrinsically slow dissociation of
the complex (Figure 2.7D). Extrapolation of this in vitro data would suggest that in vivo
the DDR2-collagen interaction equilibrium lies strongly in favor of receptor-ligand
complex. Therefore, this mode of inhibition may be poised as advantageous over
blockage of ligand binding with an orthosteric inhibitor, where an empty receptor would
be needed for drug binding.
In spontaneous mouse tumor models, genetic evidence has shown that DDR2
promotes the metastasis of breast cancer through its function in both the tumor cells, as
well as cancer associated fibroblasts within the tumor microenvironment. Therefore, in
the context of a DDR2 inhibitor, it becomes possible to target both the invasive tumor
cell, as well as stromal cells concurrently. While we have studied DDR2 inhibition in the
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context of breast cancer metastasis, DDR2 activation has also been implicated in the
progression of multiple other cancer types20,64 as well as other disease states such as
osteoarthritis65,66, and cardiac67 and pulmonary68 fibrosis. It will be important to
determine whether DDR2 inhibition with WRG-28 or derivatives would be a useful
therapeutic strategy in those settings. In the context of cancer, it is important to note
that we, and others, have shown that genetic depletion of Ddr2 or selective
pharmacologic inhibition of the receptor activation does not affect primary tumor
growth11,13,14. Thus, in the patient setting, treatment with such an anti-metastasis agent
capable of inhibiting cell invasion and migration would likely need to be administered as
an adjuvant therapy along with standard chemotherapeutic agents that reduce tumor
cell proliferation.
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Matierials and Methods
Synthesis and Chemical features of WRG-28
4-(bromomethyl)-N-ethylbenzenesulfonamide.
Adapted from 69. To ethylamine HCl (120mg, 1.5 mmol) and triethyl amine (0.3mL,
2.2mmol) in CH2Cl2 (15mL) under inert gas at 0°C, 4-bromomethyl benzene sulfonyl
chloride (300mg, 1.1mmol) dissolved in CH2Cl2 was added dropwise. Reaction brought
to room temperature and stirred overnight. An additional 15mL CH2Cl2 was added, and
washed with water (3 x 25mL), brine (1x25mL), and dried over Na2SO4. Solvent was
removed under reduced pressure, and the resulting 4-(bromomethyl)-Nethylbenzenesulfonamide used without further purification.

N-ethyl-4-(((3-oxo-5a,10a-dihydro-3H-phenoxazin-7-yl)oxy)methyl)benzenesulfonamide
4-(bromomethyl)-N-ethylbenzenesulfonamide (50mg, 0.2mmol), resorufin sodium salt
(42mg, 0.2mmol), and CsCO3 (88mg, 0.27mmol) in DMF (15mL) were heated to 100°C
overnight with stirring. EtOAc (50mL) was added and resulting organic solution washed
extensively with water. After drying over Na2SO4, solvent was removed under reduced
pressure. Resulting product was purified by silica chromatography (hexane:EtOAc) to
afford N-ethyl-4-(((3-oxo-5a,10a-dihydro-3H-phenoxazin-7yl)oxy)methyl)benzenesulfonamide as an orange solid.

1

HNMR (400 MHz, CDCl3): δ

7.94 ppm (dd, 2H), 7.76 (dd 1H), 7.62 (dd 2H), 7.45 (dd, 1H), 7.05 (t, 1H), 6.9-6.85 (m,
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2H), 6.35 (s, 1H), 5.27 (s, 2H), 4.38 (s, 1H), 3.08 (q, 2H), 1.16 (t, 3H). HRMS for
C21H18N2O5S1 [M+H]+: m/z = 411.2
Cell culture and viral infections
HEK293, HEKEBNA and HEK293T cells were from ATCC. MCF-10A cells were
provided by L. Michel (Washington University in St Louis, USA). BT549 cells were
provided by J. Weber (Washington University in St. Louis, USA). 4T1- Luc-GFP cells
were described previously11. Production of lentiviruses and infection of target cells were
described previously59 . To make stable cell lines of BT549 and 4T1 cells selection was
carried out in 3 µg/ml puromycin.
Plasmids, shRNAi lentiviruses
pFLR DDR2-Flag and pFLR SNAIL1.CBG plasmids and DDR2 shRNAis were
previously described11. pCEP-His-DDR2, pc-DDR1-Fc and pc-DS2-Fc plasmids were
provided by Birgit Leitinger40,45 (Imperial College London, UK). pCDNA3.1 DDR1-myc
was provided by Rafael Fridman (Wayne State University, USA). For mutation studies
of full length receptor, the cDNA of DDR2 was subcloned into pcDNA3.1-myc plasmid.
Overlapping PCR was used to introduce point mutations and then subcloned back into
pcDNA3.1. Plasmids for recombinant DDR2 protein were constructed by removing the
N-terminal His and Myc tags from pCEP-His-DDR2 ECD and using PCR to introduce a
C-terminal His tag to DDR2 (amino acids Lys22 to Thr398). BM-40 signal sequence was
maintained at the N-terminus. For point mutants, overlapping PCR was used to
introduce point mutations and then subcloned back into the pCEP-pu vector. For
DDR2K608E plasmid, overlapping PCR was used to introduce the point mutation, and
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then subcloned into the pFLRu vector70 with a YFP tag. All mutations and cloning were
verified by sequencing. shRNAis were subcloned into the pFLRu vector. shRNAi target
sequences are as follows: SCR control sequence 5’CCTAAGGTTAAGTCGCCCTCGCTC-3’, shDDR2 5’- GCCAGATTTGTCCGGTTCATT3’. For rescue experiments, a shDDR2 directed at the 3’ UTR with sequence 5′GCCCATGCCTATGCCACTCCAT-3’ was used to allow for expression of rescue
construct.
Reagents
Triple helical collagen binding peptides GPC(GPP)5–GPRGQOGVNleGFO(GPP)5GPC-NH2 and GPC(GPP)5–GFOGER-(GPP)5GPC-NH2 were purchased from
Richard Farndale (University of Cambridge, UK). α1β1 integrin, DDR1-Fc and DDR2myc/His were purchased from R&D systems. DDR2-Fc was purchased from Creative
Biomart.
Production and Purification of Recombinant Proteins
The production and purification of recombinant DDR proteins was performed as
previously described by others(Leitinger, 2003). A C-terminal His-tagged DDR2
extracellular domain protein (DDR2-His) and DDR2 point mutants were produced from
episomally transfected HEK293-EBNA cells.

Solid Phase Collagen Binding experiments
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Collagens or collagen peptides (100uL) were diluted in 0.01 N acetic acid coated
onto Immulon 2 HB 96-well plates (Fisher Scientific) overnight at 4°C. Collagen binding
peptides have been previously validated and described in detail41,71. For DDR proteins,
the collagen peptide included the binding sequence GPRGQOGVNleGFO. For integrin
α1β1, the collagen peptide included the binding sequence GFOGER. Wells were then
blocked for 1 h at room temperature with 1 mg/ml bovine serum albumin in phosphatebuffered saline plus 0.05% Tween 20. Recombinant proteins, diluted in incubation buffer
(0.5 mg/ml bovine serum albumin in phosphate-buffered saline plus 0.05% Tween 20),
were added for 3 h at room temperature. Wells were washed with incubation buffer
between all incubation steps. Bound DDR2-His protein or α1β1-His were detected with
anti-His conjugated HRP monoclonal antibody (1:2500 dilution), added for 1 h at room
temperature. Bound DDR1-FC or DS2-Fc protein were detected with goat anti-human
Fc coupled to horseradish peroxidase (1:2500 dilution), added for 1 h at room
temperature. Detection was acheived using o-phenylenediamine dihydrochloride
(Sigma), added for 3–5 min. The reaction was stopped with 3M H2SO4, and plates were
read in a 96-well plate reader at 492 nm. α1β1 integrin assay was performed as
described43, but with anti-His conjugated HRP used for detection.
DDR2-ligand dissociation assay
Immulon 2HB plates were coated overnight with 0.5µg/mL collagen peptide
ligand. Coat solution was removed and wells were washed once with PBS, and then
blocked for 1h at room temperature with 1mg/ml bovine serum albumin in phosphatebuffered saline plus 0.05% Tween 20. 25nM DDR2 was plated allowed to bind to
equilibrium (2 hours). At that point, the protein solution was removed and a maximal
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volume of incubation buffer that contained indicated concentrations of WRG-28 or
control DMSO was added. At indicated time points, wash off solution was removed,
and incubated with 1:5000 anti-His-HRP for 60 minutes to detect remaing bound DDR2.
Detection was achieved as indicated for the solid phase collagen binding experiments.
Peptide labeling
NHS-fluorescein (Thermo scientific) was used to label collagen toolkit peptide. Labeling
was carried out at a 5 fold molar excess of labeling reagent to peptide on ice for 2
hours. Non-reacted NHS-fluorescein was removed by dialysis, and the resulting labeled
peptide lyophilized and then resuspended. Solid phase assay was used to confirm
there was no loss of DDR2 binding upon conjugation of the peptide.
Peptide plating quantification
Increasing amounts of fluorescein conjugated collagen peptide were plated in
triplicate into wells of a Immulon 2HB plate. Plating was carried out overnight at 4°C.
At that time, fluorescence intensity of each well was detected using a Tecan Infinite 200
PRO plate reader. Wells were then washed 3 times with PBS, and post wash
fluorescence intensity was measured to determine the portion of the plated peptide that
was adsorbed onto the plate.

Size exclusion chromatography
Size exclusion chromatography was carried out at 4°C using a BioRad Biologic
Duoflow system equipped with a Superdex 200 Increase 10/300 GL column (GE).
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Experiments were run using PBS at a 0.5mL/min flow rate and elution monitored at UV
absorbance 280nm. 25µg of protein were incubated in solution with 1µM WRG-28 or
DMSO for 1 hour, then injected, and 1mL fractions were collected upon elution.
Composition of fractions was assessed by concentration using Vivaspin 500 centrifugal
concentrators (10K MWCO), and concentrated fractions run on 10% gel under nonreducing conditions. For assessment of collegn binding of different multimeric states,
1mL fractions of the indicated multimer were immediately spin concentrated. Protein
concentration was then measured using Bradford Assay, and concentration across
samples normalized Multimer samples were then subjected to binding in the solid
phase plate assay.
Biolayer Interferometry
Biolayer Interferometry (BLI) with an Octet (ForteBio, Menlo Park, CA)
intstrument was used to assess WRG-28 binding to various protein constructs. DDR2
was randomly biotinylated in vitro using EZ-link NHS-PEG4-Biotin (Thermo Scientific) at
a 1:2 molar ratio (protein: reagent). Streptavidin-coated biosensors (ForteBio) were
used to capture biotinylated DDR2 onto the surface of the sensor. After reaching
baseline, sensors were moved to association step for 600 s and then dissociation for
300 s. Curves were corrected by referencing technique using both biotin-coated pins
dipped into the experimental wells. The binding buffer was identical to that of the solid
phase assay.
Cell Surface Biotinylation
Cell surface biotinylation was used to confirm cell surface expression of protein
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constructs. HEK293 cells expressing the indicated constructs were incubated with cell
impermeable EZ-link NHS-PEG4-Biotin in PBS for 30 minutes on ice. Cells were then
washed twice with 100mM glycine in PBS to quench reaction. Cells were lysed, and the
expressed constructs immunoprecipitated using the indicated protein tag. Lysates were
run and analyzed by SDS-PAGE, blotting with Streptavidin-HRP to detect biotin. Blots
were stripped and reprobed for the indicated protein to confirm band identity. Non-biotin
treated lysates were run as a control.
Assessment of receptor dimerization
Dimerization was asses by chemical cross linking analysis. HEK293 cells
expressing the indicated constructs were treated with 0.1M BS3 (Thermo Scientific) in
PBS for 30min at room temperature, after which the reaction was quenched with 15mM
glycine. Cells were then lysed and lysates analyzed by SDS-PAGE.
Immunoprecipitation and western blots.
For collagen dependent phosphorylation, indicated concentrations of collagen I in
0.01N acetic acid were plated for 1hr at 37°C. plates were washed twice with PBS, and
cells then plated in culture medium. Cells were lysed with a non-denaturing lysis buffer
as described previously11. Five hundred micrograms of whole-cell lysate, as determined
by Bradford analysis (BioRad), was used for immunoprecipitation. Blots were probed
with indicated antibodies, followed by corresponding horseradish peroxidase-conjugated
secondary antibodies. Detection was preformed using SuperSignal Chemiluminescent
substrate (Thermo Scientific) on a ChemiDoc XRS+(BioRad). Integrated relative
densities of individual bands were quantified using ImageLab software. All
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quantification was prefomed under conditions of linear signal response.
RTK Signaling Array
MCF10A cells were starved overnight, and then stimulated with media containing
20% horse serum + EGF for 5, 15, or 60 minutes in the presence or absence of 500nM
WRG-28. Another derivative, WRG-11, was also compared at 15minutes. Cells were
lysed, and lysates were assayed using PathScan RTK signaling array (Cell Signaling).
Following detection on a ChemiDoc XRS+(BioRad), integrated relative densities of
individual dot blots were quantified using ImageLab software, and normalized to positive
blot controls. All quantification was prefomed under conditions of linear signal
response.
Cell proliferation analysis
Cells were seeded at 3 x104 cells per well in triplicate in 24 well plates in 500µL
growth medium on day 0. Cells were trypsinized, resuspended in a total volume of
500µL of medium and counted with a haemacytometer at the intervals shown.
Migration and invasion assays.
Migration assays through matrigel and 3D collagen I invasion assays were
preformed as described previously11, For 3D cell migration assays, 105 cells were
embedded in 20µl of type I collagen gel (2.0mg/mL) extracted from rat tail (BD
Biosciences). After gelling, the plug was embedded in a cell-free collagen gel (2.0
mg/mL) within a 24-well plate. After allowing the surrounding collagen matrix to gel (1 h
at 37°C), 0.5 mL of culture medium was added on the top of the gel and cultured for
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another 2 days. Invasion distance from the inner collagen plug into the outer collagen
gel was quantified. For invasion assays, Transwell cell invasion assays were performed
using either 24-well polycarbonate membrane (Corning) with 8-µm pore size, or 24-well
FluoroBlok Transwell insert (BD) with 8-µm pore size. Inserts were prepared by coating
the upper surface with 1 mg/mL of Matrigel (BD Biosciences) for 4–6 h at 37°C in a 5%
CO2 incubator. 5 x104 BT549 or 4T1-Luc cells in DMEM containing 1% FBS were
seeded into the upper chamber of the insert. The bottom chamber contained DMEM
with 10% FBS. After 24 or 48 hr, Membranes were processed. Polycarbonate
membranes were stained with HEMA3 staining kit (Fisher) and then mounted and
enumerated based on number of cells per 20x high power field, 5 fields per insert. For
FluoroBlok transwells, luminescence intensity was measured using a FluoStar Optima
microplate reader (BMG Labtech) for 10 individual fields on the bottom of each insert.
Tumor Organoid and CAF coculture
Isolation of tumor organoids and CAFs was described previously14. Primary
tumor organoids (30–50, each 200–1,000 cells) with or without CAFs (750 cells) were
cultured in 50mL droplets of 3mg/mL acid-solubilized rat-tail collagen I (BD
Biosciences), and number of invasive organoids were enumerated daily for 4 days.
Organoids were scored as invasive if they contained ≥1 protrusive projection.
Organoid Apoptosis Staining
Organoids derived from MMTV-PyMT tumor bearing mice were grown in 3D
collagen culture as indicated in experimental methods. Organoids were grown in the
presence of control DMSO or 1uM WRG-28. On day 4, positive control wells were
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treated with 1uM doxorubicin for 4 hours to induce apoptosis. Organoids were then
stained using an annexin V-FITC/PI apoptosis detection kit (Abcam), and imaged. 10
organoids/condition were imaged, and percent of organoids staining positive for annexin
V was quantified using ImageJ software.
Molecular docking
The homology model of the DDR2 extracellular domain was created by using
SWISS-MODEL protein structure homology modeling server48-50. PDB 4AG4 was used
as a template. For docking studies, PyRx using the AutoDock Vina Wizard52 was used.
For molecular visualization, docking poses generated by Autodock Vina were loaded
into Pymol.
Animal studies
All procedures and care of animals were done in accordance with a protocol
approved by the Washington University Institutional Animal Care and Use Committee
(St. Louis, MO), and were preformed in accordance with institutional and national
guidelines.
Temporal deletion of Ddr2. Ddr2fl/fl; ROSA-LSL-TdTomato or Ddr2+/+; ROSALSL-TdTomato mice were crossed to MMTV-PyMT; ROSA-CreERT2 mice. At 8 weeks,
experimental and control mice were switched to 400 citrate tamoxifen-supplemented
non-pelleted dry feed (Envigo) for 2 weeks. The tumor bearing mice were monitored
weekly and euthanized when the largest tumor reached 2 cm in diameter. Lungs were
fixed overnight in 10% formalin, cryopreserved in 30% sucrose overnight, and finally
embedded in OCT and frozen in a dry ice/ethanol bath. Frozen specimens were
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sectioned with a cryostat (6 µm) and analyzed by fluorescence microscopy for tomato
expression or stained with haematoxylin and eosin for histological analysis. For
analysis of lung metastasis, microscopically visible metastatic foci were counted from
three H&E stained sections taken 200µm apart and reported as the total number of
metastases in those three sections.
Breast implant in vivo assay. Eight-week old female BALB/cJ mice (Jackson
Labs) were anaesthetized with a ketamine/xylazine cocktail (90 mg/kg ketamine and 13
mg/kg xylazine, intraperitoneal injection) and the abdomen was sterilized using
povidone–iodine (Betadine) solution and ethanol. A small Y-shaped incision was made
in the lower abdominal skin to expose the fourth mammary gland using surgical scissors
and bleeding vessels were cauterized. 4T1-Snail.CBG cells (1x106 ) in 50 µl DMEM
were injected into the fourth mammary gland using a 29-gauge needle. The skin flaps
were replaced and closed using 9 mm wound clips, and the surgical site was swabbed
with triple-antibiotic cream. When tumors were 1cm in diameter, in vivo biochemical
response studies were conduced by bioluminescence imaging (BLI) at baseline,
followed by IV lateral tail vein injection of either control saline, or indicated doses of
WRG-28 in saline/DMSO, and BLI at indicated time points. The baseline BLI signal for
each mouse served as its own control.
For lung metastasis formation assay, 5x105 cells in 100uL DMEM were injected into the
lateral tail vein of BALB/cJ mice. Beginning on day 0, mice were treated with either
control saline, or 10mg/kg WRG-28 in saline/DMSO daily for 7 days, and BLI imaging
used to follow tumor growth at time points indicated. After 7 days, mice were
euthanized and lungs removed and fixed in 10% formalin for 24 h, cryopreserved in
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30% sucrose overnight, and finally embedded in OCT and frozen in a dry ice/ethanol
bath. Frozen specimens were sectioned with a cryostat (6 µm) and analyzed by
fluorescence microscopy for GFP expression or stained with haematoxylin and eosin for
histological analysis.
For all BLI, mice were anaesthetized with isoflurane and imaged using the IVIS 100
bioluminescent imaging system (Perkin Elmer) following an intraperitoneal injection of dluciferin (150 mg/kg).
Statistics
All data represent the mean ± SEM of the indicated number of experiments. Statistical
parameters and IC50 values were calculated using Prism. Statistical significance was
calculated by the indicated test, considering p<0.05 as statistically significant.
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Figures

A

B

Figure 2.1: In vitro screening for active DDR2 inhibitors
(A) Effect of various organic compounds on DDR2-His extracellular domain binding.
Inhibitory curves as measured by solid phase binding assay of 25nM DDR2-His binding,
500ng immobilized ligand. Cinnabarinic acid (blue), 7-hydroxy-phenoxazin-3-one (red),
Actinomycin D (green), phenoxazine (purple), WRG-28 (orange). Graph shows mean ±
SEM from a single experiment representative of at least three independent experiments,
three replicates per treatment per experiment.
(B) Solid phase binding assay of 25nM recombinant DDR2-His to the high affinity
collagen II DDR2 binding peptide. Graph shows mean ± SEM from a single experiment
representative of at least three independent experiments, three replicates per
concentration per experiment.
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Figure 2.3: Identification of WRG-28 as a potent and reversible inhibitor of DDR2
binding
(A) SAR study of the 7-hydroxy-phenoxazin-3-one derivatives and their inhibitory ability
as tested by solid phase binding assay of 25nM recombinant DDR2-His to the high
affinity collagen II DDR2 binding peptide. Data are mean ± SEM. IC50 values as
determined by 3 independent experiments (n=3).
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(B) Synthetic route of WRG-28 (a) NET3/CH2Cl2; (b) CsCO3/DMF
(C) Treatment of DDR2-his protein with 1µM WRG-28 in solution, followed by dialysis.
Protein was then allowed to bind in the in vitro assay as compared to a non-treated,
dialyzed control sample.
(D) Effect of WRG-28 on DDR2-His extracellular domain binding in the presence of
1mM glutathione. Inhibitory curves as measured by solid phase binding assay of 25nM
DDR2-His binding, 500ng immobilized ligand. Graph shows mean ± SEM three
replicates per treatment.
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Figure 2.4: WRG-28 inhibits DDR2 activation but has no effect on DDR1 activation
(A) HEK293 cells transfected with DDR2-Flag were added to plates coated with
30µg/mL collagen I for 4 hours in the presence of various concentrations of WRG-28.
DDR2 was immunoprecipitated with Flag antibody and bound products western blotted
with pTyr mAb 4G10 and reprobed with anti-DDR2 antibodies. Densitometric
quantification used to assess effect of WRG-28 on collagen-induced phosphorylation of
DDR2. Representative blot shown, quantification of 5 independent experiments
represented as mean ± SEM.
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(B) HEK293 cells stably expressing DDR2-Flag were added to plates coated with
30µg/mL collagen I for 7 hours in the presence or absence of WRG-28. Western blots
were performed.
(C) MCF10A cell proliferation curve of DMSO control or 1µM WRG-28 treated cells.
Means ± SEM. Three replicates per treatment per experiment.
(D) HEK293 cells transfected with DDR1-Myc were added to plates coated with
30µg/mL collagen I for 4 hours in the presence of various concentrations of WRG-28.
DDR1 was immunoprecipitated with Myc antibody and bound products western blotted
with pTyr mAb 4G10 and reprobed with Myc antibodies. Densitometric quantification
used to assess effect of WRG-28 on collagen-induced phosphorylation of DDR1.
Representative blot shown, quantification of 4 independent experiments represented as
mean ± SEM.
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Figure 2.5: WRG-28 is selective towards DDR2
(A-C) Biolayer interferometry analysis of WRG-28 binding to (A) DDR2-His, (B) DDR2Fc, (C) DDR1-Fc. Data are shown as black lines representing increasing concentration
of WRG-28, with global kinetic fits overlaid.
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(D) Solid phase binding assays of either 25nM α1β1 integrin (blue) or 25nM
DDR2(green) showing the relative inhibition of binding of each protein to its respective
high-affinity triple helical collagen peptide in response to WRG-28. Graph shows mean
± SEM from a single experiment representative of at least three independent
experiments, three replicates per treatment per experiment.
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Figure 2.6: WRG-28 does not affect other kinase pathways in non-DDR2
expressing MCF10A cells
(A) MCF10A cells were stimulated with 20% horse serum + EGF for indicated time
period in the presence or absence of 500nM WRG-28 and cells lysed. Lysates were
assayed using Cell Signaling PathScan RTK signaling array. Phosphoarray of RTK
signaling pathways highlighting various responsive RTKs in MCF10A cells and
densitometry used to quantify changes.
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Figure 2.7: DDR2 acts in a non-orthosteric manner to accelerate the dissociation
of receptor-ligand complex
(A) Fluorescein conjugated collagen II binding peptide was plated at known amounts
overnight at 4°C. Fluorescence of wells was measured (prewash) and then plating
solution washed and fluorescence again measured (postwash) to assess proportion of
plated peptide that remained adsorbed to the plate. Graph showing linear adsorption of
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peptide in the range assessed, with similar fluorescence pre- and post-wash. 3
measurements/plating concentration were taken.
(B) Solid phase binding assay of 25nM DR2-His to either high affinity collagen II DDR2
binding peptide unlabeled or fluorescein conjugated, plated at indicated concentrations.
Graph shows mean ± SEM, three replicates per concentration per experiment.
(C) 25nM DDR2-His binding in the presence of increasing concentration of collagen
peptide at varying concentrations of WRG-28. DMSO control (blue), 250nM WRG-28
(red), 500nM WRG-28 (green), 2µM WRG-28 (purple). Data are means ± SEM from a
single experiment representative of at least 3 independent experiments, 3
replicates/treatment per experiment.
(D) 25nM DDR2 bound to immobilized collagen II peptide in solid phase binding assay
at equilibrium was exposed to a titration of compound. Graph showing dissociation of
DDR2 ECD from ligand after exposure to compound at indicated concentrations for time
indicated. DMSO control (blue), 250nM WRG-28 (red), 500nM WRG-28 (green). Data
are independent time points from a single experiment representative of at least three
independent experiments.
(E) Effect of WRG-28 on 25ng DDR2-His or DDR2-Fc extracellular domain binding.
Inhibitory curves as measured by solid phase binding assay. Graph shows mean ± SEM
from a single experiment representative of at least three independent experiments,
three replicates per treatment per experiment.

88

A

B

C

D

E

F

Figure 2.8: WRG-28 impairs clustering of the DDR2 extracellular domain
(A) Size exclusion chromatography. Representative elution profile of DDR2-His in the
presence or absence of 1µM WRG-28 on a Superdex 200 Increase 10/300 GL column.
Oligomer (O), dimer (D), monomer (M).
(B) Native gel fraction analysis. Indicated elution fractions were concentrated and
resolved by native PAGE on a 10% gel, followed by silver staining.
(C) Area under the curve used to quantify fraction of DDR2 multimer (oligomer) as
compared to total DDR2. Three independent runs of each condition were quantified,
data represented as mean ± SEM.
(D) Protein concentration of dimer or oligomer fractions was normalized, and the given
multimeric species subjected to binding in the in vitro binding assay. Three replicates of
each condition were tested, data represented as mean ± SEM.
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(E) Two independent size exclusion chromatography traces of DDR2-His treated with
WRG-28, illustrating the peak shouldering commonly seen.
(F) HEK293 cells transfected with DDR2-Flag added to plates and stimulated with
collagen I in the presence or absence of 1µM WRG-28 for 4 hours. Cells were then
treated with 0.1M BS3 in PBS. Samples were western blotted with Myc antibodies. βtubulin used as a loading control.
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Figure 2.9: Computational prediction of WRG-28 binding site
(A) Autodock calculated binding affinities of top 9 computationally predicted binding
sites for WRG-28. Sites highlighted in red represent those clustered within the same site
at the DS-DSL interface region.
(B) Overall view of the DDR2 extracellular domain structure depicting WRG-28 in its
putative binding site
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(C) View of WRG-28 oriented in predicted cleft using surface representation of DDR2.
For protein and inhibitor atom colors rendered as follows: nitrogen (blue), oxygen (red),
sulfur (yellow). For inhibitor, carbon rendered green.
(D) Detailed view of the predicted interactions of WRG-28
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Figure 2.10: Identification of DS-DSL domain interface residues required for
DDR2-collagen binding and signaling
(A) Solid phase binding assay of 25nM recombinant DDR2-His, DDR2F96A-His, or
DDRT98A-His binding to the high affinity collagen II DDR2 binding peptide.
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(B) HEK293 cells transfected with DDR2F96A-Myc or DDR2T98A-Myc were added to
plates and stimulated with indicated concentrations of collagen I for 4 hours. Tagged
proteins were immunoprecipitated with Myc antibody and bound products western
blotted with pTyr 4G10 and then stripped and reprobed with Myc antibodies.
(C) Inhibition by WRG-28 of DDR2-His or single point mutants DDR2F96A or
DDR2T98A binding. Inhibitory curves as measured by solid phase binding assay of
DDR2-His or point mutant binding (25nM). Graph shows mean ± SEM from a single
experiment representative of at least three independent experiments, three replicates
per treatment per experiment.
(D) Solid phase binding assay of 25nM recombinant DDR2-His or DDR2F96A/T98A-His
binding to the high-affinity collagen II DDR2 binding peptide.
(E) Size exclusion chromatography. Representative elution profile of DDR2-His or
DDR2F96A/T98A-His on a Superdex 200 Increase 10/300 GL column
(F) HEK293 cells transfected with DDR2-Myc or DDR2F96A/T98A-Myc were added to
plates and stimulated with indicated concentrations of collagen I for 4 hours. Tagged
proteins were immunoprecipitated with Myc antibody and bound products western
blotted with pTyr 4G10 or Myc antibodies.
(G) Surface biotinylation. Cell surface expression of DDR2-Myc or DDR2F96A/T98AMyc was confirmed using a biotinylation assay. HEK293 cells expressing indicated
constructs were biotinylated using EZ-link NHS-PEG4-Biotin. Proteins were
immunoprecipitated using Myc antibody, and then western blotted with StreptavidinHRP.
(H) Cross linking to determine ability of DDR2 constructs to homodimerize. HEK293
cells transfected with DDR2-Myc or DDR2F96A/T98A-Myc were treated with 0.1M BS3
in PBS and analyzed by Western blotting with anti-DDR2 antibody.
(I) HEK293 cells transfected with DDR1L96F/A98T -Myc were added to plates coated with
30µg/mL collagen I for 4 hours in the presence indicated concentrations of WRG-28.
Tagged proteins were immunoprecipitated with Myc antibody and bound products
western blotted with pTyr mAb 4G10 and reprobed with Myc antibodies. Representative
blot shown, quantification of 3 independent experiments represented as mean ± SEM.
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Figure 2.11: Evaluation of an alternatively predicted binding site
(A) Overall view of the DDR2 extracellular domain structure depicting WRG-28 in
alternative binding site (Site 3 from S4A)
(B) View of WRG-28 oriented in predicted cleft using surface representation of DDR2.
For protein and inhibitor atom colors rendered as follows: nitrogen (blue), oxygen (red),
sulfur (yellow). For inhibitor, carbon rendered green.
(C) Solid phase binding assay of 25nM recombinant DDR2-His or DDR2N266A/Y268AHis binding to the high affinity collagen II DDR2 binding peptide.
(D) Effect of WRG-28 on DDR2 or DDR2N266A/Y268A extracellular domain binding.
Inhibitory curves as measured by solid phase binding assay of DDR2 extracellular
domain binding (25nM protein). Graph shows mean ± SEM from a single experiment
representative of at least three independent experiments, three replicates per treatment
per experiment.
(E) HEK293 cells transfected with DDR2N266A/Y268A-Myc were added to plates
coated with 30µg/mL collagen I for 4 hours in the presence of various concentrations of
WRG-28. DDR2 was immunoprecipitated with Myc antibody and bound products
western blotted with pTyr 4G10 or Myc antibodies.
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Figure 2.12: WRG-28 inhibition of DDR2 blunts tumor cell invasion and migration,
but does not influence proliferation
(A) Cell migration in 3D collagen I gels of BT549 cells treated with 1µM WRG-28 or
control, as compared to cells depleted of DDR2. Representative images shown.
Dashed line delineates invasive front.
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(B) Quantification of experiment described in (A). Distance traveled relative to control
cells was determined at 48hrs. (**P<0.01, ANOVA, n=4 per condition)
(C) Proliferation of BT549 control or shDDR2 depleted cells in the presence or absence
of 1µM WRG-28.
(D) Matrigel invasion of BT549 cell lines treated with 1µM WRG-28 or control as
compared to cells depleted of DDR2 at 48 hours. Representative images of H&E
stained inserts
(E) Quantification of experiment described in (D). BT549 shSCR (blue), shDDR2 (red),
or shSCR WRG-28 treated cells (green) (*p<0.05, **p<0.01, ANOVA, n=3 inserts per
condition. Experiment was preformed 3 independent times with similar results).
(F) Matrigel invasion of 4T1-GFP-luc cell lines treated with 1µM WRG-28 or control as
compared to depleted of DDR2 at 48 hours. Invasion measured by bioluminescence of
cells on fluoroblock transwell inserts. Mean ± SEM. (n=3 per condition)
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Figure 2.13: WRG-28 blocks DDR2 mediated signaling in breast tumor cells and is
effective against TKI resistant mutations
(A) BT549 cells added to collagen I coated (2mg/mL) or uncoated plates in the
presence of WRG-28 (1µM) or DMSO for 6 hours. Western blots were performed for
analysis of SNAIL1 stabilization. Representative blot shown. Quantification by
densitometric analysis of 3 independent experiments represented as mean ±
SEM(**P<0.01, n.s=not significant, ANOVA.)
(B) 4T1 cells added to collagen I coated (2mg/mL) or uncoated plates in the presence of
WRG-28 (1µM) or DMSO for 6 hours. Western blots were performed for analysis of
SNAIL1 stabilization.
(C) HEK293 cells transfected with DDR2T654I-Myc were added to plates and stimulated
with 30µg/mL collagen I for 4 hours in the presence of various concentrations of WRG28. DDR2 was immunoprecipitated with Myc antibody and bound products western
blotted with pTyr 4G10 or DDR2 antibodies.
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Figure 2.14: WRG-28 blocks the tumor promoting effects of DDR2 expressing
CAFs
(A-E) Representative images of tumor organoids scored. A. invasive WT organoid
cultured in the presence of WT breast CAFs B. WT organoid cultured in the presence of
WT breast CAFs, 1µM WRG-28 C. Ddr2-/- organoid, non-invasive D. Ddr2-/- organoids
cultured in the presence of WT breast CAFs, invasive E. Ddr2-/- organoid cultured in the
presence of WT breast CAFs, 1µM WRG-28. Scale bar=100µm
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(F) Quantification of number of invasive tumor organoids as a percent of total organoids
scored after 4 days. 30 organoids per condition were scored. WT, wild type. Data are
mean ± SEM from a single experiment representative of three independent
experiments. NS, not significant, *p<0.05, **p<0.01 one-way ANOVA
(G) Phase contrast image, Tomato fluorescence of MMTV-PyMT; Ddr2+/+; ROSA-LSLTdTomato tumor organoids, and merged image confirming that invasive foci contain
migrating tumor cells. Scale bar = 50µm.
(H) Quantification of positive annexin V staining as compared to total organoid area for
control WT organoids or WT organoids treated with 1µM WRG-28.
(I) Representative images of phase, PI staining, and annexin V staining of organoids
quantified in (H). Doxorubicin induced apoptosis was used as a positive control of
staining. Scale bar = 50µm
(J) Scratch wound assay of fibroblasts in the presence or absence of 1uM WRG-28.
Distance was measured at baseline and again at 24hrs, data representing mean +/SEM, each condition preformed in triplicate. mNF=mouse normal fibroblast. mCAF=
PyMT tumor derived mouse fibroblast.
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Figure 2.15: Genetic validation of DDR2 as a therapeutic target to prevent breast
cancer metastasis
(A) Tomato (red) staining of mammary tumor/lung sections from Ddr2fl/fl; CreERT2;
MMTV-PyMT mice ± tamoxifen administration. DAPI (blue) staining of nuclei. Scale
bar=100µm.
(B) PCR for detection of the floxed and recombined DDR2 allele for a mouse prior to
tamoxifen (tail) or after tamoxifen administration (tumor at endpoint). Tam=tamoxifen
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(C) Primary tumor growth rates of Ddr2+/+; CreERT2; MMTV-PyMT (control) and Ddr2fl/fl;
CreERT2; MMTV-PyMT (deletion at 8 weeks) mice determined by the age at which the
largest tumor reached 2 cm in diameter. n=10-26 mice per group. Data are presented
as mean ± SEM.
(D) Total tumor burden of Ddr2+/+; CreERT2; MMTV-PyMT (control) and Ddr2fl/fl;
CreERT2; MMTV-PyMT (deletion at 8 weeks) mice determined by the sum of the weight
of all tumors for each mouse when the largest tumor reached 2 cm in diameter. n=1026 mice per group. Data are presented as mean ± SEM.
(E) Quantification of lung metastases in Ddr2+/+; CreERT2; MMTV-PyMT (control) and
Ddr2fl/fl; CreERT2; MMTV-PyMT (deletion at 8 weeks) mice, calculated by the number of
microscopically visible metastases counted from three H&E stained sections of lung
from each mouse taken >200µm apart, normalized to the total lung area. *p < 0.05, two
tailed unpaired t-test; n=10-26 mice per group. Data are presented as mean ± SEM.
(F) Representative images of lungs quantified in E. Scale bar=200µm.
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Figure 2.16: WRG-28 attenuates DDR2 signaling in vivo
(A) Representative images of bioluminescence of 4T1-Snail-CBG tumor bearing mice at
4 hours following treatment with WRG-28 or saline control, as compared to their pretreatment baseline.
(B) Quantification of relative bioluminescence of 4T1-Snail-CBG tumor bearing mice at
4 hours following treatment with WRG-28 or saline control, as compared to their pretreatment baseline. Mean ± SEM *p<0.05 (n=3 controls, n=8 treatment group)
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Figure 2.17: WRG-28 administration reduces metastatic lung colonization of
breast tumor cells
(A) Tail vein metastasis assay where BALB/cJ mice are injected by tail vein with 5x105
4T1-GFP-luc expressing cells and lungs evaluated for the presence of metastatic
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tumors, comparing control, WRG-28 treated and shDDR2 depleted conditions.
Representative images of BALB/cJ mice at baseline after injection and after 7 days for
each of the various experimental groups.
(B) Quantification of experiment in (A) comparing control (blue circles), WRG-28
treated (green triangles) and shDDR2 depleted (red squares) conditions. Means ±
SEM; data derived from one experiment of five mice per condition. **p<0.01 two way
ANOVA
(C) Quantification of images in (D), showing percentage of GFP-tumor positive areas in
the lung. 2 sections through each of five lobes per animal quantified. Data derived from
2 experiments, n=9 mice for each condition. Means ± SEM. **p<0.001, one way
ANOVA.
(D) Representative images of histologic analysis for GFP expressing tumor nodules in
lungs of mice from (A), comparing WRG-28 treated to control or DDR2 depleted tumor
cells. Dashed white line delineating GFP positive tumor foci that were included in
quantification.
(E)) Bioluminescence quantification from second cohort of tail vein metastasis assay,
BALB/cJ mice injected with 4T1 GFP-luc expressing cells. Means ± SEM; data derived
from one experiment of four mice per condition. **p<0.01, two way ANOVA.
(F) H&E staining of a serial section of SCR RNAi in (D) illustrating consistency between
GFP signal and tumor foci.
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Chapter 3
TWIST1 induces expression of Discoidin Domain Receptor 2 to Promote Ovarian
Cancer Metastasis
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This chapter has been adapted from a submitted manuscript and also contains
unpublished data.
The citation for the submitted manuscript is:
TWIST1 induces expression of Discoidin Domain Receptor2 (DDR2) to Promote
Ovarian Cancer Metastasis. Whitney R. Grither, Laura M. Divine, Daniel J. Wilke, Riva
A. Desai, Andrew J. Loza, Anne K. Lohrey, Eric Meller, Gregory D. Longmore,
Katherine C. Fuh. In review, 2017.
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Introduction
Unique from other malignancies of epithelial origin, the metastatic cascade of
ovarian tumors commonly occurs via the peritoneal circulation, and the majority of
metastases are confined within the abdominal peritoneal cavity1. After tumor cell
detachment from the primary site in the ovary, tumor cells must attach to the mesothelial
cells covering the peritoneal and pleural organs, then clear the mesothelial layer to invade
through the underlying basement membrane and extracellular matrix (ECM) to form
metastatic implants2. Thus, for efficient metastasis, ovarian tumor cell interaction with the
surrounding ECM and subsequent remodeling of the ECM is critical3,4. Identifying cellular
and molecular targets important for one or more of these steps could have tremendous
clinical impact by enabling the development of therapeutics that block these critical steps.
The ability of ovarian cancer cells to adopt a mesenchymal gene program has been
shown to promote ovarian cancer metastasis5. Induction of epithelial-to-mesenchymal
transition (EMT) in ovarian cancer cells through expression of EMT transcription factors
TWIST1, SNAIL1, or ZEB1 promotes mesothelial cell clearance5. These factors also
promote the ability of an ovarian cancer cell to invade the basement membrane and
extracellular matrix, and form metastatic implants6-8.

While these EMT transcription

factors induce a mesenchymal program crucial for ovarian cancer metastasis, the specific
proteins whose expression is regulated during EMT that functionally mediate mesothelial
cell attachment, clearance, and tumor cell invasion are not fully appreciated.
Mesenchymal properties of the developing cranial mesoderm are regulated by
Twist1 transcriptional targets that influence cell-matrix interactions. Among the
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mesenchymal genes transcriptionally regulated by TWIST1 in this developing tissue is
Discoidin Domain receptor 29. TWIST1 binds to the 5’-regulatory region of Ddr2 inducing
its expression in this tissue. Discoidin domain receptor 2 (DDR2) is a unique receptor
tyrosine kinase (RTK) that has been shown to promote the metastasis of multiple
cancers10-18. Unlike most RTKs that utilize soluble growth factors as ligands, fibrillar
collagens serve as the ligand for DDR219,20.

This provides for unique cell-ECM

interactions. Fibrillar type I collagen is the major structural element of the ovarian stroma
and has been shown to increase four-fold in ovarian cancer21. DDR2 is a mesenchymal
gene not typically expressed by normal epithelium22, however, its expression is activated
in many cancer cells of epithelial origin as they progress to invasive and metastatic
cancers23. DDR2 has been shown to stabilize the EMT transcription factor SNAIL1 in
tumor cells that have undergone EMT, thereby maintaining mesenchymal cell behaviors,
including invasion and migration11,12,16.
In orthotopic transplant and spontaneous genetic models, depletion or deletion of
Ddr2 in tumor cells prevents metastasis in vivo in breast10,11 and prostate13 cancer
models. The role of DDR2 in promoting invasion and metastasis has been ascribed to
its regulation of a number of different molecular effectors, including upregulation of MT1MMP activity via a SNAIL1 mediated pathway11,16. In addition, the expression and activity
of various matrix remodeling enzymes, such as matrix metalloproteinases (MMPs) and
lysyl oxidases is influenced by the presence and activation of DDR210,24. Furthermore,
while DDR2 itself does not mediate strong adhesive contacts, it has been shown to have
an adhesion promoting role through enhancement of integrin activation state25. Whether
DDR2 contributes to ovarian cancer metastasis is not known.
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In this study, we show that TWIST1 regulates DDR2 expression in ovarian cancer
cells. We find that the presence of DDR2 in ovarian tumor cells is critical for mesothelial
cell clearance, and tumor cell invasion and migration, in part through promotion of ECM
remodeling. We also demonstrate that the action of DDR2 in ovarian tumor cells is critical
for ovarian tumor metastasis in vivo. As such, DDR2 represents a potential therapeutic
target to modulate numerous pathways critical for metastatic ovarian tumor progression.
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Results
TWIST1 regulates DDR2 Expression in Ovarian Cancer Cells
The EMT transcription factor TWIST1 has been shown to transcriptionally induce
expression of Ddr2 in developing mesenchymal neural tissue9. Ovarian cancer cells have
been shown to adopt a mesenchymal program during tumor progression, which
influences tumor cell-matrix interactions and remodeling that promote metastasis26 .
Therefore, we asked whether the TWIST1-DDR2 pathway was present in ovarian cancer
cells. In a collection of ovarian cancer cell lines the expression of DDR2 and TWIST1 was
highly correlated, particularly in cell lines with metastatic potential (Figure 3.1A). To
determine if TWIST1 regulated DDR2 expression in these ovarian cancer cells, TWIST1
expression was depleted using shRNA. In A2780 and ES2 ovarian tumor cells this
resulted in decreased DDR2 mRNA (Figure 3.1C) and protein level (Figure 3.1B). In
contast, depletion of DDR2 had no effect on TWIST1 level (Figure 3.1B).
TWIST1 expression is induced during TGF-β-induced EMT27. Therefore, we asked
whether TGF-β-induced TWIST1 expression in ovarian tumor cells resulted in DDR2
expression. Treatment of epithelial OVCAR3 ovarian cancer cells (which do not express
TWIST1 or DDR2 at baseline) with 2 ng/mL of TGF-β induced EMT, as assessed by
expression of α-SMA (Figure 3.1D). Both TWIST1 and DDR2 expression were induced
as well (Figure 3.1D) and maintained under continuous exposure to TGF-β.
In OVCAR3 cells, shRNA-mediated TWIST1 depletion did not affect EMT induction in
response to TGF-β, as as seen by expression of α-SMA (Figure 3.1E). However, in the
absence of TWIST1, DDR2 was not expressed (Figure 3.1E). These data indicate that
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as ovarian cancer cells progress to more invasive, mesenchymal phenotypes, TWIST1
promotes DDR2 expression.

DDR2 Promotes Mesothelial Cell Clearance
Upon detachment of ovarian tumor cells from the primary site, the layer of
mesothelial cells lining the peritoneal cavity must be cleared by the tumor cell for
successful attachment2. Constituitive TWIST1 overexpression in ovarian tumor cells
promotes their capacity for mesothelial cell clearance5. Therefore, we asked whether
expression of DDR2, induced by TWIST1, could be responsible for mediating mesothelial
cell clearance. We adapted an ovarian tumor spheroid mesothelial cell clearance assay28
and confirmed that ES2 cells readily clear the mesothelial monolayer, as previously
reported5 (Figure 3.2A and 3.2B). Genetic depletion of DDR2 in ES2 cells significantly
reduced their mesothelial cell clearance ability (Figure 3.2A and 3.2B) to an extent similar
to that observed when TWIST1 was depleted5 (Figure 3.2C and 3.2D).
These results indicated that the action of DDR2 in ovarian tumor cells that have
adopted an invasive, mesenchymal phenotype, is largely responsible for their capacity to
clear mesothelial cells.

DDR2 Contributes to Invasion and Migration of Ovarian Cancer Cells
Subsequent to clearing the mesothelial layer, ovarian cancer cells must invade and
migrate through the underlying basement membrane (BM) and extracellular matrix (ECM)
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for successful metastases. As TWIST1 mediated EMT is known to contribute to these
behaviors in other cancers29-32, we sought to determine whether the action of DDR2 in
ovarian tumor cells contributed to these tumor cell functions. Matrigel has been used
extensively as a BM surrogate and DDR2 depleted cells were significantly impaired in
their ability to invade through Matrigel coated transwells (Figure 3.3A and 3.3B). To
assess ECM invasion/migration ovarian tumor cells were embedded in 3D Collagen I
gels. DDR2 depleted cells were significantly impaired in their ability to invade 3D type I
collagen (Figure 3.3C and 3.3D). There were no differences in proliferation between
control and DDR2-depleted ovarian tumor cells (Figure 3.3E and 3.3F). In sum these
results indicated that the action of DDR2 in ovarian tumor cells contributed to critical tumor
cell functions within the metastatic cascade, such as mesothelial cell clearance, BM
invasion and ECM invasion/migration, but did not influence tumor cell proliferation.

DDR2 activation leads to increased SNAIL1 protein level in ovarian cancer cells
We have shown that DDR2 is a transcriptional target of TWIST1 in ovarian cancer
cells, and its activity serves to mediate many of the pro-metastatic phenotypes associated
with the TWIST1 mesenchymal program. DDR2 activation in response to collagen I
stimulation has also been shown to stabilize the EMT transcription factor SNAIL1 in
multiple cancer cell types, thereby sustaining mesenchymal cell features and tumor cell
invasion and migration11,12,16,33. Moreover, constitutive SNAIL1 expression can promote
mesothelial clearance in ovarian cancer5. Therefore, we asked whether DDR2 regulated
SNAIL1 levels in human ovarian cancer cells, and in addition to carrying out TWIST1
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mediated functions, could contribute to maintaining a mesenchymal phenotype. When
ES2 or A2780 ovarian tumor cells were added to Collagen I coated plates, SNAIL1 protein
was increased (Figure 3.4A and 3.4B). This was dependent upon the presence of DDR2
signaling, as DDR2 depletion in those same cells abrogated the increase in SNAIL1
following collagen I stimulation (Figure 3.4A and 3.4B). These data indicated that DDR2
activation by collagen I serves to stabilize SNAIL1 protein levels in ovarian cancer cells.

DDR2 regulates expression and activity of extracellular matrix remodeling
enzymes
Matrix remodeling enzymes such as matrix metalloproteinases (MMPs) and lysyl
oxidases (LOX) are known to be key contributors to ovarian tumor cell invasion and
progression, as well as mesothelial clearance3,4,34. Multiple reports have linked DDR2
activity with increased MMP and LOX expression10,35-37. Furthermore, DDR2 has been
shown to influence expression of the MMP activating enzyme, MT1-MMP (MMP14),
downstream of SNAIL1 stabilization11. As collagen I induced DDR2 activation led to
increased SNAIL1 protein in ovarian cancer cells (Figure 3.4A and 3.4B), we asked
whether the level and activity of matrix remodeling enzymes in ovarian tumor cells was
dependent upon the action of DDR2. Quantitative RT-PCR analysis of select matrix
remodeling enzymes showed that overall there was a reduction in the expression of these
enzymes in ES2 and A2780 ovarian tumor cells depleted of DDR2, even though the
expression profile of matrix remodeling enzymes differed between the tumor cell lines
(Figure 3.4C). In ES2 cells, DDR2 depletion led to decreased MMP2, MMP7, MMP13,
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and LOXL2 mRNA level (Figure 3.4C). In A2780 cells, MMP1, MMP3, and LOXL2 mRNA
levels were reduced in DDR2 depleted cells (Figure 3.4D). Although mRNA level of MT1MMP (MMP14) was not influenced by the presence of DDR2 in unstimulated cells,
Western blot analysis of ES2 and A2780 cells showed that active MT1-MMP protein level
increased in response to collagen I stimulation (Figure 3.4A and 3.4B) and this increase
was abolished when DDR2 was depleted (Figure 3.4A and 3.4B). Finally, in the ES2 cell
line gelatin zymography showed that MMP-2 level and activity was reduced in DDR2depleted cells compared to control ES2 cells (Figure 3.4C and 3.4E).
These results indicated that DDR2 activation in ovarian tumor cells regulated
expression and activity of matrix remodeling enzymes. These enzymes could facilitate
migration, invasion, and mesothelial cell clearance.

DDR2 contributes to Fibronectin cleavage by ovarian cancer cells and promotes
ovarian cancer cell spreading on Fibronection
Fibronectin (FN) cleavage and remodeling has been shown to be important for the
ability of ovarian cancer cells to clear the mesothelial cell layer covering the peritoneum
during the early stages of metastasis2,3. As MMPs are efficient at FN cleavage3,38, and
DDR2 modulates expression and activity of MMPs in ovarian cancer cells (Figure 3.4),
we asked whether the presence of DDR2 in ovarian tumor cells led to more efficient
cleavage of FN. Cell free media from collagen stimulated ES2 or A2780 shSCRM cells
was capable of rapid cleavage of human FN (Figure 3.5A-C). When DDR2 was depleted
in these cells there was a delay in the cleavage of FN, as quantified by the amount of
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remaining full length FN (Figure 3.5A-C). These data demonstrated that DDR2 activity in
ovarian tumor cells promotes efficient cleavage of FN, and as such, may contribute to the
enhanced mesothelial clearance by DDR2 expressing cells.
MMP cleavage of FN has been shown to enhance peritoneal adhesion of ovarian
cancer cells3. Additionally, while DDR2 itself does not bind FN, its presence has been
shown to promote adhesion and spreading of cells via integrin activation25. We therefore
sought to determine if depletion of DDR2 in ovarian cancer cells led to differential
adhesion and spreading of these cells on FN.

Polyacrylamide hydrogels were

functionalized with FN. When plated on these FN coated hydrogels, ES2 shSCRM control
cells appeared maximally spread at 3 hours, while DDR2 depleted ES2 cells showed a
dramatic reduction in cell spreading (Figure 3.5D and 3.5E). These results indicate that
DDR2 promotes the ability of ovarian cancer cells to adhere and spread on FN.

DDR2 is critical for ovarian tumor metastasis in vivo
To determine whether DDR2 influenced ovarian cancer cell metastasis in vivo, we
compared the ability of control scrambled shRNA (shSCRM) and shDDR2 (ES2 and
A2780) (Figure 3.6A and 3.6E) to form metastasis in a peritoneal xenograft model of
ovarian cancer. Mice were sacrificed and the tumor burden determined by measuring
tumor weight and/or counting number of tumor nodules. For both cell lines, DDR2depleted tumor-bearing mice showed less total tumor weight (Figure 3.6B and 3.6F-G).
Consistent with human disease, much of the peritoneal tumor burden in these mice
consisted of lesions attached to the mesentery and omentum (Figure 3.6C-D and 3.6H),
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and DDR2 reduced the tumor burden on these organs. These results indicated that the
action of DDR2 in ovarian tumor cells is critical for the establishment of ovarian tumor
metastasis in vivo.

DDR2 is expressed in human ovarian carcinomas and is an indicator of poor
prognosis
To determine if DDR2 expression in human ovarian tumors is associated with
clinical outcome, we first analyzed gene-expression data from a previously described
cohort of ovarian cancer patients with advanced stage, high-grade serous cancer39.
Univariate survival analysis showed that stratification of patients into “DDR2 high” and
“DDR2 low” groups based on an optimum threshold revealed that high DDR2 mRNA
expression levels were associated with shorter overall survival (p=0.02) (Figure 3.7A).
Next, we determined DDR2 expression, by IHC, in ovarian surface epithelium taken from
patients with benign ovarian disease, primary tumors, and metastatic lesions. Although
some benign ovarian disease exhibited low level DDR2 expression, 0% (0/9) of the
specimens exhibited high DDR2 expression (3+) (Figure 3.7B and 3.7C). High level of
DDR2 expression appeared to correlate with stage of the patient, as 44% (79/179) of
early stage and 74% (28/38), p<0.0001, of advanced stage specimens show high levels
of DDR2 expression (Figure 3.7B and 3.7C). Notably, 100% (12/12) of the metastatic
tumor samples showed high levels of DDR2 expression (Figure 3.7B and C). These
findings are consistent with a previous report40 and demonstrated that DDR2 expression
was induced in aggressive ovarian tumors.
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DDR2 expression level is correlated with increased invasion in patient derived
primary ovarian cancer cells
The mesenchymal gene program correlates with increased metastatic behavior in
the primary tumors of ovarian cancer patients5. We therefore assayed a number of
primary ovarian cancer (POV) cells derived from the abdominal ascites of patients with
advanced stage, high grade ovarian cancer for expression of mesenchymal proteins,
including DDR2. All POV cells expressed at least one of the mesenchymal markers
assayed (Figure 3.8A). Additionally, although variable in level, all POV cells exhibited
some degree of DDR2 expression. To determine whether correlations between
invasiveness and DDR2 expression could be observed in POV cells, we utilized an ex
vivo assay in which the Matrigel invasion capacity was examined. A subset of the POV
cells (POV1, 9, 10, 12) with similar proliferation rates (Figure 3.8D), but with varying
expression profiles of mesenchymal proteins, were subjected to the assay (Figure 3.8B
and 3.8C). Notably, POV9, which displayed the lowest expression of DDR2 among the
cells assayed, was least invasive. These data are consistent with results from the
established ovarian cell lines, and further implicate DDR2 action as critical for the invasive
capacity of ovarian cancer cells, and its potential utility as a therapeutic in the ovarian
cancer setting.
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Discussion
In summary, these studies have shown that the collagen receptor DDR2
contributes to the mesothelial clearance, invasion, and metastasis of ovarian cancer cells.
Our working model (Figure 3.9) posits that upon EMT induction by tumor environmental
signals, EMT transcription factors, including TWIST1, are expressed. During the transition
to the mesenchymal state, TWIST1 induces DDR2 expression. DDR2 then modulates
the expression and activity of matrix remodeling enzymes, including MMPs and LOXL2.
Additionally, DDR2 enhances the ability of ovarian tumor cells to cleave fibronectin, and
adhere to and spread on fibronectin substrate. This could contribute to increased
mesothelial cell clearance and invasion by ovarian tumor cells. Upon reaching the
collagen I-rich stromal matrix DDR2 activity maintains SNAIL1 levels, thereby serving a
central role in maintaining the mesenchymal phenotype of metastatic ovarian tumor cells.
DDR2 expression led to increased adhesion to fibronectin, yet DDR2 does not
directly bind fibronectin19. We have shown that DDR2 expressing cells are able to more
efficiently cleave FN. Cleavage of FN is necessary to expose high affinity sites for α5β1
and αvβ3 integrin binding, leading to enhanced adhesion of ovarian cancer cells3,41.
DDR2 has been shown to influence adhesion and spreading of cells by collagen binding
α1β1 and α2β1 integrins25. This raises that possibility that DDR2, as a signaling receptor,
could also influence the adhesive activity of integrins. As it was not determined in that
study, how exactly DDR2 influences collagen and/or fibronectin integrin adhesion remains
of interest.
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Whereas other epithelial tumors, including ovarian cancer, have been shown to
use hematogenous or lymphatogenous routes to metastasize, ovarian cancer is unique
in that cells within the ascites fluid reach distant sites within the peritoneal cavity1,42. This
leads to the requirement of ovarian tumor cells to clear and invade the mesothelial layer
that covers the peritoneal organs in order for metastatic implants to arise43. Our findings
demonstrate that DDR2 expression is associated with worse prognosis in high-grade
serous cancers (Figure 3.7). Additionally, molecular profiling of the ES2 cell line used for
many of our cell-based assays by The Cancer Cell Line Encyclopedia has shown the line
to have a TP53 mutation. Therefore, although the ES2 cell line is classically thought of
as a clear cell tumor derivative, it more likely high-grade serous44. The A2780 cell line
used in our assays does not have a TP53 mutation and is unlikely of high-grade serous
histology with PIK3CA, PTEN, and ARID1A mutations. However the results from this cell
line adds to the potential generalizability of our findings.

We have shown that DDR2

plays a critical role in mediating mesothelial cell clearance. While this could be due,
simply, to the increased ability of DDR2 expressing cells to adhere and spread, there are
other intriguing possibilities that warrant further study.

Recently, DDR1, the other

member of the discoidin domain family, was demonstrated to mediate myosin-dependent
collagen contraction via association with non-muscle myosin IIA (NM-IIA)45. It has been
demonstrated that ovarian cancer spheroids exert force on the mesothelial cellassociated ECM protein FN via α5β1 integrin in a NM-IIA dependent manner to clear the
mesothelium2. As there is a rich network of collagen fibers just below the mesothelium in
sites of ovarian cancer metastasis46, it would interesting to determine if a DDR2-NM-IIA
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mechanism of force generation exists, and if so, whether it contributes to enhanced
clearance and invasion by ovarian cancer cells.
Our findings also suggest that stabilization of SNAIL1 and regulation of MMPs may
be an important component of DDR2 signaling contributing to ovarian tumor metastasis.
Other studies have shown that TWIST1 and SNAIL1 promote mesothelial clearance by
ovarian cancer cells, and suggest that inhibiting the pathways that drive mesenchymal
programs may suppress tumor cell invasion5. As transcription factors such as TWIST1
and SNAIL1 can be difficult to target therapeutically47, modulating the activity of proteins
whose expression they regulate (e.g., DDR2) or upstream regulators that stimulate or
maintain their expression (e.g., DDR2) could be a more practical approach. In the case
of ovarian cancer metastasis, targeting DDR2 could allow for intervention at both such
levels. In human samples, advanced and metastatic ovarian tumor cells have increased
DDR2 expression, and this high expression is associated with poor prognosis of ovarian
cancer patients. While other authors have recently shown this association40, here we
provide functional data that DDR2 expression leads to mesothelial cell clearance, and
increased invasion and migration by ovarian tumor cells.

Furthermore, we have

demonstrated that these enhanced cellular functions translate to DDR2 promoting ovarian
cancer metastasis in vivo. Since DDR2 is upregulated in ovarian cancer cells, but
relatively undetectable in surrounding normal tissues, DDR2 could be a highly specific
therapeutic target with minimal toxicity to normal cells.
In conclusion, in metastatic ovarian tumor cells DDR2 expression is a product of
the mesenchymal program induced by TWIST1, and serves to maintain the mesenchymal
phenotype through SNAIL1 stabilization. Our in vitro, in vivo, and ex vivo results confirm
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that DDR2 is one of the critical factors contributing to the steps of ovarian cancer
metastasis.

Therapeutic modulation of DDR2 could provide a means of improving

treatment for patients with advanced ovarian cancer.
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Materials and Methods
Antibodies
The antibodies and sources were as follows: DDR2 (for IHC, R&D Systems), DDR2 (for
Western Blot, Cell Signaling Technologies), MT1-MMP (Millipore), Snail1 (Cell Signaling
Technologies), Twist1 (AbCam), β-Actin (Sigma), β -Tubulin (Sigma), N-cadherin (BD),
E-Cadherin (BD), a-SMA (sigma), Zeb1 (Santa Cruz).

Cell culture
Established ovarian cancer cell lines A2780 (purchased from ATCC), SKOV3.ip1 (gift
from Dr. Gordon Mills, M.D. Anderson Cancer Center, Houston, TX), OVCAR3
(purchased from ATCC), OVCAR4 (purchased from National Cancer Institute-Frederick
DCTD tumor cell line repository), and OVCAR5 (National Cancer Institute-Frederick
DCTD tumor cell line repository) were maintained in RPMI Medium (GIBCO)
supplemented with 10% heat inactivated fetal bovine serum and 1% penicillin and
streptomycin. Ovarian ES2 cells were maintained in McCoy’s 5A (modified) medium (Life
Technologies) supplemented with 10% heat inactivated fetal bovine serum and 1%
penicillin and streptomycin. All cell lines were maintained at 37°C in a 5% CO2 incubator.
To authenticate our cell lines, we use IDEXX Bioresearch which performs short tandem
repeat (STR) profile and interspecies contamination testing. Mycoplasma testing was
also performed using MycoAlert Mycoplasma Detection Kit prior to performing
experiments (Lonza).
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For TGF-B induction of EMT, OVCAR3 cells were treated with 2ng/mL TGFB1
(Sigma) for the indicated time points. During treatment, media was replenished every 48
hours. For collagen I stimulation of DDR2, cells were serum starved overnight, and then
plated on 2mg/mL collagen I (BD) for 6 hours.

Primary Ovarian Cancer Cell Culture
Ascites from patients with ovarian cancer (POV) was obtained and plated in a 1:1 ratio in
RPMI 20% FBS, 1% pen-strep. After 7-14 days, attached and proliferating cells were
passaged and used for experiments. POV 1, 9, 10, and 12 were all obtained from patients
with

advanced

stage,

high-grade

serous

ovarian

or

fallopian

tube

cancer.

Immunohistochemistry was performed with CK8 to confirm epithelial origin of these cells.
All the patients who participated in this study provided written informed consent for the
collection and research use of their materials, and the use of these samples was approved
by the Washington University Insitutional Review Board (IRB 201309050).

Plasmids and shRNA Constructs
TWIST1 shRNA, 5’-CCTGAGCAACAGCGAGGAAGA-3’ in the pLKO vector (Sigma) was
used. Two previously validated oligos for DDR2 shRNA and shSCRM control sequence
were used11. The oligos for human DDR2 shRNA, 5’- GCCAGATTTGTCCGGTTCATT-3’
and

5’-

GCCAAGTGATTCTAGCATGTT-3’,

and

scramble

control,

5’-

CCTAAGGTTAAGTCGCCCTCGCTC-3’, were cloned into the pLKO vector and infected
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cells were selected in puromycin (Sigma). For all hairpins, polyclonal populations were
tested for decreased DDR2 expression levels by western blot analysis.

Western blot analysis
Cultured cell lysates were prepared using a 9M Urea, 0.075 M Tris buffer (pH7.6).
Protein lysates were quantified using the Bradford assay, and 50-100µg of protein was
subjected to reducing SDS/PAGE using standard methods.

Gelatin Zymography
3x106 cells were plated on plastic or 2mg/mL collagen in serum-free media. At 24hrs,
supernatant was collected and run on a 10% gelatin gel under non-denaturing conditions.
Gel was developed, coomassie stained, and destained until bands were visible.

After

harvesting supernatant, cells were trypsinized and counted to ensure there were no
proliferation differences among the groups tested.

Immunohistochemical analysis using human tissue microarrays
Ovarian human tissue microarrays were obtained from US Biomax (208, 2084t)
which contained a majority of early stage and a smaller number of advanced stage
ovarian cancers. Slides were deparaffinized with xylene, rehydrated and unmasked
following standard immunohistochemical methods. The DDR2 primary antibody (R&D
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Systems, MAB2538) was used at a 1:500 dilution. Negative controls for all samples were
done using the secondary antibody alone. Antigen-antibody complexes were visualized
using the VECTASTAIN ABC system (Vector Laboratories) and DAB Substrate Kit for
Peroxidase (Vector Laboratories) following the manufacturer’s protocol. Slides were
counterstained in hematoxylin. DDR2 staining on the membrane of tumor cells was
scored microscopically according to the percentage of cells positive for DDR2 expression
both by intensity and percentage of cells with expression (0 for absent, 1 for 1%-40%, 2
for 40-60%, and 3 for > 60%).

Invasion and Migration Assays
Matrigel invasion assays were performed according to the manufacturer’s protocol
(Corning). Briefly, cells were serum starved for 24 hours and 25,000 cells were plated in
media containing 1% FBS onto Matrigel coated boyden (8um pore size) chambers. Media
containing 10% FBS and 5ug/mL fibronectin was placed in the lower chamber as
chemoattractant. Invasion assays were stained and analyzed after 48 hours. Migration
assays were performed in a similar fashion, in uncoated Boyden chambers. Invaded cells
were quantified by counting the number of invading cells per high powered field, 4 high
powered fields per insert, and 3 inserts per condition were quantified.
Collagen I invasion assays were performed where cells were mixed with 2mg/mL collagen
and plated in 48 well format. After polymerization, media was added and cells were
monitored for invasive branching over 7 days.
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Proliferation Assay
Cells were plated at densities of 4,000 cells per well into four 96-well plates in
medium as described previously. Using an 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2Htetrazolium-5-carboxanilide

inner

salt

(XTT)-based

assay

(Roche

Molecular

Biochemicals) as previously described48, proliferation was measured at 24, 48, 72 and 96
hours.
Real-time PCR with reverse transcription.
Real-time PCR reactions were done using the SYBR Green PCR Master Mix (Applied
Biosystems) in the ABI detection system (Applied Biosystems). The thermal cycling
conditions were composed of 50 °C for 2 min followed by an initial denaturation step at
95 °C for 20 s, 40 cycles at 95 °C for 3 s, and 60 °C for 30 s. The experiments were carried
out in triplicate for each data point. The relative quantification in gene expression was
determined using the 2−ΔΔCtmethod as described previously49. Primers used for PCR with
reverse transcription and real-time PCR with reverse transcription are listed in
Supplemental table.
ES2 or A2780 shRNAi-depleted of DDR2 or transduced with scrambled control
(SCRM) were cultured for 6hours under serum free conditions on 2mg/mL of collagen I,
and cell free, conditioned media was collected and incubated with 4ug human Fibronectin
(BD). Extent of cleavage was measured at time intervals of 0.25, 1, and 16 hours by SDS
Page followed by coomassie staining. Amount of intact FN (~220 kDa) quantified by
densitometry. Control FN was incubated for 16hrs with non-conditioned media.
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Cell Spreading Assay
Polyacrylamide hydrogels were produced as previously described50. Briefly, acrylamide
solution (Bio-Rad) was mixed with N-N'- methylene-bis-acrylamide solutions (BioRad)
and then polymerized between a glutaraldehyde-activated glass surface and hydrophobic
coverslip. Polymerized substrates were then activated for protein conjugation with the
heterobifunctional crosslinker Sulfo-SANPAH at 0.5 mg/mL (Pierce Chemical Co.) under
UV exposure for 15 min. After wash with HEPES buffer, then functionalized with
Fibronectin. Gels were determined by atomic force microscopy to have elastic moduli of
~120 kPa. Functionalized gels were washed with PBS, and ES2 shSCRM or shDDR2
were plated. Live cells were imaged on a Nikon Ti-E microscope with a humidity and
temperature controlled incubation chamber (LiveCell). Data were collected by 3x3 tiling
of 10X regions of view. Time-lapse imaging was performed with 6 hour duration and 20minute frame intervals. Image analysis was performed using Matlab (The Mathworks,
Natick MA) and Image J. Cell area was computed for each cell in each field of view using
custom software to detect cell boundaries. Data was plotted using R graphing library51.

Spheroid-induced mesothelial clearance assay
Mesothelial cells were cultured on 6-well plastic plates (Techno Plastic Products)
and used in the clearance assay once a confluent monolayer was formed (approximately
72 hours). Mesothelial cells were labeled 18 hours prior with CMFDA-green (Molecular
Probes), washed with PBS and incubated with fresh culture medium until use. Spheroids
were prepared 18 hours in advance. Cells were labeled with CMTPX-red (Molecular
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Probes), washed with PBS, dissociated by trypsinization and resuspended in culture
medium. Labeled cells were then counted and plated at 200 cells/well in ultra-low
attachment multiwell plates (Corning) with 10ug/mL of soluble bovine fibronectin for
increased cohesion. Spheroids were placed onto the monolayer of mesothelial cells at
the microscope and images captured at 0, 1, and 7 hours. Normalized clearance value
is determined by measuring the total mesothelial cell area cleared by the spheroid in
ImageJ, and normalizing to the size of the spheroid at time 0.

Survival analysis
For the survival analysis, the Tothill database was accessed39. Raw expression
mRNA values for DDR2 and overall survival was used as an endpoint. Samples were
dichotomized into two groups after determining the optimal cutoff level for gene
expression. Survival curves were calculated using the Kaplan–Meier method, and
statistical significance was assessed using the log-rank test to determine if there was a
statistically significant association between DDR2 expression and overall survival.

Orthotopic Model of Ovarian Cancer
All procedures involving animals and their care were performed in accordance with
the guidelines of the American Association for Accreditation for Laboratory Animal Care
and the U.S. Public Health Service Policy on Human Care and Use of Laboratory Animals.
All animal studies were also approved and supervised by the Washington University
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Institutional Animal Care and Use Committee in accordance with the Animal Welfare Act,
the Guide for the Care and Use of Laboratory Animals and NIH guidelines (Protocol
20140178).
For genetic studies, A2780 shSCRM or shDDR2 were injected intraperitoneally
(i.p.) with 7.5x106 cells in 0.5 ml of PBS into female 6- to 8- week old (n=8 per group)
Balb/c nude (Taconic). ES2 shSCRM or shDDR2 cells were injected intraperitoneally
(i.p.) with 10x106 cells in 0.5 ml of PBS into female 6- to 8- week old (n=8 per group)
NU/NU nude (Charles River) mice. Mice were monitored for adverse events and
sacrificed with CO2 exposure and cervical dislocation at 14 days (A2780 model) and 28
days (ES2 model) after i.p. injection. At the completion of each experiment, aggregate
tumor weight, location, and number of tumor nodules were recorded for each group.

Statistical Analysis
Statistical analysis was performed using Prism software (GraphPad). Two-tailed
unpaired Student’s t test was performed to analyze statistical differences between groups.
P values < 0.05 were considered statistically significant.
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Figure 3.1: TWIST1 regulates DDR2 expression in Ovarian Cancer Cells
(A) Western blot analysis of DDR2 and Twist1 protein expression in established ovarian
cancer cell lines
(B) A2780 or ES2 ovarian cancer cell lines were infected with lentivirus expressing the
indicated shRNAi. Western blotting preformed using the indicated antibodies.
(C) Q-PCR analysis of mRNA isolated from A2780 or ES2cells shRNA-depleted of
DDR2, TWIST1 or transduced with scrambled control (SCR). Three replicates of each
gene were done for each experiment. Data are representative of two independent
experiments. *p<0.05 versus shSCRM control, Student’s t test.
(D) Western blot of indicated proteins from whole cell lysates of OVCAR3 cells treated
with 2ng/mL TGF-B to biochemically induce EMT for indicated times.
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(E) Western blot of indicated proteins from whole cell lysates of OVCAR3 shTwist1 cells
treated with 2ng/mL TGF-B to biochemically induce EMT for indicated times.
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Figure 3.2: DDR2 promotes mesothelial cell clearance
(A) ES2 ovarian cancer spheroids expressing SCRM or DDR2 shRNAi labeled with
CMTCX dye (red) were added to a confluent monolayer of primary mesothelial cells that
were labeled with CMFDA dye (green) and monitored over 7 hours. Images show
respresentative mesothelial clearance and 0 and 7 hours.
(B) Quantification of experiment in (A). >5 spheroids averaged per condition. Error
bars denote SEM. **p<0.01, Student’s t test.
(C) ES2 ovarian cancer spheroids expressing SCRM or TWIST1 shRNAi labeled with
CMTCX dye (red) were added to a confluent monolayer of primary mesothelial cells that
were labeled with CMFDA dye (green) and monitored over 7 hours. Images show
respresentative mesothelial clearance and 0 and 10 hours.
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(D) Quantification of experiment in (C). >5 spheroids averaged per condition. Error
bars denote SEM. **P<0.05, Student’s t test.
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Figure 3.3: DDR2 contributes to invasion and migration of ovarian cancer cells
but does not influence proliferation.
(A-B) Matrigel invasion assays. A. ES2 and B. A2780 cells were depleted of DDR2 or
control (SCRM) and added to Matrigel coated Boyden chambers (8um pore size).
Representative images and quantification plotted as number of cells invading through to

142

lower surface per high powered field (hpf). Means and s.d. are shown for 3 individual
chambers per group, 4 hpf per chamber. Unpaired t-test, **p<0.01, ***p<0.001.
(C) Collagen I invasion assays of ES2 shDDR2 or control (shSCRM) cells.
Representative photographs taken at day 3 and day 6.
(D) Quantification of collagen invasion. 20 cells per well, 3 wells per condition
quantified. Mean and s.d. are shown, unpaired t-test **p<0.01
(E-F) Cellular proliferation curves for (E) ES2 and (F) A2780 shSCRM and shDDR2
cells measured by XTT assay.
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Figure 3.4: DDR2 stabilizes SNAIL1 and regulates expression and activity of
matrix remodeling enzymes
(A-B) A. ES2 or B. A2780 cells depleted of DDR2 or control (SCRM) were added to
collagen I coated (+) or uncoated (-) plates for 6 hours. Western blotting with the
indicated antibodies was performed on cell extract.
(C-D) Q-PCR analysis of mRNA isolated from C. ES2 or D. A2780 shRNA-depleted of
DDR2 or transduced with scrambled control (SCRM). Three replicates of each gene
were done for each experiment. Data are representative of two independent
experiments. *p<0.05 student’s t test
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(E) Gelatin zymography was conducted on the supernatants from ES2 cells depleted of
DDR2 or control (SCRM) that had been plated on collagen I coated (+) or uncoated (-)
plates for 6 hours.
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Figure 3.5: DDR2 contributes to fibronectin cleavage by ovarian cancer cells and
promotes ovarian cancer cell spreading on fibronection
(A) ES2 or A2780 shRNAi-depleted of DDR2 or transduced with scrambled control
(SCRM) were cultured for 6 hours under serum free conditions on 2mg/mL of collagen I,
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and cell free media was incubated with recombinant human fibronectin (FN). Extent of
cleavage was measured at time intervals of 0.25, 1, and 16 hours by SDS Page
followed by coomassie staining.
(B-C) Quantification of cleavage of intact FN by B. A2780 or C. ES2 plotted as a
fraction of remaining intact FN as compared to control. Amount of remaining
intact FN (~220 kDa) quantified by densitometry. Data are representative of 2
independent experiments
(D) Quantification of cell area when plated on fibronectin coated hydrogels for 3 hrs.
Dots represent individual cell areas, with box plot overlay depicting the median and
interquartile ranges of area spread.
(E) Representative images of ES2 shSCRM or shDDR2 cells plated on fibronectin
coated hydrogels.
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Figure 3.6: DDR2 is critical for ovarian cancer metastasis in vivo
(A) A2780 cells stably expressing shRNA targeting sequence for scramble control
(shSCRM) or DDR2 (shDDR2). Beta-Actin was used as a protein loading control.
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(B-D). Representative images and quantification of Balb/c Nu mice injected IP with
7.5x106 A2780 shSCRM or shDDR2 cells. Tumor burden was assessed at 14 days
post injection in the B. entire peritoneal cavity C. Mesentary only D. Omentum only.
N=10 mice per group. Means and s.d. Unpaired t-test, *P<0.05, **P≤0.01
(E) ES2 cells stably expressing shRNA targeting sequence for scramble control
(shSCRM) or DDR2 (shDDR2). Beta-Actin was used as a protein loading control.
(F-H) Quantification of Nu/Nu mice injected IP with 10x106 ES2 shSCRM or shDDR2
cells. Tumor burden was assessed at 14 days post injection by measuring F. total
tumor burden G. number of tumor nodules H. Tumor burden in the mesentery or
omentum only. N=4 mice per group. Means and s.d. Unpaired t-test, *P<0.05, **P≤0.01
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Figure 3.7: DDR2 is expressed in human ovarian carcinomas and is an indicator
of poor prognosis
(A) Overall survival of Advanced-stage III, IV serous ovarian cancers by Kaplan-Meier
methods and log rank test. MST: Median survival time.
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(B) Representative images of DDR2 immunohistochemical staining in i) early stage IA
primary tumor ii) advanced stage IV primary tumor iii)mesenteric metastatic implants
(C) Classification of immunohistochemical analysis of DDR2 staining in normal (benign)
ovary, human primary ovarian tumors, and metastatic implants.
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Figure 3.8: DDR2 expression level is correlated with increased invasion in patient
derived primary ovarian cancer cells
(A) Western blot of patient derived primary ovarian tumor (POV) cells for expression of
indicated proteins.
(B-C) A subset of POV cells were added to Matrigel coated Boyden chambers to assay
invasion. B. Representative images of inserts and C. quantification plotted as number
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of cells invading through to lower surface per high powered field (hpf). Means and s.d.
are shown for 3 individual chambers per group, 4 hpf per chamber.
(D) POV cells were plated and and proliferation was measured with an XTT assay at
24hr time intervals
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Figure 3.9: Proposed role for DDR2 in ovarian cancer metastasis
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Kinase Independent Functions of Discoidin Domain Receptor 2
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Introduction
The majority of cellular functions mediated by receptor tyrosine kinases (RTKs)
can be attributed to their catalytic kinase activity. In response to their cognate ligands,
RTKs catalyze the phosphorylation of select tyrosine residues in target proteins, and
this modification is a pivotal component of cellular communication and signaling. The
phosphorylated tyrosine residues within the RTK itself serve as docking sites for
cytoplasmic signaling proteins containing Src homology-2 and protein tyrosine binding
domains, which then assemble signaling complexes to activate a cascade of
intracellular biochemical signals that define a response to a given external signal1. This
signal transduction plays key roles in cellular processes such as growth, differentiation,
metabolism, and motility2.
While this kinase dependent signaling by RTKs is undeniably important to the
function and homeostasis of cells, an accumulating body of evidence suggests that a
number of non-catalytic properties of RTKs are also essential for their function. These
roles include acting as scaffolds for protein complexes, allosteric effects on other
enzymes, and DNA binding3. For example, EGFR has been shown to interact with and
stabilize the sodium/glucose cotransporter SGLT1. This stabilization occurs
independent of EGFR kinase activity, promotes glucose uptake into cancer cells to
maintain intracellular glucose levels4. Another example is in the case of the receptor
ErbB4 ,where upon cleavage of its ectodomain, a C-terminal fragment translocates to
the nucleus to affect the transcription of target genes. That C-terminal fragment of
ErbB4 is able to activate transcription by associating with YAP2 transcription factor, and
this occurs even when the fragment is lacking the kinase domain, suggesting this
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function may be independent of kinase activity of ErbB43,5. Within the DDR family, there
is also evidence of kinase independent function. The C-terminus of DDR1 contains a
PDZ-binding motif, which has been shown to interact with the cell polarity protein
Par3/Par6 complex to decrease actomyosin contractility and support collective cell
migration, independent of ligand induced stimulation6. Previous studies have illustrated
that DDR2 plays a role in fibroblast migration independent of collagen binding7.
Therefore, the possibility of non-catalytic function of a given RTK must be taken into
consideration when evaluating its function. Evidence from these studies suggests the
potential for kinase-independent functions within the DDR family of proteins.
The fibrillar collagen receptor DDR2 has been found to promote tumor cell
invasion in 2D and 3D culture models8 and metastasis in vivo9. While in 3D collagen
cultures an abundance of ligand exists to stimulate kinase activity of the receptor, DDR2
expressing cells showed increased invasion through Matrigel-coated transwells. This is
surprising, given that Matrigel, a basement membrane surrogate, is predominately
composed of laminin, collagen IV, perlecan, and various growth factors10. As DDR2
only recognizes fibrillar collagens as ligand, these components are unable to directly
drive signaling through the DDR2 receptor.
Additional evidence for kinase independent functions of DDR2 were observed
when assessing cell spreading (Figure 3.5D-E). We found that DDR2 expressing
ovarian cancer cells show increased adhesion and spreading to fibronectin coated
hydrogels. In the absence of ligand, this suggests a that a non-kinase role of DDR2
could be promoting this increased ability of cells to spread. Taken together, these
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findings led us to hypothesize that DDR2 may have functions independent of its kinase
activity that promote adhesive and invasive behaviors of cancer cells,
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Results
DDR2 functions independent of kinase activity to promote Matrigel invasion
To determine whether the ability of cancer cells to invade through basement
membrane extract (Matrigel) was independent of kinase activity of DDR2 we employed
an approach where DDR2 expression in cells was rescued with a single point mutant
form of the receptor that renders it kinase deficient (DDR2K608E)11. We first confirmed
that this point mutation did indeed prevent ligand induced activation of the receptor. We
overexpressed a pCDNA WT DDR2 or DDR2K608E plasmid in HEK293 cells, followed by
stimulation with 30ug/mL of soluble collagen for 4 hours (Figure 4.1A). Cells were then
lysed, DDR2 immunoprecipitated, and western blotting was preformed demonstrating
that the DDR2K608E mutant was not activated in response to collagen stimulation. Both
breast and ovarian cancer lines showed that DDR2 contributed to matrigel invasion
(Figures 2.12D-E and 3.3A-B). Therefore, both a human breast (BT549) and ovarian
(ES2) cancer cell line were depleted of DDR2 using lentiviral shRNA constructs
targeting the 3’UTR of DDR2. The 3’UTR DDR2 shRNA allows for rescue expression of
the protein since the hairpin will not target the exogenous copy of the protein. DDR2
expression was then rescued via lentiviral transduction with either wild type DDR2 or
DDR2K608E. Western blot analysis indicated efficient knockdown of DDR2 and
subsequent rescue with the kinase deficient receptor (Figure 4.1B and 4.1C). These
cells were then plated on Matrigel-coated transwells and allowed to invade for 48hrs. in
shRNAi-depleted BT549 cells with a kinase dead mutant (DDR2K608E). DDR2K608E
expression rescued the invasive potential of the tumor cells through Matrigel (Figure
4.2A and 4.2B). We obtained similar results with the ES2 cell line, where again
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DDR2K608E expression rescued the invasive potential of the tumor cells (Figure 4.2C and
4.2D). These results indicated that there is likely a non-ligand mediated function of
DDR2 that is promoting invasion in this assay.
Further, being that the developed inhibitor of DDR2 (WRG-28) acts via the
extracellular domain to inhibit DDR2 receptor binding and activation, we wanted to
assess whether it was capable of inhibiting non-kinase functions of the receptor.
Treatment with WRG-28 was still able to inhibit invasion of the BT549 DDR2K608E
expressing cells (Figure 4.2A and 4.2B). This demonstrated that WRG-28, through its
allosteric action upon the extracellular domain of DDR2, has the potential to inhibit both
kinase-dependent and kinase-independent functions of the receptor.

Kinase driven DDR2 function predominates in 3D collagen
We next wanted to determine the role of DDR2 kinase activity in a setting where
an abundance of ligand is present. Given the dramatic phenotype attributed to the
activity of DDR2 on cell invasion in 3D collagen (Figures 2.12A-B and 3.3C-D), we
assessed the ability of DDR2K608E expressing cells to rescue the ability of cells to invade
in that assay. In contrast to what was seen in Matrigel invasion assays, in 3D collagen
invasion assays rescue of DDR2 expression with DDR2K608E in knockdown cells was
unable to rescue invasion in either BT549 (Figure 4.3A) or ES2 (Figure 4.3B) cells,
indicating that DDR2 kinase activity is important for driving 3D invasion through collagen
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DDR2 enhances cell adhesion spreading independent of kinase activity
DDR2 has previously been shown to promote cellular adhesion via activation of integrin
activation12. While that study examined adhesion in the context of collagen ligand, we
also documented increase in cell adhesion and spreading of DDR2 expressing cells on
fibronectin (Figure 3.5D-E). Additionally, other groups have shown that DDR2
influences fibroblast spreading on both collagen and fibronectin coated surfaces7.
Given that fibronectin does not serve as a cognate ligand for DDR2, we set out to
determine whether DDR2 was functioning independent of its kinase activity to regulate
this behavior. To do this, we preformed time lapse imaging of cells as they adhered to
and spread on polyacrylamide hydrogels coated with various substrates. In BT549
cells, we examined the ability to spread on both collagen I and fibronectin coated
hydrogels (Figure 4.4A and 4.4B). At 2 hours shRNAi-depleted BT549 cells there was a
dramatic reduction in cell spreading on either substrate, as compared to the shSCR
control cells. Reintroduction of DDR2 expression with the DDR2K608E kinase dead
mutant led to rescued ability of the cells to spread on both substrates, thus indicating
that the enhancement in spreading by DDR2-expressing cells is not a function of kinase
activity of the receptor, or presence of its ligand.
We next carried out similar experiments with ES2 cells. However, rather than
varying the ligand present, we carried the experiment out for longer time points. As can
be seen (Figure 4.5A and 4.5B), consistent with previous findings (Figure 3.5D-E)
depletion of DDR2 in ES2 cells results in decreased spreading on fibronectin, and this
decrease persists out to 6 hours. Similar to what was observed with BT549 cells,
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rescue in the DDR2 depleted cells with the DDR2K608E kinase dead mutant resulted in
an increase in cell spreading ability.
Additionally, we wanted to test the ability of WRG-28 to inhibit DDR2 enhanced
spreading. When the ES2 shDDR2 rescue DDR2K608E cells were treated with WRG-28,
the ability of cells to spread on fibronectin was diminished (Figure 4.5C). These results
again illustrated that the inhibitor could display efficacy towards the kinase independent
functions of the DDR2 receptor.

Co-Immunoprecipitation followed by Mass Spectrometry Profiling identifies
Candidate DDR2 interacting proteins
We have attributed a number of tumor cell phenotypes to DDR2, and identified
some of these DDR2 driven behaviors as being independent of receptor kinase
signaling. While a few identified pathways of DDR2 signaling, including stabilization of
SNAIL1 and phosphorylation of SRC as a downstream effector8,13, have been
delineated, there is relatively little known about downstream effectors of the receptor.
Further, as these are among the first reports of kinase independent functions of the
receptor, it is not known how these functions are being mediated. Therefore, we
conducted a mass spectrometry proteomics screen in order to identify potential
interacting partners of DDR2. The goal of this study was to identify candidate
interacting partners of DDR2, to allow for assessment as to how the receptor could be
working at a mechanistic level.
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To conduct this screen, lentivirus was used to introduce a DDR2-Flag-His-His
version of the receptor into BT549 cells. This served to both increase the DDR2 pool in
the cell, as well as provide a tag for more efficient pull down. In one sample, cells were
unstimulated, and in a second sample, cells were stimulated with collagen for 3 hours.
Parental BT549 cells that did not contain the tagged receptor construct were used as a
control sample. Prior to lysis, cells were treated with the membrane impermeable
cross-linker, DTSSP. DTSSP is a reducible crosslinker, and therefore does not interfere
with downstream proteomics analysis. The purpose of DTSSP was to capture cell
surface interactions DDR2 might be making with other membrane proteins. Given that
many cell surface interactions are driven by transmembrane contacts14, we wanted to
ensure that these were not lost during cell lysis. After crosslinking, cells were lysed,
and then immunoprecipitated using Flag-M2 agarose beads. A small amount of the
immunoprecipitated sample was run on a Western blot to confirm quality of the sample
(Figure 4.7). SRC was used as a positive control as it is known to interact and coimmunoprecipitate with DDR215.
Mass spectrometry analysis of the co-immunoprecipitation samples revealed 87
identified proteins in the non-collagen stimulated sample, and 164 in the collagen
stimulated sample. Results are listed in Tables 4.1 and 4.2.
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Discussion
Accumulating evidence shows that non-catalytic properties of RTKs also
contribute to their functions3. We have found that DDR2 displays such kinase
independent functions. We examined cancer cell lines in a number of assays, where we
found that DDR2 kinase independent activity drives invasion through Matrigel, but not
collagen I. Further, expression of the DDR2K608E kinase dead mutant rescued cells
ability to adhere and spread on both fibronectin and collagen I coated hydrogels.
Additionally, to identify potential DDR2 interacting partners that could be driving these
kinase independent behaviors, we preformed a co-immunoprecipitation experiment of
DDR2 from BT549 breast cancer cells, followed by mass spectrometry proteomics
identification of binding partners.
In regards to these presumed kinase independent functions of DDR2, although
fibrillar collagen is not a predominant component of Matrigel, proteomic analysis of
Matrigel have noted trace amounts of fibrillar collagen16 Therefore, although not
abundant, it could still be possible that DDR2 is binding to this trace amount of collagen,
although previous studies have shown Matrigel is not capable of stimulating DDR2
activation17. Additionally, given the cell spreading results where the matrix composition
is controlled and there is clearly no ligand present, it appears that DDR2 exerts
functions independent of kinase signaling. While there is clearly a kinase independent
role to cell adhesion and spreading, how exactly DDR2 is mediating these behaviors on
non-ligand substrate is unknown. Previous studies suggest that this could be occurring
via an enhancement of integrin activation12. However, the mechanism by which DDR2
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could be enhancing activation of integrins, and whether the same mechanism is
responsible for DDR2 enhanced spreading on different substrates, is unknown.
While it is currently unknown which, or how many, of DDR2’s pro-metastatic
functions in vivo are dependent upon catalytic activity or not, the data herein confirm
that an allosteric inhibition strategy (WRG-28) has the promise to disrupt such kinase
independent functions, in contrast to canonical TKI strategies. If indeed these nonkinase roles of the receptor show significance in the setting of disease, this becomes an
additional strength to a mechanism of inhibition such as that seen for WRG-28.
In our studies, re-expression of a kinase deficient DDR2 receptor in DDR2
knockdown cells was unable to rescue invasion through 3D collagen, indicating that in
some contexts, signaling through DDR2 is critical to drive invasive behavior. The ability
of DDR2 to stabilize SNAIL1 levels to sustain EMT has been shown to be dependent on
the kinase activity of the receptor8. As EMT has been shown to be important for cancer
cell invasion, it is possible that SNAIL1 stabilization may be one of the actions of DDR2
that is important for cell invasion through a 3D collagen matrix. Additionally, it is likely
that there are other pertinent pathways activated downstream of DDR2 phosphorylation,
and it would be on interest to uncover these downstream effectors.
In vitro we have identified phenotypes attributed to kinase independence. It will
be important to determine if these cell based assays translate to significance in the in
vivo setting. Given the results of the 3D collagen assay, it is possible that in vivo
invasion through the collagen rich tumor microenvironment is predominately driven by
kinase dependent actions of the DDR2 receptor. However, DDR2 appears to promote
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invasion through basement membrane independent of kinase activity. It is possible that
early stages of metastasis, such as breaching the basement membrane, may be
achieved efficiently by the kinase deficient rescue in vivo. Whether or not alternative
pathways exist to compensate and drive invasion through collagen in the setting of a
kinase deficient DDR2 receptor in vivo remains uncertain. Therefore, in addition to end
point metastasis, it will be important to examine local invasion at the primary site as
well, to allow determination of the role DDR2 signaling is playing in an in vivo context.
Finally, our co-immunoprecipitation mass spectrometry screen uncovered a
number of candidate proteins that could be interacting with DDR2 at the protein level.
Among these putative interacting partners are other membrane receptors, proteins
involved in force generation, and proteins involved in receptor trafficking. There are a
number of interesting candidates, and follow up studies will be necessary to elucidate at
a mechanistic level how DDR2 is exerting its pro-metastatic functions.
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Materials and Methods
Cell culture
Ovarian ES2 cells were maintained in McCoy’s 5A (modified) medium (Life
Technologies) supplemented with 10% heat inactivated fetal bovine serum and 1%
penicillin and streptomycin. HEK293 and HEK293T cells were from ATCC and
maintained in DMEM + 10% heat inactivated fetal bovine serum and 1% penicillin and
streptomycin.. BT549 cells were provided by J. Weber (Washington University in St.
Louis, USA) and were maintained in DMEM + 10% heat inactivated fetal bovine serum
and 1% penicillin and streptomycin..All cell lines were maintained at 37°C in a 5%
CO2 incubator. Production of lentiviruses and infection of target cells were described
previously18 . To make stable cell lines of BT549 and 4T1 cells selection was carried out
in 3 µg/ml puromycin.
Plasmids, shRNAi lentiviruses
pFLR DDR2-Flag-His-His was previously described8. For DDR2K608E plasmid,
overlapping PCR was used to introduce the point mutation in DDR2 cDNA, and then
subcloned into the pFLRu vector19 with a YFP tag. All mutations and cloning were
verified by sequencing. shRNAis were subcloned into the pFLRu vector. shRNAi target
sequences are as follows: SCR control sequence 5’CCTAAGGTTAAGTCGCCCTCGCTC-3’, shDDR2 directed at the 3’ UTR with
sequence 5′- GCCCATGCCTATGCCACTCCAT-3’ was used to allow for expression of
rescue construct.
Invasion and Migration Assays
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Matrigel invasion assays were performed according to the manufacturer’s protocol
(Corning). Briefly, cells were serum starved for 24 hours and 25,000 cells were plated in
media containing 1% FBS onto Matrigel coated boyden (8um pore size) chambers. Media
containing 10% FBS and 5ug/mL fibronectin was placed in the lower chamber as
chemoattractant. Invasion assays were stained and analyzed after 48 hours. Invaded
cells were quantified by counting the number of invading cells per high powered field, 4
high powered fields per insert, and 3 inserts per condition were quantified.
For ES2 cells, collagen I invasion assays were performed where cells were mixed
with 2mg/mL collagen and plated in 48 well format. After polymerization, media was
added and cells were monitored for invasive branching over 7 days.
For BT549 cells, 105 cells were embedded in 20µl of type I collagen gel (2.0mg/mL)
extracted from rat tail (BD Biosciences). After gelling, the plug was embedded in a cellfree collagen gel (2.0 mg/mL) within a 24-well plate. After allowing the surrounding
collagen matrix to gel (1 h at 37°C), 0.5 mL of culture medium was added on the top of
the gel and cultured for another 2 days. Invasion distance from the inner collagen plug
into the outer collagen gel was quantified.
Cell Spreading Assay
Polyacrylamide hydrogels were produced as previously described20.

Briefly,

acrylamide solution (Bio-Rad) was mixed with N-N'- methylene-bis-acrylamide solutions
(BioRad)
and then polymerized between a glutaraldehyde-activated glass surface and hydrophobic
coverslip. Polymerized substrates were then activated for protein conjugation with the
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heterobifunctional crosslinker Sulfo-SANPAH at 0.5 mg/mL (Pierce Chemical Co.) under
UV exposure for 15 min. After wash with HEPES buffer, then functionalized with
Fibronectin. Gels were determined by atomic force microscopy to have elastic moduli of
~120 kPa. Functionalized gels were washed with PBS, and ES2 shSCRM or shDDR2
were plated. Live cells were imaged on a Nikon Ti-E microscope with a humidity and
temperature controlled incubation chamber (LiveCell). Data were collected by 3x3 tiling
of 10X regions of view. Time-lapse imaging was performed with 6 hour duration and 20minute frame intervals. Image analysis was performed using Matlab (The Mathworks,
Natick MA) and Image J. Cell area was computed for each cell in each field of view using
custom software to detect cell boundaries. Data was plotted using R graphing library21.
Co-Immunoprecipitation/Mass Spectrometry proteomic analysis
BT549 or BT549 DDR2-Flag-His-His cells were grown in DMEM + 10% FBS.
One plate of BT549 DDR2-Flag-His-His cells was stimulated with 50µg/mL rat tail
Collagen I in the media for 2 hours at 37°C. At that time, all samples were treated with
DTSSP (Thermo Scientific) according to manufacturer’s protocol. After quenching of
the crosslinker, cells were lysed using co-immunoprecipitation buffer (1% NP-40, 50 mM
NaCl, 50 mM tris-HCl, 5 mM EDTA, + protease inhibitors) for 30min on ice. 1mg of total
protein pre-cleared for 1hr at 4°C with 15uL protein G agarose beads, and then
incubated with 50uL Flag-M2 agarose beads (Sigma) overnight at 4°C. After washing
the beads three times with co-IP buffer, the protein was eluted from the beads with SDS
sample buffer. 10% of the eluent was used to assess quality of the immunoprecipitation
by Western blot.
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Samples were sent to MS Bioworks (Ann Arbor, MI) for proteomic analysis conducted
using the following workflow:
Sample Preparation
50% of each submitted sample was processed by SDS-PAGE using a 10% Bis-Tris
NuPAGE gel (Invitrogen) with the MES buffer system, the gel was run approximately
2cm. The mobility region was excised into 10 equally sized bands. In-gel digestion with
trypsin was performed on each band using a ProGest robot (DigiLab) with the following
protocol: washed with 25mM ammonium bicarbonate followed by acetonitrile, reduced
with 10mM dithiothreitol at 60°C followed by alkylation with 50mM iodoacetamide at RT,
digested with trypsin (Promega) at 37°C for 4h, quenched with formic acid and the
supernatant was analyzed directly without further processing.
Mass Spectrometry
Half of each gel digest was analyzed by nano LC-MS/MS with a Waters NanoAcquity
HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a
trapping column and eluted over a 75µm analytical column at 350nL/min; both columns
were packed with Luna C18 resin (Phenomenex). The mass spectrometer was operated
in data-dependent mode, with the Orbitrap operating at 60,000 FWHM and 17,500
FWHM for MS and MS/MS respectively. The fifteen most abundant ions were selected
for MS/MS.
Data Processing
Data were searched using a local copy of Mascot with the following parameters:
176

Enzyme: Trypsin/P Database: SwissProt Human (concatenated forward and reverse
plus common contaminants). Fixed modification: Carbamidomethyl (C) Variable
modifications: Oxidation (M), Acetyl (N-term), Pyro-Glu (N-term Q), Deamidation (N/Q)
Mass values: Monoisotopic Peptide Mass Tolerance: 10 ppm Fragment Mass
Tolerance: 0.02 Da Max Missed Cleavages: 2 Mascot DAT files were parsed into the
Scaffold software for validation, filtering and to create a non- redundant list per sample.
Data were filtered using at 1% protein and peptide FDR and requiring at least two
unique peptides per protein.
Proteins were given a NSAF Calc, which contains the conversion to Spectral
Abundance Factor (SAF) and subsequent Normalized Spectral Abundance Factor
(NSAF). This was based on the equation: NSAF = (SpC/MW)/∑(SpC/MW)N Where SpC
= Spectral Counts, MW = Protein molecular weight in kDa, N = Total Number of
Proteins
Proteins interactions identified were considered significant if 1. Protein had at
least 5 SpC in the experimental sample. 2. Protein was not detected in the control
sample OR 3. Protein was detected with a 4-fold or more increase based on dividing
NSAF values
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Figure 4.1: Rescue of DDR2 expression with a kinase-dead DDR2 receptor
(A) HEK293 cells transfected with DDR2K608E-Myc were added to plates and stimulated
with 30µg/mL collagen I for 4 hours in the presence of various concentrations of WRGshDDR2
28. DDR2 was immunoprecipitated with Myc antibody and bound products western
rescue DDR2 K608E
blotted with pTyr 4G10 or DDR2 antibodies
(B) BT459 cells depleted of DDR2 (shDDR2) were infected with lentivirus expressing a
kinase dead DDR2 (DDR2K608E). Western blot analysis was preformed to confirm reexpression of DDR2.
(C) ES2 cells depleted of DDR2 (shDDR2) were infected with lentivirus expressing a
kinase dead DDR2 (DDR2K608E). Western blot analysis was preformed to confirm reexpression of DDR2.
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Figure 4.2: DDR2 functions independent of its kinase activity to promote Matrigel
invasion
(A) Matrigel invasion of BT549 cell lines treated with 1µM WRG-28 or control as
compared to depleted of DDR2 or shRNAi depleted cells rescued with a kinase dead
DDR2 (DDR2K608E) at 48 hours. Representative images of H&E stained inserts, 20x hpf.
(B) Quantification of experiment described in (A). BT549 shSCR (blue), shDDR2
(green), or shDDR2 rescued with DDR2K608E (red). Striped bars indicated WRG- 28
treated cells (**p<0.01, ANOVA, n=3 inserts per condition, 4hpf per insert. Experiment
was preformed 3 independent times with similar results.
(C) Matrigel invasion of ES2 cell lines treated comparing control SCR to depleted of
DDR2 or shRNAi depleted cells rescued with a kinase dead DDR2 (DDR2K608E) at 48
hours. Representative images of entire H&E stained inserts.
(D) Quantification of experiment described in (C). ES2 shSCR (blue), shDDR2 (red), or
shDDR2 rescued with DDR2K608E (green). (*p<0.05, compared to control. ANOVA, n=3
inserts per condition, Matlab program used to quantify total area occupied by H&E
stained cells as compared to total measured area of the insert)
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Figure 4.3: DDR2 kinase activity predominates in 3D collagen invasion
(A) Cell invasion in 3D collagen gels of control BT549 shSCR cells as compared to cells
depleted of DDR2, or depleted cells rescued with a kinase dead DDR2 (DDR2K608E).
Distance traveled relative to control cells was determined at 48hrs. Representative
images shown. Solid white line delineates original cell boundary, dashed black line
delineates invasive front.
(B) Collagen invasion of control ES2 shSCR cells as compared to cells depleted of
DDR2, or depleted cells rescued with a kinase dead DDR2 (DDR2K608E) looking at
single cell invasion through collagen I. Representative images shown.
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Figure 4.4: DDR2 influences BT549 cell spreading on collagen I and fibronectin
independent of kinase activity
(A) Representative images of ES2 shSCR, shDDR2, or shDDR2 rescued with DDR2K608E mutant cells plated on Fibronectin coated hydrogels after 2 hours.
(B) Quantification of cell area when plated on either collagen I or fibronectin coated
hydrogels for 2hrs. Dots represent measure areas of individual cells, with box plot
overlay depicting the median and interquartile ranges of area spread.

181

A

B

C

6000

4000

Genotype
WT
shDDR2
Rescue

Footprint Area (pixels)

Footprint Area (pixels)

3000

2000

4000

2000

1000

0

0
3

6

ES2 WT

ES2
shDDR2

ES2
shDDR2
DDR2 K608E
rescue

ES2
shDDR2
DDR2 K608E
rescue
+ 1uM WRG-28

3 hours, Fibronectin 120KPa

Figure 4.5: DDR2 influences ES2 cell spreading on fibronectin independent of
kinase activity and this is blocked by WRG-28
(A) Representative images of ES2 shSCR, shDDR2, or shDDR2 rescued with DDR2K608E mutant cells plated on fibronectin coated hydrogels after 3 and 6 hours.
(B) Quantification of cell area when plated on fibronectin coated hydrogels for at both 3
and 6hrs. Dots represent measure areas of individual cells, with box plot overlay
depicting the median and interquartile ranges of area spread
(C) Quantification of cell area when plated on fibronectin coated hydrogels for 3hrs for
ES2 shSCR, shDDR2, shDDR2 rescued with DDR2-K608E, and shDDR2 rescued with
DDR2-K608E treated with 1uM WRG-28. Dots represent measure areas of individual
cells, with box plot overlay depicting the median and interquartile ranges of area spread
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Table 1: Putative DDR2 interacting proteins in the absence of collagen ligand
Control
Spectral
Counts

Identified Proteins
Phospholipid phosphatase 3
Disintegrin and metalloproteinase domain-containing
protein 12
Integrin alpha-6
Integrin alpha-3
E3 ubiquitin-protein ligase NEDD4
mRNA decay activator protein ZFP36L1
Receptor-type tyrosine-protein phosphatase S
Lysosomal-associated transmembrane protein 4B
Neuropathy target esterase
CD320 antigen
Acyl-CoA desaturase
Interferon-induced transmembrane protein 1
Non-receptor tyrosine-protein kinase TYK2
Hexokinase-2
Death-associated protein kinase 1
Guanine nucleotide-binding protein G(s) subunit alpha
isoforms short
AMP deaminase 2
Ceramide glucosyltransferase
MICOS complex subunit MIC60
SWI/SNF complex subunit SMARCC2
Myeloid-associated differentiation marker
Hepatocyte growth factor receptor
Tumor necrosis factor receptor superfamily member 3
Pro-neuregulin-1, membrane-bound isoform
Desmoglein-2
Myotubularin-related protein 14
Transmembrane 9 superfamily member 2
Kinase D-interacting substrate of 220 kDa
H(+)/Cl(-) exchange transporter 7
Sorting nexin-17
Probable ATP-dependent RNA helicase DDX23
Low-density lipoprotein receptor-related protein 12
ATP-binding cassette sub-family D member 3
Histone-binding protein RBBP7
Myosin phosphatase Rho-interacting protein
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Collagen Unstimulated
Sample Spectral
Counts

0

5

0
0
0
0
0
0
0
0
0
0
0
0
0
0

5
5
5
5
5
5
5
5
5
6
6
6
6
6

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

6
6
6
6
6
6
7
7
7
7
7
7
7
8
8
8
8
9
9
9

Arrestin domain-containing protein 3
TGF-beta receptor type-2
Matrix metalloproteinase-14
NEDD4-like E3 ubiquitin-protein ligase WWP2
Guanine nucleotide-binding protein G(k) subunit alpha
Inactive tyrosine-protein kinase 7
CD166 antigen
Neurogenic locus notch homolog protein 2
Drebrin
Teneurin-2
Histone H2B type 1-J
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
beta-1
Solute carrier family 12 member 2
Kin of IRRE-like protein 1
Guanine nucleotide-binding protein subunit beta-4
Forkhead box protein K1
E3 ubiquitin-protein ligase CHIP
Solute carrier family 12 member 4
Spectrin beta chain, non-erythrocytic 2
Dynactin subunit 1
Synaptotagmin-11
Myosin-14
Discoidin domain-containing receptor 2
Guanine nucleotide-binding protein G(i) subunit alpha-2
Microtubule-associated protein 2
Plasma membrane calcium-transporting ATPase 4
Gap junction alpha-1 protein
Pleckstrin homology-like domain family B member 2
Golgi apparatus protein 1
Structural maintenance of chromosomes protein 3
Thrombospondin-3
CD109 antigen
Unconventional myosin-Va
X-ray repair cross-complementing protein 6
Epidermal growth factor receptor
Hsp90 co-chaperone Cdc37
Cation-independent mannose-6-phosphate receptor
SCY1-like protein 2
Merlin
Ras-related protein Rab-7a
Low-density lipoprotein receptor-related protein 10
Transmembrane protein 59
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0
0
0
0
0
0
0
0
0
0
0

9
10
10
11
11
11
11
12
12
12
13

0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
5
2
3
3
3
3
6
2
3
2
10
5
3
2
2
2

13
14
14
15
16
17
17
18
18
18
37
237
24
23
21
42
16
23
16
14
14
27
9
13
8
40
19
11
7
7
7

A-kinase anchor protein 11
Protein prune homolog 2
Ephrin type-A receptor 2
Sodium/potassium-transporting ATPase subunit alpha-1
Coronin-1B
ATP-binding cassette sub-family E member 1
NEDD4 family-interacting protein 1
Replication factor C subunit 1
Ras GTPase-activating protein nGAP
Myoferlin
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4
8
14
9
2
3
5
2
2
50

14
28
47
28
6
9
15
6
6
150

Table 2: Putative DDR2 interacting proteins in the presence of collagen ligand
Collagen
Stimulated
Control
Sample
Spectral
Spectral
Counts
Counts

Identified Proteins
Acyl-CoA desaturase
Gamma-glutamylcyclotransferase
Serpin B7
Long-chain-fatty-acid--CoA ligase 3
Immunoglobulin kappa variable 3-15
Immunoglobulin heavy variable 3-23
Hemopexin
Calpain-1 catalytic subunit
Neutrophil elastase
Prolactin-inducible protein
Histone H1.5
Zinc-alpha-2-glycoprotein
Kallikrein-7
Ras-related protein Rab-9A
H(+)/Cl(-) exchange transporter 7
Hexokinase-2
Neutrophil defensin 1
Trichohyalin
Lysosomal-associated transmembrane protein 4A
Sorting nexin-17
Sodium-coupled neutral amino acid transporter 2
Extracellular glycoprotein lacritin
Kallikrein-9
Low-density lipoprotein receptor-related protein 12
Unconventional myosin-If
Syntaxin-6
Mammaglobin-B
Ig mu chain C region
Fibrinogen alpha chain
Glucosylceramidase
Annexin A4
Annexin A3
Tumor necrosis factor receptor superfamily member 1A
Integrin alpha-3
Bone morphogenetic protein receptor type-1A
Tumor necrosis factor receptor superfamily member 3
NADP-dependent malic enzyme
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0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6

Bone morphogenetic protein receptor type-2
Receptor-type tyrosine-protein phosphatase kappa
E3 ubiquitin-protein ligase RNF149
Myotubularin-related protein 14
Phosphoglucomutase-2
Myeloid-associated differentiation marker
Transmembrane 9 superfamily member 2
Probable ATP-dependent RNA helicase DDX23
Teneurin-2
CDKN2A-interacting protein
Serpin B13
Immunoglobulin heavy variable 3-7
Creatine kinase U-type, mitochondrial
Annexin A8
Guanine nucleotide-binding protein subunit alpha-11
Guanine nucleotide-binding protein G(s) subunit alpha isoforms
short
Neurogenic locus notch homolog protein 2
Kallikrein-6
Arrestin domain-containing protein 3
Tropomodulin-2
Probable ATP-dependent RNA helicase DDX41
Immunoglobulin lambda-like polypeptide 5
Thymidine phosphorylase
Leukocyte elastase inhibitor
TGF-beta receptor type-2
Sodium-dependent phosphate transporter 1
Cystatin-A
Immunoglobulin kappa variable 1-5
Ig kappa chain C region
Ig gamma-4 chain C region
ATP-binding cassette sub-family D member 3
Lipocalin-1
Serpin B5
Receptor-type tyrosine-protein phosphatase S
Guanine nucleotide-binding protein subunit beta-4
Kallikrein-13
Alpha-2-macroglobulin-like protein 1
Fibrinogen beta chain
Glutamine synthetase
Forkhead box protein K1
Ig alpha-1 chain C region
Myeloperoxidase
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0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

6
6
6
6
6
6
6
6
6
6
6
7
7
7
7

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

7
7
7
7
7
7
8
8
8
8
8
9
9
9
9
9
9
9
9
9
9
10
10
10
10
11
11

Cathepsin D
Insulin-degrading enzyme
Matrix metalloproteinase-14
Inactive tyrosine-protein kinase 7
Ceramide glucosyltransferase
Kin of IRRE-like protein 1
Solute carrier family 12 member 4
NEDD4-like E3 ubiquitin-protein ligase WWP2
Polymeric immunoglobulin receptor
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Guanine nucleotide-binding protein G(k) subunit alpha
Synaptotagmin-11
Fibrinogen gamma chain
Drebrin
Ig gamma-1 chain C region
Cellular retinoic acid-binding protein 2
14-3-3 protein sigma
Ig gamma-3 chain C region
Protein S100-A7
Complement C4-A
Histone H2B type 1-J
Serotransferrin
Tropomyosin beta chain
Myosin-14
Serpin B4
Complement C3
Lactotransferrin
Discoidin domain-containing receptor 2
X-ray repair cross-complementing protein 6
Ankycorbin
Guanine nucleotide-binding protein G(i) subunit alpha-2
Serpin B3
Gap junction alpha-1 protein
Merlin
Lysozyme C
Microtubule-associated protein 2
Ig gamma-2 chain C region
Glutathione S-transferase omega-1
FACT complex subunit SSRP1
Ras-related protein Rab-7a
EF-hand domain-containing protein D2
Coronin-1B
Plasma membrane calcium-transporting ATPase 4

188

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
3
2
6
5
3
5
2
3
2
3
2
2
2
2

11
11
11
11
11
11
11
13
13
13
15
15
16
16
17
17
17
18
20
21
22
29
35
35
44
54
59
213
24
29
18
53
38
22
36
14
19
12
18
11
11
10
10

Actin-related protein 2/3 complex subunit 3
NEDD4 family-interacting protein 1
Heat shock protein beta-1
Mitogen-activated protein kinase kinase kinase 7
Lamina-associated polypeptide 2, isoform alpha
LIM domain and actin-binding protein 1
Gelsolin
Twinfilin-2
Pleckstrin homology-like domain family B member 2
Immunoglobulin kappa variable 4-1
Golgi apparatus protein 1
Protein S100-A8
SCY1-like protein 2
Ephrin type-A receptor 2
Epidermal growth factor receptor
4F2 cell-surface antigen heavy chain
Plastin-3
Galectin-7
Protein-glutamine gamma-glutamyltransferase E
Fatty acid-binding protein, epidermal
Protein S100-A9
Sodium/potassium-transporting ATPase subunit alpha-1
Filaggrin
Proteasome subunit beta type-5
Ras-related protein Rab-8A
Sequestosome-1
Unconventional myosin-Va
Proteasome subunit alpha type-7
Tropomyosin alpha-1 chain
Transaldolase
CD109 antigen
26S protease regulatory subunit 7
Glutaminyl-peptide cyclotransferase-like protein
Ras-related protein Rab-5C
ATP-binding cassette sub-family E member 1
Low-density lipoprotein receptor-related protein 10
Splicing factor 45
Neurabin-2
Transmembrane protein 59
Carnitine O-palmitoyltransferase 1, liver isoform
14-3-3 protein sigma
E3 ubiquitin-protein ligase Itchy homolog
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4
5
3
5
3
4
4
2
2
2
3
10
5
14
3
3
3
3
3
6
7
9
4
2
2
2
6
5
10
3
3
6
4
2
3
2
2
2
2
7
7
7

20
24
14
22
13
17
17
8
8
8
12
39
19
52
11
11
11
11
11
22
25
32
14
7
7
7
21
17
34
10
10
20
13
6
9
6
6
6
6
20
20
20
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Chapter 5
Conclusions and Future Directions
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In summary, we have demonstrated that DDR2 was a candidate therapeutic
target for breast cancer metastasis by temporally depleting Ddr2 in early stage tumors
in MMTV-PyMT mice. We developed small molecule inhibitors of DDR2 that target the
extracellular domain of the receptor to inhibit ligand binding in a non-orthosteric manner.
We were able to show that the developed inhibitor actively inhibits DDR2 activation and
downstream signaling in response to collagen in both breast tumor cells and in vivo.
We also elucidated a region at the interface of the two DDR2 extracellular domains that
is important for receptor binding and activation. Furthermore, we have documented
kinase independent functions of the DDR2 receptor, and identified putative interacting
partners of the protein in breast cancer cells. The developed inhibitor is able to show
efficacy towards kinase independent functions of the receptor, illustrating the potential
advantage of such an inhibition strategy over traditional kinase inhibition.

In ovarian

cancer, we established DDR2 as critical for metastasis. Additionally, we detailed a
pathway whereby DDR2 expression is regulated in invasive tumor cells. Upon induction
of EMT, the EMT transcription factor TWIST1 drives the expression of DDR2, which in
turn stabilizes the transcription factor SNAIL1 to sustain EMT. DDR2 in ovarian cells
drives the cleavage and remodeling of fibronectin, which promotes mesothelial cell
clearance by the cancer cell.
Small molecule targeting of DDR2
DDR2 is a critical regulator of breast cancer metastasis, with pro-invasive roles in
the tumor and stromal compartments. The work outlined here demonstrates the
potential of DDR2 as a therapeutic target in the setting of metastasis. We have shown
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that WRG-28, a non-orthosteric inhibitor that acts on the DDR2 extracellular domain, is
effective in inhibiting the pro-metastatic functions of DDR2 both in vitro, and preliminarily
in vivo. While this compound was efficacious as tested, further medicinal chemistry
work will be necessary to optimize the compound for further development. Solubility of
WRG-28 is sub-optimal, and addition of chemical moieties that enhance the aqueous
solubility, or a formulation that does such, is needed. Furthermore, it will be important
to conduct pharmacokinetic and pharmacodynamics studies to determine how the
compound (or future derivatives) are metabolized, and how long they remain in vivo
before being cleared. Such work will be necessary before this inhibitor can be tested in
longer term models of metastasis.
It is important to note that in the therapeutic setting, a DDR2 inhibitor such as
WRG-28 would not be useful as a single agent, as DDR2 does not have an appreciable
effect on breast tumor proliferation. Therefore, it will be most efficacious in conjunction
with other conventional chemotherapeutics that kill tumors or inhibit their growth. The
subset of breast cancer patients that would most benefit from such a therapy remains a
point of interest. Previous work has shown the important role DDR2 plays in the early
stages of metastasis to facilitate collective migration away from the primary site1. Our
work where DDR2 was temporally deleted in early stage tumors of MMTV-PyMT mice
suggests that an ideal patient may be someone with early stage disease that is at risk
for progressing to invasive disease. In such a case, DDR2 inhibition would be a
preventative measure. However, many patients present with evidence of disseminated
disease2. Data collected using late stage models of metastasis indicate that DDR2
inhibition may still be beneficial in later stage patients. When 4T1 cells depleted of
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DDR2 were injected intravenously into mice, there was significantly less tumor burden
in the lung than seen with 4T1 control cells, and treatment with WRG-28 showed a
similar trend as the knockdown cells (Figure 2.17). This suggests that DDR2 plays a
role in these later stages, and a DDR2 targeted therapy may be clinically useful even in
this setting where tumor cells have disseminated.
Role of DDR2 in late breast metastasis
We have shown that DDR2 depletion in 4T1 cells inhibits tumor seeding and
colonization in the lungs following intravenous injection of these cells into the tail veins
of BALB/cJ mice, and inhibition of control 4T1 cells with the DDR2 inhibitor WRG-28
shows a similar effect.
How exactly DDR2 is functioning to promote metastasis in these later stages is
still unknown, and warrants further study. It is possible that similar to the pro-invasive
phenotypes seen in the primary site1, DDR2 could be acting to promote invasion and
migration into the lung parenchyma. In order to seed in the lung, tumor cells must
extravasate from the vasculature. Whether DDR2 plays a specific role in tumor cell
extravasation, distinct from its role in tumor migration, is unknown, and a possibility
worth exploring. Additionally, DDR2 could be promoting survival in the circulation,
increasing the number of cells available to seed in the lungs. DDR2 stabilizes SNAIL1
levels3, and SNAIL1 has been shown to promote tumor cell survival4. Whether DDR2
plays a role in cell survival dependent or independent of its stabilization of SNAIL1
remains unknown. Measuring levels of circulating tumor cells in the bloodstream of mice
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after injection of wild type or DDR2 depleted cells would be one way to address this
question.
Once in the lung parenchyma, there also remains the possibility that DDR2 could
facilitate production and/or remodeling of ECM within the lung that influences
colonization or growth. While we have not collected direct evidence in the setting of
breast cancer, given the role of DDR2 in ovarian cells to cleave fibronectin and clear the
mesotheial cell layer at secondary sites (Figures 3.5 and 3.2), it seems possible that this
type of remodeling could be occurring in breast cancer secondary sites as well. In order
to determine patient populations that could benefit from DDR2 inhibition, it will be
important to fully elucidate the roles of the receptor at these late stages of metastasis.
Of note, given the stromal contribution of DDR2 in breast metastasis, we
hypothesized that stromal DDR2 in the secondary site (i.e. lungs) may also be
contributing to tumor cell seeding and metastasis. To test this possibility, we injected
C57BL/6 mice that were either wild type or DDR2 ubiquitous null (DDR2-/-)
intravenously via the tail vein with the highly metastatic PyMT-BO1 GFP/luc cell line5.
Over the course of 8 days, tumor colonization and growth in the lung was assessed by
bioluminescent imagining. It did not appear that stromal DDR2 contributed to growth or
colonization by these tumor cells in this model (Figure 5.1). Therefore, this data
suggests that while in the primary site stromal DDR2 plays a major role in contributing
to metastasis, the effects of DDR2 in the later stages of breast cancer metastasis may
be confined to the tumor cell itself.
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Therapeutic targeting of DDR2 in other disease states
DDR2 has gained significant attention as a therapeutic target in the treatment of
lung cancer, where potential activating mutations in the Ddr2 gene have been
documented 6,7. While we have not tested WRG-28 in the setting of these specific point
mutations, given the data collected showing that the inhibitor retains activity against
activating “gatekeeper” mutations, it seems likely the compound would be efficacious in
these settings as well. However, this will have to be addressed directly.
We have also demonstrated DDR2 as an important mediator of ovarian cancer
metastasis. However, at this point, we have only addressed the importance of DDR2 in
the tumor cell. It will be important to determine if DDR2 plays a role in the stromal
compartment in this disease. As the metastatic course of ovarian cancer differs from
breast, the stromal role of DDR2 in secondary sites that becomes of particular interest.
Given that the majority of ovarian cancer cases present at advanced stage8, the stromal
contribution becomes critical from a therapeutic standpoint, as intervention prior to
tumor establishment at the metastatic site may not be possible in this patient population.
In addition to cancer, there other diseases where therapeutic targeting of DDR2
has shown promise. Including fibrosis and osteoarthritis (OA)9,10. In OA, DDR2
expression is increased in chondrocytes of OA patients and mouse models of OA 11 12.
Activation of DDR2 in chondrocytes leads to MMP13 upregulation, one of the major
degradative enzymes of collagen II in the articular cartilage 12. Overexpression of
DDR2 alone in chondrocytes does not result in OA in normal mice, likely because
normal articular chondrocytes are not directly exposed to collagen II 13. However, injury
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can expose chondrocytes to collagen II and the development of OA 13. Genetically
reducing DDR2 levels in mouse genetic models and injury models of OA attenuates OA
progression 14 15. Whether DDRs contributes to rheumatoid arthritis has not been
experimentally tested but DDR2 is highly expressed in synovial fibroblasts from patients
with RA 16,17, and may act as one of the stimulators of the over-expression of MMP-1 in
RA synovial fibroblasts18. A DDR2-CYR61-MMP1 signaling pathway has been
proposed to contribute to RA pathogenesis17. Therefore, in the setting of arthritis,
DDR2 may be a promising therapeutic target. Further, given that the OA is confined
within a joint space, therapeutic targeting of DDR2 in this setting may be more practical,
as patients may still benefit even in later stages of the disease; however, this notion
must be tested.
Additionally, DDR2 has been shown to play a role in induction of fibrosis and
angiogenesis in bleomycin induced lung fibrosis models19. When Ddr2 deficient mice
were administered bleomycin, they showed a dramatic decrease in fibrosis and
activation markers within the lung as compared to the wild type mice19. As a potential
therapeutic for idiopathic pulmonary fibrosis, DDR2 may be promising. Indeed, it was
shown that targeting DDR2 using siRNA beginning at the onset of bleomycin
administration greatly reduced lung fibrosis. Some benefit was still seen when DDR2
siRNA administration begin at day 14 (of a 28-day model)19. However, given the
irreversible loss of lung function that occurs with progression of this disease, it is likely
there is some critical window after which DDR2 directed therapeutics may not be
beneficial.
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Identification of important regulatory regions in the DDR2 extracellular domain
During our efforts to identify the potential binding site of WRG-28, we uncovered
residues within the extracellular domain of DDR2 that are critical for the receptor
function. Double mutants harboring F96A and T98A mutations were unable to bind to
collagen in vitro, and did not activate in response to collagen in cells. These residues
lie at the interface of the two extracellular domains. While such interdomain residues
have been shown to be important in the function of other receptors20,21, how exactly
they are mediating DDR2-collagen binding at a molecular level is unknown. Analysis of
the extracellular domain in vitro shows that oligomers, which are present in the wild type
protein, are notably absent in the DDR2F96A/T98A mutants (Figure 2.10E). We
demonstrated that these oligomers bind to ligand with higher affinity than corresponding
dimeric DDR2 ECD (Figure 2.8D). The functional dependence of these oligomers in
DDR2 is unknown; however, the lack of binding of the DDR2F96A/T98A mutant would
suggest that they are important. Work by others on DDR1 has shown that
oligomerization of the ECD is critical for its function22. Some reports have suggested
this clustering to be important for DDR223, therefore will be important to determine the
functional relevance of this oligomeric species.
It will also be important to make use of this DDR2F96A/T98A mutant in intact cells, to
determine the impact on oligomerization of full length receptor. While such higher order
clustering has been deemed important for DDR1 function24,25, its role in DDR2 has not
been examined. We are currently using YFP-tagged version of the DDR2 receptor in
live cells to answer this question. DDR2-YFP, DDR2W52A-YFP (collagen binding
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mutant), and DDR2F96AT98A-YFP mutants are being expressed in cells depleted of
DDR2, and receptor clustering in response to collagen I activation will be examined.
Additionally, the identification of these functionally important residues within the
DDR2 extracellular domain opens the door to potential new therapeutic strategies. In
addition to optimization of the already developed inhibitor WRG-28, rational based
design of small molecules directed to this area of the protein could also be conducted.
As this portion of the protein appears to be crucial for directing ligand binding, it would
also be a possibility to develop antibodies directed to this region of the receptor as a
potential therapeutic option.
Determining the molecular basis for DDR2 inhibition by WRG-28
Computational modeling suggests that an interface region between the two
DDR2 extracellular domains could be serving as the binding site for WRG-28 (Figure
2.9). Mutations within those residues lead to a receptor that is unable to bind collagen
(DDR2F96AT98A) providing data on the critical nature of this region for proper receptor
function, which could correlate to the ability of WRG-28 to mediate its effects. While
DDR1 is not inhibited by WRG-28, when DDR1 residues in this region are replaced with
the corresponding DDR2 residues (DDR1L96F/A98T), it becomes amendable to inhibition
by WRG-28 (Figure 2.10). While this points to the importance of this region for the
inhibitory ability of WRG-28, in the absence of structural data, it is impossible to know
the molecular basis of binding and recognition for this inhibitor with DDR2. Further,
given the data suggesting that the compound may be acting to disrupt clustering of the
extracellular domain (Figure 2.8), it is possible that the binding site could be a
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composite site formed by two or more interacting protomers. While a crystal structure
may elucidate interactions of WRG-28 with DDR2, dimers were not seen in the crystal
structure of the DS domain of DDR2 in complex with collagen peptide26, and only a
suggestion of dimer was observed when the extracellular domain of DDR1 was
crystalized27. Therefore if a composite site is needed for WRG-28 recognition, it may
not be truly reflected in a crystal structure. Given that dimers and oligomers of the
extracellular domain form in solution, an NMR solution based structure may be a more
optimal approach to elucidate the molecular basis of interactions for DDR2 and WRG28.
Establishing DDR2 as a critical regulator of metastasis in ovarian cancer
Using cell based assays in vitro, and xenograft in vivo models, we show that
DDR2 in ovarian cancer cells promotes metastasis. We establish this role using human
derived ovarian cancer cell lines, which is important to predict clinical relevance.
However, one shortcoming of this approach is that it necessitates use of
immunocompromised mice for in vivo experiments. While there is one mouse derived
ovarian cancer line available (ID8 cells, C57BL/6 derived) for use in syngeneic models,
the metastatic burden in this particular cell line is low, and it lacks mutations
characteristic of high grade serous carcinoma. Recently, derivatives of this cell line
were engineered to delete either p53 (Trp53-/-) or p53 and Brca2 (Trp53-/-;Brca2-/-),
more closely mimicking the human disease28, and inducing a more aggressive
metastatic phenotype. We have obtained these lines and confirmed that they express
high levels of DDR2. Knockdown of DDR2 in these cell lines and subsequent
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transplantation will allow for the assessment of the contribution of DDR2 to metastasis
in a syngeneic model of ovarian cancer metastasis.
Additionally, there is currently no data regarding the potential importance of
DDR2 within the ovarian stromal environment. Ovarian metastases contain high levels
of collagen I deposition, and given the importance of DDR2 in the breast tumor stroma,
it remains possible that DDR2 plays a role in the ovarian stroma as well. Using the ID8
p53-/- or ID8 p53-/-;Brca2-/- lines transplanted into either wild type C57BL/6 or DDR2-/C57BL/6 mice will allow us to assess the stromal contribution of DDR2 in ovarian
cancer.
While the data demonstrates that DDR2 is important for ovarian cancer
metastasis, whether DDR2 is a viable therapeutic target in this cancer remains of
question. Notably, the majority of ovarian cancer patients present with late stage
disease, where metastatic foci are already present. In the context of our studies, most
assays were representing cellular events that occur early in the ovarian metastatic
cascade. Whether DDR2 plays a role once metastatic lesions are present is unknown,
and more sophisticated genetic approaches that allow for temporal deletion of the
receptor will be required to answer this question.
Regulation of DDR2 expression
In normal tissues, DDR2 is primarily a mesenchymal gene, while DDR1 is
expressed in epithelial tissues10. It has previously been shown that under conditions of
forced EMT, cancer cells will switch from expression of the epithelial DDR1, to
expression of DDR229. The molecular basis of this switch during cancer EMT was
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unknown. Recently, it was reported that Ddr2 was a transcriptional target of TWIST1 in
the developing cranial mesoderm30, leading us to hypothesize that TWIST1 may be
inducing DDR2 after EMT induction in cancer cells. Using ovarian cancer cells, we
demonstrated that in cells that display a mesenchymal phenotype and express
biochemical markers of EMT, TWIST1 also drives DDR2 expression (Figure 3.1A and
B). Additionally, TWIST1 is required to induce DDR2 expression in TGF-B induced
EMT (Figure 3.1D and E). Whether or not this dependency is present for other methods
of EMT induction is unknown, and warrants further study. While TWIST drives DDR2
expression in ovarian cancer, it will be important to determine if this same mode of
regulation is consistent in other cancers where EMT has been shown to be important for
metastasis. Furthermore, the molecular basis for the concurrent downregulation of
DDR1 in cells undergoing EMT29 is unknown.
It has long been speculated that upon reaching a metastatic site, a cancer cell
that has undergone EMT must go through MET to become epithelial in nature and begin
proliferation to form a metastatic foci, and recent data supports this notion31. DDR1, the
epithelial expressed member of the DDR family, has also been shown to be important in
ovarian cancer metastasis32,33. An interesting possibility is that upon undergoing MET,
metastatic cells once again express DDR1, which drives cellular processes favorable for
the newly seeded cells. Determining whether this switching occurs and what its
potential contribution is to metastasis is of particular interest. Furthermore, determining
the molecular mediators of this reverse switch will be important to more fully understand
the regulation of these receptors in ovarian cancer, and may be applicable to other
cancers as well.
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Kinase independent functions of DDR2
DDR2 is a member of the receptor tyrosine kinase family. As an RTK many prometastatic functions of DDR2 are dependent on its kinase activity. These include its
ability to stabilize the EMT transcription faction SNAIL13, and phosphorylation of Src as
downstream effector34. However, it is not uncommon for RTKs to function independent
of signaling to drive various cellular processes. Indeed, we uncovered a number of
cellular phenotypes driven by DDR2 that are rescued by expression of a kinase dead
(DDR2K608E) version of the receptor (Figures 4.2, 4.4, and 4.5). In addition to
documenting this effect in cell culture, it will be important to determine whether these
kinase independent roles of the receptor contribute to metastasis in vivo. Given the
dramatic reduction in metastasis when DDR2 is knocked down in the 4T1-BALB/c
transplant model3, this metastasis model would be ideal to evaluate these functions.
Rescue of DDR2 knockdown with either wild type or a kinase deficient DDR2 receptor
followed by transplantation and evaluation of metastasis should be conducted, in order
to begin to determine if these non-signaling functions of the receptor contribute to
metastasis.
Additionally, a mass spectrometry proteomics screen was conducted to identify
potential interacting partners of DDR2, in order to shed light on how the receptor may
be working independent of its kinase function at a mechanistic level. In addition to
potentially identifying kinase independent functions of the receptor, these putative
interacting partners may also help to shed light on various DDR2 signaling pathways in
cells, as there is relatively little known about downstream kinase function of the
receptor. While there is much work to be done to validate these candidate proteins and
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determine if their interaction with DDR2 is functional, here I highlight some of the
potentially interesting candidate proteins.
Receptors with Pro-Invasive Associations
Putative interacting partner: PTK7
We have confirmed that Tyrosine-protein kinase-like 7 (PTK7) interacts with
DDR2 at a protein level in breast cancer cells (Figure 5.2B). It is highly expressed in
human BT549 breast cancer cell lines, and the expression level of the full length protein
does not change with DDR2 knockdown or overexpression (Figure 5.2A). In a
fibrosarcoma cell line, PTK7 was found to direct cancer cell motility and metastasis 35.
In cancer, PTK7 functionality is selectively regulated by MMP-14 and ADAMs. While
the full length PTK7 receptor is anti-migratory, upon cleavage a soluble N-terminal
fragment is shed, and intracellular C-terminal fragment is cleaved at the membrane by
gamma-secretase to release a cytoplasmic tail fragment that can transport to the
nucleus. This cleavage allows for the regulation of multiple genes and signaling
pathways in cancer cells36. Interestingly, MMP-14 was also identified as a putative
DDR2 interacting protein in the co-immunoprecipiitation screen. While DDR2 has
previously been shown to increase the levels and activity of MMP-143,37, this is the first
indication of a potential interaction at a protein level. It will be interesting to determine
whether the DDR2/PTK7 interaction is of functional consequence. One possibility that
by scaffolding both proteins, DDR2 brings PTK7 and MMP-14 into proximity to allow for
the cleavage of PTK7 that is required for its pro-invasive functions. Future studies
examining the levels of PTK7 cleavage products in the presence or absence of DDR2
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will help further elucidate the function of this interaction. Alternatively, it is possible that
soluble PTK7 could influence the ability of DDR2 to phosphorylate in response to
collagen. Such a mechanism has been seen for DDR1, where in the presence of Wnt5a protein the receptor is greatly enhanced in its ability to respond to collagen
stimulation38. Additionally, PTK7 plays a crucial role in planar cell polarity as a regulator
of Wnt signaling39, and planar cell polarity is important for collective cell migration.
Recent work in our lab has illustrated that DDR2 in basal epithelial cells regulates
collective invasion of breast tumor organoids1. It would be interesting to determine if an
interplay between DDR2 and PTK7 could be mediating this role of DDR2 in collective
invasion.

Putative interacting partner: CD109 antigen
Recently, CD109 was identified as a pro-metastatic factor in an in vivo screen of
lung cancer metastasis40. While knockdown of CD109 dramatically reduced lung
metastasis in that study, the mechanistic basis for this reduction is still unclear. Whether
or not CD109 interaction with DDR2 plays a role in its pro-metastatic function is of
interest. We have shown that knockdown of DDR2 in BT549 cells does not influence
levels of CD109, and are now in the process of evaluating the reciprocal relationship.
CD109 has been reported to interact with the EGF receptor and enhance its response
to EGF stimulation41. Future studies should look at whether the presence of CD109
plays a role in attenuating the ability of DDR2 to respond to collagen.
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DDR2 and Mechanical Forces
Putative interacting partners: Myosin-14 (non-muscle IIc), unconventional myosin Va,
unconventional myosin-If
Cells interact with the surrounding ECM in several ways. Cell-matrix interactions
are mediated by receptors, the most common of which are the matrix binding integrin
receptors that bind multiple ECM components. Focal adhesions (FA) are formed in the
areas where ECM-cell contacts are made, and important biochemical signals are
relayed by these adhesions42. For FAs to stabilize and connect to the actin
cytoskeleton, they undergo a process of maturation. During this process, myosin IIcontractility is increased, providing a contractile force along actin filaments that provides
the cellular tension necessary for FA maturation43. It has been reported that DDR2
promotes focal adhesion formation by interacting with non-muscle myosin IIA via the
juxtamembrane 2 region of DDR244. Additionally, DDR1 has been shown to interact with
NMIIA to mediate cell motility45 and collagen tractional remodeling24.
How DDR2 is interacting with non-muscle myosin to potentiate cell adhesion and
contractility, and what consequences this has in the context of tumors is an active area
of investigation. Myosin-generated force is utilized by ovarian cancer spheroids to
promote mesothelial cell clearance and allow the tumor cell clusters to access the submesothlial microenvironment46. We have demonstrated that DDR2 promotes
mesothelial cell clearance by tumor spheroids (Figure 3.2A-B). Therefore, mesotheilal
clearance by ovarian tumor spheroids could be an interesting context in which to
examine the role DDR2 plays in myosin mediated force generation.
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DDR2 Receptor Trafficking
Putative interacting partners: Rab5c, Rab-8a, Rab7a and Rab9a, sorting nexin 17
We identified a number of proteins involved in endosomal transport: Rab5c (early
endosome), Rab-8a (post-Golgi to membrane), Rab7a and Rab9a (late endosome)
Receptors that rapidly recycle back to the plasma membrane (such as transferrin
receptor), release ligand in the early endosome, whereas receptors such as EGFR
remain ligand bound and active even at the low pH of later endosomes47. While some
receptors maintain signaling within the endosome, some signaling requires receptor
endocytosis or occurs exclusively on endosomal membranes. It has been shown that
DDR1 undergoes cytoplasmic internalization and incorporation into the early endosome,
at time scales much faster than receptor activation (5 minutes for endocytosis, versus
60-90 minutes for maximal activation)25. How this endocytosis interplays with receptor
activation and signaling is unknown. There have not been studies addressing endocytic
trafficking of DDR2.
Additionally, sorting nexin 17 (SNX17) was found to associate with DDR2.
Members of the SNX family form retromer complexes that are recruited to Rab7-positive
late endosomes and rescue cargo receptors from degradative pathways47. SNX17 has
been previously shown to bind β1 integrin tails in endosomes to stabilize the protein and
recycle it back to the cell surface to be reused48.
Whether DDR2 is being endosomally trafficked, and how that may play a role in
signaling by the receptor is a potential area of future study, especially given the delayed
kinetics of activation for the DDR2 receptor. Given that a phosphorylation specific
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DDR2 antibody (DDR2 p-Tyr740) is now available, it would be interesting to conduct colocalization with various markers (membrane, early endosome, late endosome, nucleus)
by immunofluorescence after ligand stimulation to determine in which cellular
compartments active DDR2 receptor is found.
Recently published work assessing DDR2 in mesenchymal stem cells suggest an
upregulation of phosphorylated DDR2 receptor within the nucleus of stimulated cells,
suggesting that activation induces DDR2 localization in the nucleus49. The functional
relevance of that nuclear pool is unknown. The nuclear fractions of RTKs have been
reported to interact with promoters of target genes and function as transcription factors50
or serve as coregulators of transcription51. Therefore, the trafficking of DDR2 and
potential translocation into the nucleus warrants further investigation to determine if it
produces a relevant biologic activity, or if it is merely a housekeeping mechanism of
degradation.
Transcriptional Regulation by DDR2
Putative interacting partner: Notch2
When the Notch receptor is activated, this leads to the proteolytic cleavage of the
receptor and release of the Notch intracellular domain (ICD). This Notch ICD
translocates to the nucleus to interact with C promoter-binding factor 1 and initiate
transcription of Notch target genes, many of which are transcription factors. 52. DDR1
has been reported to bind to the Notch1 receptor, and activation of DDR1 with collagen
led to induced activation of Notch and subsequent downstream signaling, and increased
active form of Notch1 in the nuclear fraction53. A number of reports correlate DDR2
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expression to changes in transcription level of various proteins1,49,54. In addition to
regulation of the SNAIL1 transcription factor, potential signaling through cross-activation
of Notch could be a mediator in the transcriptional activation of various proteins by
DDR2.
Matrix interacting proteins
Putative interacting proteins: Integrin α3, Integrin α6
In both breast and ovarian cells, DDR2 was found to promote enhanced
adhesion and spreading to fibronection—a matrix protein that does not serve as a
binding ligand of DDR2 (Figures 4.4 and 4.5). How exactly DDR2 is mediating this
enhancement is still an unanswered question. One possibility is cross talk or
enhancement of direct matrix binding proteins. Among the proteins to coimmunoprecipitate with DDR2 were: Integrin α3, the alpha subunit that combines with β1 integrin to form a receptor for fibronectin and laminin; and Integrin α6, the alpha subnit
that combines with β-1 integrin to form a receptor for laminin. There are numerous
possibilities as to how DDR2 could be interacting with these proteins. It should first be
evaluated whether DDR2 is directly interacting with these proteins, or whether they are
co-immunoprecipitating as part of a complex formed within focal adhesion. It has
previously been shown that DDR2 can enhance the activation of α1β1 and α2β1 to
promote adhesion 55, however a mechanistic basis for this activation is unknown.
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Figure 5.1: Role of stromal DDR2 in secondary site growth and colonization
To model the later stages of metastasis, C57BL/6 wild type or DDR2-/- mice were
injected via tail vein with the syngeneic BO1-GFP/luc breast cancer cell line, and growth
and colonization in the lungs assessed over 8 days.
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Figure 5.2: PTK7 co-immunoprecipitation validation
(A) Expression of PTK7 in control BT549 shSCR, BT549 shRNA depleted of DDR2, or
BT549 DDR2 overexpressing cells, showing no overall changes in amount of full length
PTK7.
(B) Confirmation that PTK7 co-immnoprecipitates with DDR2 in BT549 cells expressing
a DDR2-Flag-His-His protein
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